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Background
Advances in the diagnosis and therapy of cancer have led to improved prognoses and exten-
sion of survival time in patients with a malignancy [1]. Such progress, however, has involved ag-
gressive therapy and support. As a consequence, patients with a malignancy more frequently 
encounter acute complications resulting in critical illness during the course of their disease and 
an increasingly large proportion of these patients require admission to an intensive care unit 
(ICU). This thesis studies the epidemiology and outcome of critical illness arising as an acute 
complication of cancer and/or its treatment. 
Cancer and intensive Care
Admission of cancer patients to the ICU was once considered inappropriate because their long-
term prognosis was perceived to be poor as a consequence of their underlying disease. In 
1999, in guidelines for ICU admission, a taskforce of the American College of Critical Care Med-
icine concluded that patients with hematological or metastasized solid malignancies were poor 
candidates for ICU admission [2]. These patients were considered to have a very high risk (up 
to 90%) of mortality. At that time, immediate treatment limitations or even refusal of ICU ad-
mission for these patients were advocated [3]. Over the past few decades, however, significant 
strides have been made in reducing the overall mortality from cancer while simultaneously 
improving the quality of life of survivors. 
 Recent studies reported that patients with a malignancy represent a large proportion 
of ICU patients. The SAPS-3 study, performed in an international population comprising almost 
20,000 ICU patients, showed that 3% of these patients had metastatic cancer, 6% had non-met-
astatic cancer and 2% had hematological cancer [4]. Similarly, in a substudy from the Sepsis Oc-
currence in Acutely Ill Patients (SOAP) study conducted in 198 European ICUs, 15% of patients 
had a malignancy, mostly solid tumors but also hematological malignancies [5]. Importantly, 
this latter study reported a hospital mortality of 58% in ICU patients with hematological can-
cer and 27% in patients with solid malignancies, compared with 23% in ICU patients without 
cancer [5]. In a Brazilian study involving 1,090 patients with cancer requiring ICU admission 
for reasons other than routine postoperative care, hospital mortality was 51% and 6-month 
mortality was 61%; most of these patients had non-metastasized solid cancer, and most pa-
tients required mechanical ventilation [6]. In an investigation that analyzed 717 consecutive 
cancer patients admitted to 28 Brazilian ICUs during a two-month period, overall mortality in 
cancer patients was 30% [7]. Others have also reported the improvement in prognosis after 
ICU admission for patients with hematological cancer. In hematopoietic stem cell transplant 
recipients who received invasive mechanical ventilation, mortality was uniformly higher than 
90% in studies before 1993, but gradually decreased to 52% in 2000 [8]. 
 Most patients with cancer enter the ICU for postoperative care. Indeed, in light of the 
increased life expectancy and advances in cancer treatment, the surgical intensivist is confront-
ed with greater numbers of oncology patients undergoing aggressive surgical treatments with 
curative intent or for palliation (e.g. for alleviating obstruction, infection, bleeding or pain). 
Although postoperative mortality of elective cancer surgery has been the topic of many inves-
tigations, none specifically addressed postoperative care in the ICU in this patient group [9-15]. 
In a large observational study evaluating the outcomes of 88,504 surgical patients admitted 
to the ICU in Austria during an 11-year period, non-metastatic cancer was an independent 
risk factor for postoperative hospital mortality (odds ratio 1.20) [16]. However, this study did 
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not discriminate between elective and emergency surgery or different types of surgical proce-
dures [16]. One relatively small investigation encompassing 381 cancer patients specifically ad-
dressed postoperative ICU care after elective surgery, reporting a median length of stay on the 
ICU of 2 days and an ICU mortality of 6%; unfortunately, the type of surgery was not specified 
[7].  Particular subgroups of cancer patients are more likely to need acute surgery during their 
disease. In this respect patients with colorectal cancer stand out: a recent report even sug-
gested that one in four cases of bowel cancer are diagnosed only after emergency admission 
to the hospital [17]. At present, however, little is known about postoperative ICU care in these 
patients. Clearly, there is a lack of knowledge on the outcome of cancer patients admitted to 
the ICU after elective or emergency surgery.  
 Together, these data show that ICU treatment is not futile for all patients with cancer. 
Hence, there is a need to increase our knowledge on the outcome of cancer patients in the 
ICU and to raise awareness amongst oncologists and intensive care physicians regarding the 
improved prognosis of patients with malignancy in need for ICU care.   
Infections in cancer patients
Cancer patients are more susceptible to infection and infections are a major cause of pro-
longed hospitalization in patients who have cancer [18]. This increased infection risk at least in 
part is the consequence of aggressive cancer therapies resulting in disruption of mucosal barri-
ers, neutropenia, cellular and humoral immune dysfunction, splenectomy and/or the presence 
of indwelling vascular catheters. In addition, local tumor effects contribute to the increased 
vulnerability for infection; the source of infection is often related to the anatomic site of the 
primary tumor, e.g. patients with lung cancer more commonly acquire pneumonia, whereas 
patients with prostate cancer more often encounter genitourinary infections [18]. Organisms 
that cause infections in cancer patients span the entire range from bacteria, viruses, fungi to 
protozoa. Importantly, infections by microorganisms with low virulence can result in significant 
morbidity and mortality in patients with cancer [19, 20]. 
 The most severe clinical manifestation of infection is sepsis, defined as the detrimental 
response of the host to invading pathogens. Patients with cancer are ten times more likely to 
develop sepsis than patients who do not have cancer. Moreover, cancer is associated with a 
30% higher risk for death from sepsis and sepsis is responsible for approximately 10% of all can-
cer deaths [20, 21]. Hematologic malignancies (66.4 per 1000) are more frequently associated 
with severe sepsis than solid tumors (7.6 per 1000) and have a higher mortality rate [5, 21]. 
 Chemotherapy-induced neutropenia is a clear risk factor to acquire an infection, and 
infections account for the majority of chemotherapy-associated deaths [22]. In neutrope-
nic patients bacteria are the most common cause of infection and at least 50% of patients 
with neutropenic fever have bacteremia. Since the 1990s Gram-positive bacteria outnumber 
Gram-negative organisms, at least in part due to the increasing use of intravascular catheters. 
Fungi are frequent causes of infections in neutropenic patients who received broad-spectrum 
antibiotics; other risk factors include prior use of steroids, advanced age, intensity of chemo-
therapy and the presence of an indwelling central catheter [18]. Fungal infection in patients 
who are neutropenic is most frequently caused by Candida species, followed by Aspergillus 
species. 
 An important risk factor for infections in cancer patients is the use of central vascular 
catheters (CVC).  Indeed, CVC-related blood stream infections are a major cause of morbidity 
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and mortality in cancer patients, estimated to occur in 1.0 to 1.9/1,000 catheter days [23]. 
Catheters can be tunneled (e.g. Hickman, Groshong and Broviac catheters), non-tunneled or 
implantable (e.g. Port-A-Cath). Non-tunneled CVC infection often originates from extraluminal 
colonization of the catheter, usually from the skin. In tunneled CVC or implantable devices 
contamination of the catheter hub and intraluminal infection are the most frequent routes of 
infection. Common causative organisms in CVC-related blood stream infections include coag-
ulase-negative staphylococci, Staphylococcus aureus, aerobic Gram-negative bacilli and Can-
dida albicans [18]. Besides by infection, the use of CVCs can be complicated by thrombosis. 
Septic thrombosis is a serious condition frequently associated with persistent bacteremia or 
fungemia. 
outline of the thesis
The general objective of the research presented in this thesis is to obtain more insight in the 
occurrence and outcome of acute critical illness in patients with cancer. 
 Chapter 2 seeks to provide insight into the proportion of cancer patients that requires 
ICU admission during the course of their disease. For this the patient registration systems of 
four hospitals is used, containing encoded “Diagnosis Treatment Combinations” (DTC) that 
specify information about the type of care, diagnosis and treatment; to identify the patients 
from this primary cohort admitted to an ICU during the 5-year study period (January 2006 – 
January 2011), encrypted data are linked with the database of the Dutch National Intensive 
Care Evaluation (NICE) registry. 
 The NICE registry is also used in Chapters 3-5, to determine the characteristics and out-
come of cancer patients admitted to the ICU. In 1996 the NICE foundation started collecting 
data of patients admitted to Dutch ICUs [24]. The participating ICUs provide information on all 
ICU admissions with the aim to assess and compare the performance of the ICUs and to im-
prove the quality of care. For each ICU admission variables are collected that describe patient 
characteristics, severity of illness during the first 24 hours of ICU admission, and the ICU and 
in-hospital mortality and length of stay. NICE makes use of the   Acute Physiology and Chronic 
Health Evaluation (APACHE) IV scoring system to classify patients according to admission diag-
nosis and comorbidities [25]. APACHE IV is based on age, chronic health conditions and phys-
iologic data collected on the worst measurement for each component on ICU day 1. Chronic 
health variables are AIDS, cirrhosis, hepatic failure, immunosuppression, lymphoma, leukemia 
or myeloma and metastatic tumor. Physiological data include pulse rate, mean blood pressure, 
temperature, respiratory rate, PaO2/FIO2 ratio (or P(A-a)O2 for intubated patients with FIO2 
0.5), hematocrit, white blood cell count, creatinine, urine output, blood urea nitrogen, sodi-
um, albumin, bilirubin, glucose, acid base abnormalities and neurological abnormalities based 
on Glasgow Coma Score.  Besides the APACHE IV score, the Simplified Acute Physiology Score 
(SAPS) II is used to calculate a score for each patient based on the most abnormal data from 
the first 24 hours following ICU admission; from this the severity of illness is quantified and 
the corresponding probability of in-hospital mortality calculated. As an indicator for quality 
assessment of intensive care, the observed mortality in the ICU population is compared with 
the calculated case–mix corrected mortality in that population. Each ICU admission diagnosis 
is first classified as non-operative or postoperative, next by body system or a transplant or 
trauma-related category, and then by diagnosis selecting one of 430 well defined diseases, 
injuries, surgical procedures or events that were most immediately threatening to the patient 
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and required the services of the intensive or coronary care unit. The NICE data definitions 
are contained in a data dictionary (www.stichtingNICE.nl). At least two physicians per ICU are 
obliged to attend a central training session organized by the NICE board, during which the 
data definitions are discussed. Physicians who have attended the central training session sub-
sequently train their local staff. At present, approximately 85% of all Dutch ICUs participate in 
NICE. In this thesis, NICE data collected between January 2007 and September 2012 are used. 
Figure 1 shows the overall population contained within the NICE registry during this period. In 
total 378,362 patients were admitted to the ICU during this period, of whom 13.9% had cancer. 
Figure 1: Patients included in the NICE registry (January 2007 – August 2012) and 
overview of different cancer subgroups studied in this thesis
1 All patients admitted to an ICU participating in NICE in the Netherlands between January 2007 and August 2012 
2  Planned medical cancer patients are rare. This group is not included in one of the Chapters of this thesis. Sub-
groups were hematologic malignancies (n=100), gastro-intestinal cancer (n=52), malignancies of the central 
nerve system (n=10), lung cancer (n=12), genito-urinary malignancy (n=7), thyroid cancer (n=1), head and neck 
cancer (n=5), and not further specified i.e. neoplasm non-operative (n=99). 
3 Unplanned medical cancer patients are studied in Chapter 3 (data from January 2007-January 2011)  
4 Planned surgical cancer patients are studied in Chapter 4 (data from January 2007-January 2012)
5  58.6% of unplanned surgical cancer patients involve emergency colorectal cancer surgery; these patients are 
studied in Chapter 5 (data from January 2007 – August 2012).
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 Chapter 3 focuses on cancer patients with acute (unplanned) admission to the ICU be-
tween January 2007 and January 2011, with the aim to compare their characteristics and out-
comes with those of critically ill patients without cancer. Chapter 4 focuses on the outcome 
of cancer patients admitted to the ICU after major elective surgery between January 2007 and 
January 2012, stratified according to cancer diagnosis. Chapter 5 focuses on a subgroup of sur-
gical oncology patients, in particular patients with colorectal cancer admitted to the ICU after 
emergency colorectal surgery between January 2007 and September 2012; these patients are 
compared with patients admitted to the ICU after emergency colorectal surgery for non-malig-
nant disease (i.e. diverticular disease, fistula or abscess, gastrointestinal obstruction, perfora-
tion or rupture, or peritonitis). 
 Chapters 6 and 7 describe infectious complications in patients with cancer. Chapter 6 
seeks to compare causative microorganisms in bloodstream infections in patients with or with-
out cancer in a 600-bed teaching community hospital (Reinier de Graaf Hospital). For this all 
positive blood cultures from adult patients between January 2005 and January 2011 are ana-
lyzed. Chapter 7 presents a retrospective analysis of the indications, duration of use, complica-
tions and reasons for removal of Port-A-Caths in cancer patients treated in the Reinier de Graaf 
Hospital from January 2005 to December 2010, comparing these with findings in patients who 
received a Port-A-Cath in the same period for reasons not related to cancer. 
 Chapter 8 (and 9) contains the summary of this thesis, as well as a general discussion 
and future perspectives. 
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Abstract
Introduction: Knowledge of the proportion of cancer patients that is admitted to an ICU is 
limited. The aim of this study was to obtain insight into which proportion of cancer patients is 
admitted to an ICU and how their survival, demographic and clinical characteristics relate to 
cancer patients who were not admitted to the ICU. 
Methods: Patients registered with a cancer diagnosis between January 1st 2006 and January 
1st 2011 were selected from the information systems of four hospitals in the Netherlands. 
To determine which of these patients were admitted to the ICU their data were linked to the 
Dutch National Intensive Care Evaluation registry. 
results: 36,860 patients with cancer were identified, of whom 2,374 (6.4%) were admitted to 
the ICU. Most ICU admissions involved cancers that received only surgical treatment (11.8% of 
all cancers in the general population). Among different cancer diagnoses, esophageal cancer 
(27.3%) and other types of gastrointestinal cancer most commonly lead to ICU admission. Al-
though more women (54.0%) than men were registered with cancer, the proportion of male 
cancer patients admitted to an ICU was much higher (9.3 vs. 4.0%, p < 0.001).  Long-term sur-
vival of cancer patients admitted to the ICU was much lower (median survival time 771 days) 
than in patients not admitted to the ICU (median survival time not reached, p < 0.001). None-
theless, survival after ICU admission stratified according to cancer diagnosis was substantial. 
Conclusion: One out of 16 patients with cancer was admitted to an ICU. Men with cancer had a 
two-fold higher risk of ICU admission than women with cancer. Although mortality was higher 
in patients who were admitted to the ICU, our data indicate that intensive care support for 
patients with cancer should not be considered futile. 
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Introduction
The prognosis of cancer patients has improved due to earlier diagnosis and better therapeutic 
options [1]. As a consequence of more aggressive therapies, the need of cancer patients for 
intensive care unit (ICU) support during the course of their disease has increased  [2]. Recent 
data indicate that the outcome of cancer patients on the ICU has improved significantly [3, 4]. 
Although once deemed unfitting because of their perceived poor prognosis, ICU admission 
is now considered appropriate for patients with a malignancy for specified indications [5, 6]. 
Reasons for ICU admission in patients with cancer include postoperative care, complications 
caused by the malignancy and/or its treatment and crises unrelated to the tumor or its therapy 
[7, 8]. Amongst cancer patients the best candidates for ICU admission are those with promising 
treatment possibilities or when calamities occur in the absence of active malignancy [9]. 
 Previous investigations reported on the incidence of cancer and its impact on the out-
come in general ICUs [10-12]. These studies showed that a cancer diagnosis on admission to 
a general ICU is relatively common, varying between 13.5 to 21.5%, and that the outcome of 
these patients is strongly dependent on the type of admission, with planned surgical and un-
planned medical admission types bearing the relatively best and worst prognosis respectively 
[10-12].   
 Although information about the influence of cancer on ICU outcome has become in-
creasingly available during recent years [3, 4, 10-13], knowledge on the proportion and char-
acteristics of cancer patients from a general population that is admitted to an ICU is highly 
limited. This information is of considerable interest, not only for insight in epidemiology and 
health care costs associated with different cancer diagnoses, but also for general and specialist 
physicians providing treatment and care to patients with a malignancy. The aim of this study 
was to obtain insight into which proportion of cancer patients is admitted to an ICU during the 
course of their illness and to analyze differences between cancer patients who were and who 
were not admitted to the ICU with regard to demographics, cancer diagnosis, type of treat-
ment and outcome. Therefore, we performed a retrospective study encompassing a 5-year 
period and involving almost 37,000 cancer patients in the Netherlands. 
Methods
Patient selection
The primary cohort consisted of all adult patients with a cancer diagnosis registered between 
January 1st 2006 and January 1st 2011 in four hospitals in the Netherlands. Two academic 
hospitals (Academic Medical Center, University of Amsterdam, Amsterdam and Leiden Univer-
sity Medical Center, Leiden) and two community teaching hospitals (Reinier de Graaf Hospital, 
Delft and Maasstad Hospital, Rotterdam) participated. Patients were selected from the hospital 
information systems based on encoded “Diagnosis Treatment Combinations” (DTC),  a nation-
wide coding and reimbursement system for all patients entering a hospital, either as outpa-
tient or inpatient, providing information about the type of care, diagnosis and all treatment 
modalities specified by the attending physician [14, 15]. A DTC is opened upon first contact 
with a patient, and the DTC starting date is registered. The choice for a DTC is made according 
to specific guidelines [14, 15]. For each patient a DTC remains active as long as he or she re-
ceives treatment or is in follow-up for the specified diagnosis. One patient can have more than 
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one DTC, for example in the presence of two different primary tumors. For the current analysis 
all patients with a DTC related to an oncological diagnosis were included, with the exception 
of patients with a primary malignancy of the central nervous system (since not all participating 
hospitals were primary care givers of this type of patients) or superficial skin cancer (since 
these tumors are not expected to lead to ICU admission or to influence survival).  To identify 
patients from this primary cohort who were admitted to an ICU during the study period,  data 
were linked to the database of the Dutch National Intensive Care Evaluation (NICE) registry 
using a deterministic linkage algorithm [16, 17]. NICE contains information on all admissions to 
the ICUs of 84 hospitals in the country (i.e. approximately 90% of all ICUs in the Netherlands) 
[18, 19].  NICE collects variables for each ICU admission including demographic data, reasons 
for ICU admission, comorbidities, severity of illness (APACHE IV) during the first 24 hours of ICU 
admission, and the ICU and in-hospital mortality and length of stay. In order to avoid patient 
identification, identifying variables such as hospital patient ID and the first four letters of the 
surname are included in an encrypted form in NICE. For the current analysis, patient identifying 
information in the DTC database derived from the hospital information systems were encrypt-
ed based on the same encryption algorithm as used in NICE. ICU admissions were linked with 
patients from the primary cohort in case the DTC encoding cancer was either active or closed 
less than one year before ICU admission. The date of death was extracted from the hospital 
information systems and the NICE registry. 
Ethics
The need for ethical committee approval was waived by the Dutch Central Committee on Re-
search Involving Human Subjects, because the study was purely observational and because 
only de-identified patient data were used. 
Statistical analysis
Samples median test was used to test whether the median age differed for patients with and 
without ICU admission. Pearson chi-squared test was used to evaluate whether the distribu-
tion of the different categories of variables age, gender, phase of active cancer treatment, 
therapy combination and type of cancer differed between cancer patients with and without 
ICU admission. 
 General Linear Models (GLM) analyses were used to determine the contribution of the 
type of cancer on  admission to the ICU during an active cancer diagnosis. The calculated odds 
ratios were adjusted for gender, phase of active cancer treatment, therapy combinations, and 
age. Time to ICU admission was defined as time from first day of the first DTC until ICU ad-
mission. Patients were censored at one year after the last DTC was closed (end of follow up). 
Furthermore, patients of whom the last DTC was not closed before January 1, 2011 and no ICU 
admission was found before January 1, 2012 were censored at January 1 2012. Cumulative per-
centages after 30 days, 365 days and 730 days of ICU admission were obtained by calculating 
survival tables for type of cancer and gender. The log rank (Mantel-Cox) test was performed to 
test whether cumulative survival differed between men and women. For all cancer diagnoses 
a Kaplan-Meier curve was constructed for time to ICU admission. 
To analyze survival after ICU admission for patients with one or more ICU admissions during an 
active cancer diagnosis, Kaplan-Meier curves were plotted for different types of cancer and for 
gender. First ICU admission date was chosen as starting time, date of death was the endpoint. 
23
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To compare survival after the first diagnosis of cancer between patients with and without ICU 
admissions during an active cancer diagnosis Kaplan-Meier curves and Cox Proportional Haz-
ard (Cox PH) regression were applied. The starting date of het first DTC was chosen as starting 
time, date of death was the endpoint. Patients of whom the last DTC was closed when they 
were still alive were censored at the day the last DTC was closed. Furthermore, patients of 
which the last DTC was not closed before January 1 2011, were censored at January 1 2011. 
Table 1: Study Population Demographics
1 Combinations of treatments are indicated independent of the order in which these were provided. 
2 p: ICU admission versus no ICU admission.
 all iCu admission no iCu admission p2
(% ICU admission) (% within this group) (% within this group)
All  patients 36,860 (6.4) 2,374 34,486 <0.001
Number of cancer diagnosis 40,716 (6.0) 2,458 38,258 <0.001










< 45 y 5,186 (2.8) 143 (6.0) 5,043 (14.6) <0.001
45-65 y 11,063 (5.8) 646 (27.2) 10,417 (30.2) <0.001
>60-75 y 14,323 (8.1) 1,158 (48.8) 13,165 (38.2) <0.001
>75 y 6,288 (6.8) 427 (18.0) 5,861 (17.0) 0.214
Gender     
Male 16,967 (9.3) 1,581 (66.6) 15,386 (44.6) <0.001
Female 19,893 (4.0) 793 (33.4) 19,100 (55.4) <0.001
Phase of Active Cancer 
treatment
    
Curable solid tumors 7,770 (13.4) 1,038 (42.2) 6,732 (17.6) <0.001
Incurable solid tumors 4,190 (4.6) 194 (7.9) 3,996 (10.4) <0.001
Hematological malignancies 4,263 (7.1) 304 (12.4) 3,959 (10.3) 0.002
Follow up / maintains 24,493 (3.8) 922 (37.5) 23,571 (61.6) <0.001
Treatment (combinations1)
Surgery 7,661 (11.8) 904 (36.8) 6,757 (17.7) <0.001
Surgery and Chemotherapy 2,044 (9.3) 190 (7.7) 1,854 (4.8) <0.001
Surgery and Radiation 
Therapy 
1,289 (8.1) 104 (4.2) 1,185 (3.1) 0.002
Surgery, Chemotherapy, 
Radiation Therapy
914 (10.5) 96 (3.9) 818 (2.1) <0.001
Chemotherapy 3,426 (6.2) 213 (8.7) 3,213 (8.4) 0.137
Chemotherapy and Radia-
tion Therapy
1,238 (7.0) 87 (3.5) 1,151 (3.0) 0.309
Radiation Therapy 7,502 (2.3) 169 (6.9) 7,333 (19.2) <0.001
Palliative care 911 (4.2) 38 (1.5) 873 (2.3) 0.017
Other/none 15,731 (4.2) 657 (26.7) 15,074 (39.4) <0.001
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The calculated hazard ratio was adjusted for gender, phase of active cancer treatment, therapy 
combinations, types of cancer and age. Age was modeled using natural cubic regression splines 
[20], with four degrees of freedom in both Cox PH regression and logistic regression. The ap-
propriate number of degrees of freedom was assessed by univariate analyses using analysis of 
variance (ANOVA). The proportional Hazard assumption was tested. For all analyses p-values 
below 0.05 were considered statistically significant.
results
Patients and ICU admissions
The primary cohort consisted of 36,860 patients with in total 40,716 cancer diagnoses, indicat-
ing that approximately 10% of patients had more than one cancer diagnosis (Table 1). Between 
January 1st 2006 and January 1st 2011 2,374 of these patients (6.4%) were admitted at least 
once to the ICU. Patients admitted to the ICU were older (median age 66 years) than patients 
not admitted to the ICU (median age 62 years, p < 0.001). The proportion of cancer patients ad-
mitted to the ICU was highest in the age group 60-75 years (7.6%) and lowest in the age group < 
45 years (2.6%). Supplementary Table 1 shows the age distribution stratified according to can-
cer diagnosis. The phase and type of active cancer treatment were analyzed according ICU ad-
mission or not (Table 1), revealing that the proportion of active treatments with curative intent 
for a solid tumor was much greater in the ICU group (42.2%) than in the non-ICU group (17.6%, 
p < 0.001). As a comparison, the fraction of hematological malignancies in the ICU group was 
only modestly higher (12.4%) than in the non-ICU group (10.3%, p < 0.002). The proportion of 
incurable solid tumors and malignancies in follow-up were lower in the ICU group (both p < 
0.001). With regard to different cancer therapies, most ICU admissions involved cancers that 
received surgical treatment only (11.8% of all cancers in the primary cohort and 36.8% of all 
ICU admissions). As a comparison, only 17.7% of cancers that did not require ICU admission 
received surgical therapy only. Moreover, all therapy combinations that included surgery re-
sulted in relatively higher ICU admission rates. Supplementary Table 2 shows the distribution of 
different types of cancer treatment in the primary cohort and percentage ICU admission strat-
ified according to cancer diagnosis. Figure 1 shows the time to ICU admission from opening of 
the DTC for all patients by Kaplan-Meier curve, revealing that most ICU admissions in cancer 
patients take place in the first year.
Different types of malignancy
The most frequent types of malignancy in the primary cohort were breast cancer (20.2% of all 
cancer diagnoses), hematological malignancy (10.5%), lung cancer (8.7%), colorectal carcino-
ma (8.3%), and prostate cancer (7.2%) (Table 2). Esophageal cancer most commonly lead to 
ICU admission (27.3% of patients with this diagnosis, Table 2); in accordance, esophageal can-
cer was after adjustment still associated with the highest odds ratio (3.27) for ICU admission 
amongst all cancer diagnoses (Table 3). Patients with other types of gastrointestinal cancer, 
including colorectal (10.4%) and pancreatic and biliary cancer (9.4%), lung cancer (6.3%) and 
patients with hematological malignancies (6.2%) also were relatively frequently admitted to 
the ICU (Table 2). 
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Indications for ICU admissions
According to the APACHE IV ICU admission diagnoses, only 26.9% of ICU admissions were di-
rectly linked with cancer (Table 4). 56.2% of ICU admissions were surgical versus 43.6% medi-
cal. 23.6% of all ICU admissions of patients were associated with surgery for cancer, whereas 
32.6% of admissions were associated with surgery not directly related to the cancer diagnosis. 
Only 3.3% of ICU admissions were medical and directly linked with cancer; the majority of 
medical admissions were because of infection and sepsis (18.5% of all ICU admissions of cancer 
patients).
Gender differences
The primary cohort of cancer patients comprised more women (54.0%) than men (Table 1). 
In contrast, in the ICU group the proportion of men was much higher (66.6%, versus 44.6% 
men in the non-ICU group, P < 0.001). Compared to female patients, the proportion of male 
cancer patients admitted to an ICU was much higher (9.3 versus 4.0%, P < 0.001). This gender 
difference with more men than women admitted to the ICU was present in all cancer diagnosis 
specific subgroups, although differences for esophageal cancer and melanoma did not reach 
statistical significance (Table 2).  
Mortality
Figure 2 shows 1500-day mortality stratified according to ICU admission status. Clearly, pa-
tients who were admitted to the ICU had a strongly reduced survival (median survival time 771 
days) when compared with patients who were not admitted to the ICU (median survival time 
not reached during the observation period; p < 0.001).  Figure 3 shows survival data of cancer 
patients admitted to the ICU stratified according gender; median survival times were 590 days 
for men and 497 days for women (not significant). Figure 4A-J shows survival of patients admit-
Figure 1: Kaplan-Meier curve for time until intensive care unit admission for all 
cancer diagnoses
iCu admission  
        30 days 1.13 %
        365 days 4.58 %
        770 days 5.72 %
The graph shows the time to ICU admission from opening of the Diagnosis Treatment Combination for all 
40.716 cancer diagnoses.
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Table 3:  Logistic regression for ICU admission for different types of cancer
Odds ratio1
(95% Confidence Interval) p
Non-gender specific malignancy
Lung cancer Reference
Head and neck cancer 0.96 (0.77 – 1.19) 0.707
Colorectal cancer 0.94 (0.79 – 1.12) 0.468
Pancreatic and biliary cancer 1.06 (0.88 – 1.28) 0.527
Esophageal cancer 3.27 (2.74 – 3.89) <0.001
Other types of GI-cancer 1.18 (0.96 – 1.45) 0.126
Urinary tract cancer 0.48 (0.39 – 0.60) <0.001
Melanoma 0.23 (0.12 – 0.43) <0.001
Sarcomas 0.39 (0.29 – 0.51) <0.001
Hematological malignancy 0.62 (0.08 – 5.15) 0.661
Other types of cancer 0.75 (0.59 – 0.95) 0.018
Gender specific malignancy
Breast cancer 0.20 (0.15 – 0.25) <0.001
Ovarian and endometrial cancer 0.21 (0.15 – 0.31) <0.001
Cervical cancer 0.09 (0.04 – 0.18) <0.001
Other  types of gynecological  cancer 0.10 (0.04 – 0.26) <0.001
Prostate cancer 0.26 (0.21 – 0.32) <0.001
Testicular cancer 0.19 (0.09 – 0.39) <0.001
1 The calculated odds ratios were adjusted for gender, phase of active cancer treatment, therapy combinations, 
type of cancer and age  by adding these covariates in the logistic regression model.
Table 4:  Reason for admission in the ICU 
Type of ICU admission based on APACHE IV (%)
Surgery for cancer 579 (23.6)
Other types of surgery
- Gastro-intestinal surgery 322 (13.1)
- Respiratory tract surgery (other than cancer) 163 (6.6)
- Cardiovascular surgery 196 (8.0)
- Other 121 (4.9)
Medical cancer 80 (3.3)
Other types of non-surgical admissions 
- Cardiac 173 (7.0)
- Respiratory  143 (5.8)
- Infection / sepsis 455 (18.5)
- Thrombosis / hemorrhage 91 (3.7)
- Neurological 44 (1.8)
Other non-surgical causes for ICU admission 87 (3.5)
Missing 4 (0.2)
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Figure 2: Survival of cancer patients with or without ICU-admission
 iC admission
––––
no iC admission 
- - - - -
survival   
        30 days 0.96 0.98
        365 days 0.70 0.82
        730 days 0.51 0.72
        50%* 771 days  
Survival of cancer patients who were (solid line) or who were not (dotted line) admitted to the ICU. This analysis 
encompassed 36,860 adult patients registered with a cancer diagnosis between January 1st 2006 and January 
1st 2011 in four hospitals in the Netherlands. Of these patients, 2,374 were admitted to the ICU during the study 
period. The graph shows Kaplan-Meier curves starting at the date of cancer diagnosis registration; p value indi-
cates the difference between groups.
*p= <0.001




- - - - -                
survival   
        30 days 0.82 0.78
        365 days 0.60 0.53
        730 days 0.44 0.38
        50%* 590 days 497 days
Kaplan-Meier curves starting at the date of ICU admission. Men (solid line) and women (dotted line); p value 
indicates the difference between groups. 
*p= 0.110
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ted to the ICU stratified according to cancer diagnosis. Median survival times were relatively 
long for prostate cancer (not reached within 4 years), breast cancer (959 days) and esophageal 
cancer (774 days), and relatively short for hematological malignancies (41 days). 
discussion
To the best of our knowledge our study is the first to report on the proportion of cancer pa-
tients from the general population that is admitted to an ICU during the course of their illness, 
stratified according to cancer diagnosis and phase and type of treatment. Of 36,860 patients 
registered in four hospitals with at least one cancer diagnosis 6.4% was admitted to the ICU. 
Of all solid tumors treated with curative intent, 13.4% were admitted to the ICU. Of all sol-
id tumors considered incurable, still 4.6% received ICU care. Surgery was the most common 
treatment associated with ICU admission: of all cancers treated with surgery solely or in com-
bination with other modalities 10.9% required ICU care.  Among different cancer diagnoses, 
patients with esophageal cancer entered the ICU most frequently (27.3%). 
 Previous studies have documented that most ICU admissions of cancer patients involve 
postoperative care after elective surgery [17, 21, 22]. Accordingly, our data show that the ma-
jority of cancer patients entered the ICU during the course of their disease because of surgi-
cal treatment. Of interest, however, of all cancer patients who were admitted to the ICU for 
surgical reasons, only 41.9% of cases involved surgical treatment directly related to cancer. 
Hence, more than half of cases were related to surgical interventions not directly linked with 
the primary cancer diagnosis, most notably gastrointestinal and cardiovascular surgery. In ac-
cordance with previous investigations [12, 23-25], infection and sepsis were the most common 
indications for admission in medical cancer patients. 
 Although in this population of cancer patients women were more prevalent than men, 
the proportion of men that entered the ICU was more than twice as large when compared with 
women. While for the overall population this gender difference can be partly explained by the 
high prevalence of breast cancer (which very rarely results in ICU admission), men more often 
entered the ICU across all cancer diagnoses. Previous studies, performed in general popula-
tions (i.e., not restricted to cancer patients), also indicated that men are more likely to receive 
ICU care [26-29]. A large population-based study conducted in Canada demonstrated that older 
women with critical illness were less likely than critically ill men to be admitted to an ICU [28]. 
Similarly, a prospective study involving 25,998 adult patients admitted to 31 ICUs in Austria 
documented gender-related differences in ICU care, with male patients  - despite presenting 
with a lower severity of illness - more likely than female patients to receive a high level of care, 
as defined by the number of invasive procedures [27]. Although in that investigation women 
had a higher observed mortality rate than men, there was no difference in outcome after ad-
justment for the severity of illness [27]. Overall ICU mortality did not differ between sexes in 
another study [30]. Our current study extends these data by showing that long-term survival 
of cancer patients admitted to the ICU does not differ between men and women. At present it 
is unclear what drives the apparent gender difference with regard to ICU admission of cancer 
patients, although some studies have suggested that males have more comorbid conditions at 
the point of cancer diagnosis, which may drive more frequent ICU admission [31-34]. 
 According to literature, more than 60% of cancer patients have an expected survival 
beyond 5 years [1, 35], illustrating the need to study long-term outcome in patients with a 
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malignancy. Previous studies of long-term survival of ICU patients have suggested an increase 
in mortality during several years after hospital discharge when compared with an age- and gen-
der-matched population [36, 37]. Among different diagnoses, cancer patients had the greatest 
relative risk of mortality (more than 3-fold) during 5 years after hospital discharge following ICU 
admission in a cohort of 12,180 ICU patients from 25 hospitals  in Finland [37]. In accordance, 
the presence of a new malignancy was associated with a high risk of death within the first year 
after discharge (hazard ration 4.60) in a single-center study conducted in Australia comprising 
almost 20,000 ICU patients that survived to discharge [38]. A more recent study conducted in 
the Netherlands analyzed mortality up to 3 years after hospital discharge of patients who had 
received ICU care. Whereas 1- and 3-year mortalities after hospital discharge were 12.5% and 
27.5% respectively for the total ICU population, in cancer patients mortality was almost twice 
as high at both time points [17]; these data are in line with our current long-term survival data 
of cancer patients after ICU admission. Although these data cannot be compared directly, they 
support that ICU admission involves a selection of patients with relatively favorable therapeu-
tic perspectives, for example because major surgery requiring postoperative ICU care will be 
limited to patients with early stage solid tumors carrying the better prognosis. The finding that 
in our overall population cancer patients who were not admitted to the ICU did much better 
than patients who were not admitted to the ICU (Figure 2) appears to contradict this hypothe-
sis, but may be explained by the fact that certain cancer diagnoses, such as breast and prostate 
cancer, have a relatively favorable prognosis and are overrepresented in the group of patients 
without ICU admission during follow-up (Table 2). 
 A limitation of this and previous studies that addressed long-term outcome after ICU 
admission [17, 36-38] is that causes of death after hospital discharge were not specified and 
may be unrelated to ICU admission or cancer diagnosis. In addition, since 90% of all ICUs par-
ticipate in the NICE registry we may have missed ICU referrals of some patients enrolled in our 
general cohort. 
 In conclusion, we report detailed information about the subgroup of cancer patients 
admitted to an ICU during a 5-year study period, comparing their demographics, diagnoses, 
phase and type of therapy with those in patients from the same cohort who did not receive ICU 
care. Patients with gastrointestinal malignancies, most notably esophageal cancer, were most 
often admitted to the ICU. In accordance, most patients entered the ICU for postoperative 
care. Our long-term survival analysis of patients who received ICU care shows that the use of 
aggressive support measures for cancer patients is not futile. 
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Figure 4: Kaplan Meijer survival curve of cancer patients according to type of cancer (A-J)
(A) Lung cancer, (B) Head and neck cancer,  (C) Colorectal cancer, (D) Pancreatic and biliary cancer, (E) Esopha-
geal cancer,  (F) Other types of gastrointestinal cancer, (G) Urinary tract cancer, (H) Hematological malignancy, 
(I) Breast cancer, (J) Prostate cancer
a. lung cancer
survival  
        30 days 0.82
        365 days 0.60
        730 days 0.41
        50% 659 days
B. head and neck cancer
survival  
        30 days 0.83
        365 days 0.54
        730 days 0.43
        50% 683 days
C. Colorectal cancer
survival  
        30 days 0.79
        365 days 0.59
        730 days 0.41
        50% 526 days
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D. Pancreatic and biliary cancer
survival  
        30 days 0.82
        365 days 0.52
        730 days 0.36
        50% 394 days
e. esophageal cancer
 survival  
        30 days 0.93
        365 days 0.71
        730 days 0.54
        50% 829 days
f. other types of Gi-cancer
 survival  
        30 days 0.79
        365 days 0.54
        730 days 0.39
        50% 543 days
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G. urinary tract cancer
survival  
        30 days 0.87
        365 days 0.53
        730 days 0.32
        50% 383 days
h. hematological malignancy
survival  
        30 days 0.54
        365 days 0.33
        730 days 0.24
        50% 78 days
i. Breast cancer
survival  
        30 days 0.82
        365 days 0.62
        730 days 0.49
        50% 679 days




        30 days 0.88
        365 days 0.83
        730 days 0.77
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Supplementary Table 2: Cumulative Intensive Care Unit admissions according to cancer 
diagnosis and type of treatment
surgery surgery and  
Chemotherapy
surgery and  
Radiation Therapy
surgery, Chemo-
therapy and  
Radiation Therapy
Non-gender specific  
malignancy
all iCu (%) all iCu (%) all iCu (%) all iCu (%)
Lung cancer 221 98 (44.3) 57 12 (21.1) 27 2 (7.4) 33 3 (9.1)
Head and neck cancer 246 27 (11.0) 32 0 (0.0) 112 24 (21.4) 40 7 (17.5)
Colorectal cancer 1,126 243 (21.6) 389 30 (7.7) 141 41 (29.1) 89 9 (10.1)
Pancreatic, biliary cancer 718 200 (27.9) 119 3 (2.5) 21 4 (19.0) 7 0 (0.0)
Esophageal cancer 347 247 (71.2) 179 102 (57.0) 44 31 (70.5) 132 79 (59.8)
Other types of GI-cancer 442 123 (27.8) 96 22 (22.9) 10 1 (10.0) 19 3 (15.8)
Urinary tract cancer 1,053 102 (9.7) 323 23 (7.1) 40 10 (25.0) 40 6 (15.0)
Melanoma 132 4 (3.0) 61 0 (0.0) 79 0  (0.0) 7 1 (14.3)
Sarcomas 463 18 (3.9) 25 13 (52.0) 89 10 (11.2) 29 2 (6.9)
Hematological malignancy 13 3 (23.1) 8 8 (0.0) 0 0  (0.0) 15 4 (26.7)
Other types of cancer 477 49 (10.3) 520 2 (0.4) 31 1 (3.2) 3 0 (0.0)
Gender specific malignancy      
Breast cancer 587 11 (1.9) 526 8 (1.5) 317 5 (1.6) 472 6 (1.3)
Ovarian, endometrial cancer 744 18 (2.4) 142 6 (4.2) 76 1 (1.3) 8 0 (0.0)
Cervical cancer 354 1 (0.3) 11  0 (0.0) 143 1 (0.7) 33  0 (0.0)
Other types of gyn. cancer 201 2 (1.0) 0 0 (0.0) 37 0 (0.0) 0 0  (0.0)
Prostate cancer 758 40 (5.3) 20 2 (10.0) 216 9 (4.2) 7 1 (14.3)
Testicular cancer 64 3 (4.7) 30 1 (3.3) 12  0 (0.0) 5  0 (0.0)
total 7,946 1,189 (15.0) 2,538 232 (9.1) 1395 140 (10.0) 939 121 (12.9)
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Continuing Supplementary Table 2
Chemotherapy  and 
Radiation Therapy
Chemotherapy Radiation therapy Palliative Care other, none
all iCu (%) all iCu (%) all iCu (%) all iCu (%) all iCu (%)
372 13 (3.5) 527 17 (3.2) 1,256 34 (2.7) 35  0 (0.0) 1,065 90 (8.5)
52 4 (7.7) 64 4 (6.3) 547 13 (2.4) 12  0 (0.0) 800 69 (8.6)
92 12 (13.0) 210 4 (1.9) 71 17 (23.9) 83 3 (3.6) 1,292 99 (7.7)
30 0 (0.0) 193 2 (1.0) 17 3 (17.6) 108 2 (1.9) 1,629 121 (7.4)
112 13 (11.6) 147 19 (12.9) 82 5 (6.1) 45 3 (6.7) 712 90 (12.6)
14 2 (14.3) 94 3 (3.2) 12 1 (8.3) 69 3 (4.3) 620 52 (8.4)
35 2 (5.7) 178 13 (7.3) 38 3 (7.9) 38 4 (10.5) 668 33 (4.9)
17 2 (11.8) 29 0 (0.0) 11  0 (0.9) 13  0 (0.0) 288 4 (1.4)
30 0 (0.0) 97 7 (7.2) 513 10 (1.8) 11  0 (0.0) 949 15 (1.6)
202 48 (23.8) 1,433 207 (14.4) 70 9 (15.7) 272 24 (8.8) 2,312 111 (4.8)
16 0 (0.0) 71 5 (7.0) 298 11 (3.7) 152 3 (2.0) 1,131 43 (3.8)
        
224 5 (2.2) 292 3 (1.0) 3,955 65 (1.6) 36  0 (0.0) 1,840 27 (1.5)
9 0 (0.0) 28 4 (14.3) 85 4 (4.7) 11  0 (0.0) 501 6 (1.2)
13 0 (0.0) 7  0 (0.0) 84 1 (1.2) 7 1 (14.3) 363 4 (1.1)
0 0 (0.0) 58  0 (0.0) 10 0 (0.0) 0  0 (0.0) 199 3 (1.5)
23 1 (43) 74 1 (1.4) 494 28 (5.7) 24 1 (4.2) 1,340 58 (4.3)
13 1 (7.7) 75 2 (2.7) 5  0 (0.0) 1  0 (0.0) 191 1 (0.5)
1,254 103 (8.2) 3,577 291 (8.1) 7,548 204 (2.7) 917 44 (4.8) 15,900 826 (5.2)
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Abstract 
Background: Acute admission to an intensive care unit (ICU) of cancer patients is considered 
with increasing frequency due to a better life expectancy and more aggressive therapies. The 
aim of this study was to determine the characteristics and outcomes of cancer patients with 
unplanned admissions to general ICUs, and to compare these with outcomes of critically ill 
patients without cancer. 
Materials and Methods: All unplanned ICU admissions in the Netherlands collected in the 
National Intensive Care Evaluation registry between January 2007 and January 2011 were an-
alyzed.
results and Conclusion: Of the 140,154 patients with unplanned ICU admission 10.9 % had 
a malignancy. Medical cancer patients were more severely ill on ICU admission in compari-
son with medical non-cancer patients, as reflected by higher needs for mechanical ventilation 
(50.8% vs 46.4%, p<0.001 ) and vasopressors within 24 hours after admission (41.5% vs 33.0%, 
p<0.001), higher Acute Physiology and Chronic Health Evaluation (APACHE) IV scores (88.1 vs 
67.5, p<0.001) and a longer ICU stay (5.1 vs 4.6 days, p<0.001). In contrast, surgical cancer 
patients only displayed a modestly higher APACHE IV score on admission when compared with 
non-cancer surgical patients, whereas the other afore mentioned parameters were lower in 
the surgical cancer patients group. In-hospital mortality was almost twice as high in medical 
cancer patients (40.6%) as in medical patients without cancer (23.7%). In-hospital mortality of 
surgical cancer patients (17.4%) was slightly higher than in patients without cancer (14.6%). 
These data indicate that unplanned ICU admission is associated with a high mortality in pa-
tients with cancer when admitted for medical reasons.
43
u n p l a n n e d  a d m i s s i o n  o f  c a n c e r  pat i e n t s 
Introduction
Survival of cancer patients has increased over the last three decades due to a greater aware-
ness of early signs and better treatment possibilities [1]. These treatments are more intense 
and may cause significant toxicity and side effects due to chemotherapy, radiation therapy 
and/or extensive radical surgery. The more aggressive care has led to an increase in the need 
for vital life support and life-sustaining treatments. Consequently, referral to an intensive care 
unit (ICU) is increasingly considered in cancer patients [2]. 
 Decisions for ICU admissions in patients with advanced cancer are complex, and the 
knowledge of survival rates and prognostic factors is essential to these decisions. Ten years 
ago, in  guidelines for ICU admission, a taskforce of the American College of Critical Care 
 Medicine concluded that patients with hematological or metastasized solid malignancies are 
poor candidates for ICU admission considering their high risk of mortality [3]. In accordance, 
cancer patients are more likely to be denied ICU admission [4]. More recent data suggest that 
the prognosis of critically ill cancer patients admitted to an ICU has improved considerably [5, 
6]. However, these encouraging data are almost exclusively derived from single-center studies 
conducted in specialized hemato-oncologic ICUs, which may not reflect outcome of cancer 
patients on general ICUs. 
 Two relatively large multicenter studies examined the impact of cancer on the outcome 
of patients admitted to general ICUs [7, 8]. These studies did not distinguish between planned 
and unplanned cancer patients. Many ICU admissions in cancer patients are planned, especial-
ly in the context of postoperative care. The dilemma whether or not to admit a patient with 
a malignancy to the ICU in particular applies to unplanned emergency situations. Therefore, 
the objective for the present study was to analyze the characteristics and outcome of cancer 
patients with unplanned admissions to general ICUs, and to compare these with outcomes of 
critically ill patients without cancer. For this we analyzed all ICU admissions in the Netherlands 
collected in the National Intensive Care Evaluation (NICE) registry from January 2007 through 
January 2011 [9]. 
Materials and Methods
Patient data
The database of the Dutch National Intensive Care Evaluation (NICE) registry was used in this 
observational study [9]. In 1996 the NICE foundation started collecting data on patients admit-
ted to Dutch ICUs. The participating ICUs provide information on all ICU admissions with the 
aim to assess and compare the performance of the ICUs and to improve the quality of care. 
For each ICU admission variables are collected that describe patient characteristics, severity 
of illness during the first 24 hours of ICU admission, and the ICU and in-hospital mortality and 
length of stay. The data are encrypted such that all patient-identifying information, including 
name and patient identification number, are untraceable. The recorded variables were  used to 
calculate probabilities of death for each patient using the Acute Physiology and Chronic Health 
Evaluation (APACHE) IV prognostic model [10]. Data for the current study were collected from 
all consecutive admissions to 80 ICUs between January 2007 and January 2011. The study 
was strictly observational and every clinical decision was at the discretion of the responsible 
physician. 
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Ethics
The NICE initiative is officially registered according to the Dutch Personal Data Protection Act. 
The need for ethical committee approval is waived by the Central Committee on Research 
Involving Human Subjects, because the study was purely retrospective and because only anon-
ymous patient data were used. 
Selection of patients with a malignancy
Patients were identified as being admitted with a malignancy when their APACHE IV reason 
for admission contained the term cancer, neoplasm, leukemia, lymphoma, malignancy and/or 
tumor or if one of the APACHE II  fields metastasized neoplasm or hematological malignancy 
was chosen as co-morbid condition within the six months prior to ICU admission.
Statistical analysis
Categorical variables are presented as percentages and continuous variables are presented 
as mean and standard deviation (SD), or in case of non-normally distributed variables as me-
dian and interquartile range (IQR). We used χ2 tests for comparisons of categorical variables, 
independent t test to assess differences for normally distributed continuous variables, and the 
Mann-Whitney U-test to assess differences for non-normally distributed continuous variables. 
Standardized mortality ratios (SMRs) were calculated by dividing the actual in-hospital mortal-
ity by the expected mortality as calculated by the APACHE IV prognostic model. Multivariate 
logistic regression analyses were performed to assess the associations between the type of 
malignancy and in-hospital mortality. To adjust for severity of illness, the APACHE III severity of 
illness score (consisted of the APACHE III/IV acute physiology score (APS), age, and comorbid-
ities) was included in the model as covariate [10, 11]. We applied the APACHE IV inclusion cri-
teria to select patient data for the multivariate logistic regression analyses and the calculation 
of SMRs [10]. Results were considered statistically significant if p-values were below 0.05. All 
statistical analyses were performed using PASW statistics 18 (SPSS, Chicago).
results
Patients
251,748 patients were admitted to the participating ICUs during the study period (Figure 1).  Of 
these, 34,067 (13.5%) had a diagnosis of malignancy on admission to the ICU; 217,681 patients 
(86.5%) did not have such a diagnosis. In this overall cohort, most ICU admissions in patients with a 
malignancy were planned (54.2% versus 45.8% unplanned); for patients without cancer most ICU 
admissions were unplanned (68.0% versus 32.0% planned).  This difference was mainly caused by a 
large proportion of planned surgical procedures in cancer patients who most commonly had a very 
brief and uncomplicated stay on the ICU (data not shown).  Since our primary objective was to ex-
amine the impact of cancer on the outcome of non-elective  ICU admissions, our analysis focused 
on this subgroup. For this analysis 15,211 unplanned patients with a malignancy  and 124,943 un-
planned patients without a malignancy  were available (Figure 1 and Table 1). Most unplanned ICU 
admissions amongst patients with cancer were for a surgical indication (59.3%), whereas most un-
planned ICU admissions in non-cancer patients were for a medical reason (67.0%). Of the 15,211 
unplanned patients with a malignancy, 14,087 satisfied the APACHE IV inclusion criteria and were 
included in the multivariate logistic regression analyses and for the calculation of SMRs.
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Table 1 shows patient characteristics, comorbidities and severity of illness scores of all patients 
with unplanned ICU admissions, stratified according to the presence or absence of cancer  and 
the indication for admission (medical versus surgical). Medical cancer patients  had a higher 
incidence of confirmed infection, pneumonia and sepsis when compared with medical patients 
without cancer. Infections (including pneumonia and sepsis) were less common in surgical pa-
tients in general and differences (albeit statistically significant) between cancer and non-cancer 
patients were modest at best. As expected, immunodeficiency was far more common amongst 
the medical cancer patients. In addition, the proportion of medical cancer patients with acute 
renal failure and need for vasopressors and mechanical ventilation was higher than in medical 
patients without a malignancy. With regard to chronic comorbidity differences between cancer 
and non-cancer patients were modest, with the former group harboring fewer patients with 
heart failure. In accordance with the observed differences in acute comorbidity, cancer pa-
tients had much higher APACHE IV scores than patients without cancer, especially those with 
a medical indication for ICU admission. Medical, but not surgical, cancer patients had a longer 
length of stay on the ICU than the corresponding patients without cancer.
Mortality  
Figure 2 shows mortality rates stratified according to distinct patient subgroups. ICU and 
in-hospital mortality were almost twice as high in unplanned medical cancer patients as in 
medical patients without cancer (ICU mortality 30.4% vs. 16.2% respectively; in-hospital mor-
tality 44.6% vs. 23.7% respectively; both p < 0.001). In contrast, ICU mortality in unplanned 
surgical cancer patients and unplanned surgical non-cancer patients was similar (9.0% vs. 8.9% 
respectively; p = 0.8); in-hospital mortality was higher in surgical cancer patients than in surgi-
cal non-cancer patients (17.4% vs. 14.6% respectively; p < 0.001). 
total cohort: 251,748
• Cancer : 34,067 (13.5%)
• Non-cancer 217,681 (86.5%)
Cancer patients: 34,067
• Planned : 18,475 (54,2%)
• Unplanned: 15,211 (44.6%)
• Admission type missing: 381 (1.2%)
unplanned medical  
cancer patients
N = 6,189 (40.7%)
unplanned medical 
non-cancer patients
N = 83,741 (67.0%)
unplanned surgical 
cancer patients
N = 9,022 (59.3%)
unplanned surgical 
non-cancer patients
N = 41,202 (33.0%)
Non-cancer patients: 217,681
• Planned : 69,607 (32.0%)
• Unplanned: 124,943 (57.4%)
• Admission type missing: 23,131 (10.6%)
Figure 1: Overview and selection of patients admitted to the participating ICUs from
January 2007 until January 2011
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Severity of illness and outcome in cancer patients
The NICE registry collects information about the primary cancer diagnosis only when cancer 
is one of the main reason for admission to the ICU; in other cases malignancy is scored as he-
matological malignancy or neoplasm/metastasized carcinoma without further specification. 
Table 2 shows diagnoses of cancer patients with unplanned ICU admissions. For the majority 
of medical cancer patients malignancy was not the main reason for ICU admission (71.8%). In 
medical patients for whom cancer was the primary reason for admission, the most common di-
agnoses included respiratory tract carcinoma (7.5%) and hematological malignancy (leukemia 
5.6%; lymphoma 4.9%); in this subgroup of medical cancer patients confirmed infection was 
frequently present in especially patients with hematological malignancy and lower gastrointes-
tinal carcinoma (32.4 – 40.5%)(Table 3). Mortality was high across all diagnoses, especially so 
in patients with hematological malignancy and respiratory tract carcinoma (hospital mortality 
48.5 – 53.2%). In general, the APACHE IV model adequately predicted mortality in medical 
cancer patients with cancer as main reason for ICU admission, as reflected by SMRs approach-
ing 1.00.  In contrast to medical cancer patients, the majority of surgical cancer patients had 
cancer as main indication for ICU admission (75.8%), the most common being lower gastroin-
testinal carcinoma (32.2%)(Table 3). Patients with lower gastrointestinal carcinoma displayed 
ICU and in-hospital mortalities of 7.6% and 16.2% respectively; ICU and in-hospital mortalities 
amongst surgical patients with upper gastrointestinal carcinoma were also relatively high (8.2% 
and 15.7% respectively)(Table 4). Mortality rates amongst surgical patients with other cancer 
diagnoses were much lower. Notably, mortality was lower than predicted by the APACHE IV 
model in most subgroups of surgical cancer patients.
figure 2: iCu and hospital mortality rates in unplanned cancer versus non-cancer 
population for medical and surgical patient groups
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Adjusted effect estimates of type of malignancy on in-hospital mortality
We performed multivariate logistic regression analyses to assess the associations between the 
type of malignancy and in-hospital mortality (Table 5). In unplanned medical cancer patients 
admission for respiratory tract cancer (adjusted odds ratio 2.15), upper gastrointestinal cancer 
(1.42) and leukemia (1.35) were associated with a higher risk for mortality.  Patients with he-
matological cancer as comorbidity had lower risk for  mortality. In unplanned surgical cancer 
patients adjusted risk was lower for patients admitted with respiratory tract cancer, urological 
cancer and female cancer whereas mortality risk was higher in patients with metastasized solid 
tumor as comorbidity.
discussion
We here report on the characteristics and outcome of more than 15,000 cancer patients with 
an unplanned emergency admission to general ICUs. Our main finding is that medical can-
cer patients have strongly increased hospital mortality (40.6%) when compared with medical 
non-cancer patients (23.7%), which is associated with a higher incidence of acute comorbidity 
and a greater severity of illness on admission in the former group. 
 The current study used data extracted from the Dutch National Intensive Care Evalua-
tion (NICE) database, collected during a four year period, to obtain insight in the epidemiology 
and outcome of cancer patients on general ICUs. Our study differs from several previous inves-
tigations that reported on prognostic factors for cancer patients on ICUs in that these mainly 
Table 2: Cancer diagnosis in the unplanned population in the NICE registry 







primairy cancer diagnosis 1 (%)
• Respiratory tract cancer 7.5 11.3 <0.001
• Leukemia 5.6 0.1 <0.001
• Lymphoma 4.9 0.2 <0.001
• Upper  gastrointestinal cancer 3.9 12.3 <0.001
• CNS malignancy 2.7 5.4 <0.001
• Lower gastrointestinal cancer 2.2 32.2 <0.001
• Urological tract cancer 1.0 10.2 <0.001
• Other 0.2 1.5 <0.001
• Female cancer 0.1 2.5 <0.001
underlying malignancy 2 (%) 71.8 24.2 <0.001
• Hematological malignancy 29.6 4.3 <0.001
• Metastasized solid tumor 42.2 19.8 <0.001
Total (%) 100 100
1 Patients admitted for a primary cancer diagnosis (APACHE IV).
2 Patients admitted for other reasons, but having an underlying malignancy
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involved specialized oncologic ICUs, making extrapolation to general ICUs cumbersome [5, 6, 
12]. Our investigation should be compared with two recent multicenter studies investigating 
the outcome of cancer patients in general ICUs [7, 8]. Taccone et al. used data collected during 
the Sepsis Occurrence in Acutely Ill Patients (SOAP) study, performed during two weeks in 198 
ICUs from 24 European countries, to assess the characteristics and outcome of 473 cancer 
patients in general ICUs [7]. Soares et al. prospectively enrolled 717 cancer patients in a two-
month observational study performed in 28 Brazilian ICUs [8]. Important differences between 
these studies and ours include the number of patients evaluated (140,154 of whom 15,211 
with a cancer diagnosis in the current investigation) and the period during which data were 
collected (four years). In addition, our study focused on unplanned emergency ICU admissions, 
considering that this type of admission represents a common dilemma for clinicians. Whereas 
Taccone et al. [7] did not discriminate between planned and unplanned admissions, Soares 
and colleagues [8] distinguished medical patients versus scheduled and emergency surgical pa-
tients. These two previous investigations together with the present study indicate that a cancer 
diagnosis on admission to a general ICU is far from seldom: in our overall cohort (comprising 
251,748 patients), 13.5% of patients admitted to the ICU had a diagnosis of malignancy versus 
15.0% in the SOAP cohort [7] and 21.5% in the Brazilian study [8]. The current investigation fur-
ther shows that amongst unplanned ICU admissions the proportion of cancer patients is lower 
(15,211 of 140,154 or 10.9%), which may reflect the reduced willingness of clinicians to admit 
cancer patients to the ICU in emergency situations. 
Table 5: Adjusted effect estimates of type of malignancy on in-hospital mortality for 
unplanned medical and surgical cancer patients
1 Adjusted for APACHE III severity of illness score. 
2 All patients satisfying the APACHE IV inclusion criteria.  
3 Patients admitted for a primary cancer diagnosis (APACHE IV).
4 Patients admitted for other reasons, but having an underlying malignancy. 






• Respiratory tract cancer 2.15 (1.75-2.64) 0.61 (0.45-0.82)
• Leukemia 1.35 (1.06-1.71) 0.41 (0.05-3.6)
• Lymphoma 0.89 (0.68-1.18) 1.29 (0.41-4.05)
• Upper gastrointestinal cancer 1.42 (1.05-1.92) 1.05 (0.854-1.30)
• CNS malignancy 0.78 (0.54-1.12) 0.70 (0.46-1.06)
• Lower gastrointestinal cancer 0.84 (0.60-1.19) 0.97 (0.85-1.12)
• Urological tract cancer 0.83 (0.49-1.42) 0.50 (0.37-0.67)
• Female cancer - 0.28 (0.14-0.56)
• Other 0.88 (0.18-4.34) 0.42 (0.18-0.95)
underlying malignancy4
• Hematological malignancy 0.78 (0.68-0.90) 1.30 (0.98-1.72)
• Metastasized solid tumor 0.91 (0.80-1.03) 1.77 (1.51-2.06)
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 Mortality rates especially differed between medical cancer and non-cancer patients, 
whereas differences between surgical cancer and non-cancer patients were either not existing 
(ICU mortality: 9.0 versus 8.9% respectively) or modest (hospital mortality: 17.4 versus 14.6% 
respectively). Medical cancer patients demonstrated almost doubled ICU and hospital mor-
tality rates (30.4 and 40.6% respectively) when compared with non-cancer medical patients 
(16.2 and 23.7% respectively). In the SOAP cohort ICU and hospital mortality amongst cancer 
patients were 20% and 27% respectively; of note, however, in this cohort 62.4% of cancer 
patients were admitted postoperatively [7].  In the Brazilian investigation by Soares et al, who 
unlike Taccone et al [7] did discriminate between planned and unplanned surgical ICU admis-
sions, ICU and hospital mortality for cancer patients admitted for unplanned surgery were 23 
and 37% respectively; medical cancer patients did much worse with ICU and hospital mortality 
of 44 and 58% respectively [8]. As such, the mortality rates reported in the current survey are 
much lower, which may be related to differences in selection for ICU admission and/or ICU 
care in Brazil and the Netherlands. Although stratification based on type of malignancy yielded 
relatively small subgroups, absolute numbers were sufficient to establish mortality rates in 
different cancer categories. This analysis showed that the prognosis of medical cancer patients 
admitted to the ICU is grim for all types of cancer. Multivariate analyses showed that amongst 
medical cancer patients with unplanned ICU admission  respiratory tract cancer, upper gastro-
intestinal cancer  or leukemia were associated with a higher mortality. 
 In the present analysis patients with a hematological malignancy demonstrated the 
highest ICU and hospital mortality rates: 42.8 and 53.2% respectively for patients with leu-
kemia as their primary diagnosis versus 37.2 and 48.5% respectively for patients with lym-
phoma. These mortality rates in hematological patients, although very high, are lower than 
reported earlier (60%-70%) [13, 14]. It appears that the prognosis of hematological patients 
has improved over the years. This is in agreement with a study by Azoulay et al. who found 
by multivariable analysis, that admission after 1996 (compared with admission between 1990 
and 1996) was associated with a better outcome in medical ICU-patients with cancer, mostly 
leukemia, lymphoma or myeloma patients [13]. 
 Lung cancer was the most frequent solid tumor in our cohort of unplanned ICU admis-
sions. In accordance, previous studies have documented that lung cancer is the most common 
solid tumor to require ICU admission, accounting for 16% of all cancer-related admissions [15]. 
As expected, mortality was much higher in medical patients with lung cancer than in surgical 
patients with this type of malignancy. [16]The ICU and hospital mortality of these patients was 
33.5 and 48.6% respectively, which is in the same order of magnitude as reported previously 
[17]. Notably, studies published over the most recent 15 years demonstrate a clear trend to-
ward improved survival of lung cancer patients admitted to the medical ICU [16].  
 While mortality is high for medical cancer patients, treatment cannot be considered 
futile based on cancer diagnosis alone. Even for patients with leukemia, the category with 
highest mortality in our study, the likelihood to survive up to the hospital discharge was almost 
50%. Different prognostic models have been developed to more precisely predict the outcome 
of critically ill patients based on diagnosis, comorbidity and severity of illness. These general 
prognostic models were reported to underestimate the risk of dying for cancer patients ad-
mitted to the ICU [18]. However, most investigations that addressed the usefulness of general 
prognostic models in cancer patients requiring ICU care are limited by relatively small sam-
ple sizes and restriction to specific patients groups and/or specialized oncologic ICUs [19, 20]. 
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Therefore, we here reported SMRs based on the APACHE IV model in our large cohort of cancer 
patients admitted to general ICUs. In contrast to earlier studies [18], we found lower mortality 
than predicted in most patient groups  
 In particular medical cancer patients presented with acute comorbid diseases more fre-
quently than medical non-cancer patients. Acute comorbidity, not the long-term prognosis 
of the underlying malignancy, has been implicated as an important factor in mortality after 
a critical illness in cancer patients [21, 22]. A high proportion of medical cancer patients had 
confirmed infection. In accordance, severe sepsis is a common complication in cancer patients; 
the incidence of severe sepsis is four times higher in cancer than in non-cancer patients [23] 
and approximately 15% of septic shock patients have cancer or a hematologic malignancy [24]. 
Previous investigations have further indicated that clinically documented infections represent 
a frequent cause for ICU admission in cancer patients [21, 25, 26]. In addition, acute renal fail-
ure was relatively common in medical cancer patients, confirming previous smaller studies [12, 
13].  
A limitation of our study is that the type of malignancy is only recorded when cancer is the 
main reason for admission to the ICU; otherwise malignancy is scored as hematological ma-
lignancy or neoplasm/metastasized carcinoma without further specification. In addition, our 
data set does not provide information of the stage of cancer or chemotherapeutic regimens 
used. This is caused by the fact that data collection within the NICE registry does not focus 
specifically on cancer patients. As such, prospective investigations on the outcome of patients 
suffering from specific types and/or stages of cancer and/or treated with common chemother-
apeutics remain of interest.  Lastly, follow up of our patients was limited to hospital discharge. 
We cannot exclude that some patients may have died soon after hospital discharge, e.g. after 
discharge to  a palliative care unit or hospice outside the medical institute with the ICU facility. 
This may lead to a too optimistic view on survival after ICU admission in cancer patients. 
 We here present the largest survey to date on the epidemiology and outcome of cancer 
patients on general ICUs. In a cohort of 140,154 critically ill patients with an unplanned ICU 
admission 10.9% had a diagnosis of a malignancy on admission. ICU and hospital mortality 
in medical cancer patients were almost twice as high as in medical patients without cancer, 
whereas differences in mortality amongst surgical cancer and non-cancer patients were mod-
est.  However even in patient groups with the highest mortality risk, survival up to hospital 
discharge was approximately 50%. These data indicate that the decision for unplanned ICU ad-
mission of cancer patients should take the different type of admission (medical versus surgical) 
on mortality risk into account.  In addition, prospective studies examining the impact of the 
type and stage of malignancy, as well as previous therapies (e.g. different chemotherapeutic 
regimens and radiation), on ICU outcome are warranted to assist the oncology and ICU staff in 
the decision whether or not to admit a cancer patient to the ICU.
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Abstract
Background: Postoperative care for major elective cancer surgery is frequently provided on the 
Intensive Care Unit (ICU). 
Objective: To analyze the characteristics and outcome of patients after ICU admission following 
elective surgery for different cancer diagnoses.  
Methods: We analyzed all ICU admissions following elective cancer surgery in the Netherlands 
collected in the National Intensive Care Evaluation registry between January 2007 and January 
2012.
results: 28,973 patients (9.0.% of all ICU admissions; 40% female) were admitted to the ICU 
after elective cancer surgery.  Of these admissions 77% were planned; in 23% of cases the 
decision for ICU admission was made during or directly after surgery. The most frequent malig-
nancies were colorectal cancer (25.6%), lung cancer (18.5%) and tumors of the central nervous 
system (14.3%).  Mechanical ventilation was necessary in 24.8% of all patients, most frequently 
after surgery for esophageal (62.5%) and head and neck cancer (50.2%); 20.7% of patients 
were treated with vasopressors in the acute postoperative phase, in particular after surgery for 
esophageal cancer (41.8%). The median length of stay on the ICU was 0.9 days (interquartile 
ranges [IQR] 0.8 – 1.5); surgery for esophageal cancer was associated with the longest ICU 
length of stay (median 2.0 days) with the largest variation (IQR 1.0 – 4.8 days). ICU mortality 
was 1.4%; surgery for gastrointestinal cancer was associated with the highest ICU mortality 
(colorectal cancer 2.2%, pancreatico-cholangiocarcimoma 2.0%). 
Conclusion: Elective cancer surgery represents a significant part of all ICU admissions, with a 
short length of stay and low mortality.  
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Introduction
Although more and more potentially curative cancer treatment-strategies are of multidisci-
plinary nature, surgical removal of the tumor is still a key component.  To achieve long term 
survival aggressive surgical procedures are not unusual, making direct postoperative manage-
ment a significant aspect of cancer treatment [1, 2]. A subgroup of cancer patients is admitted 
to the Intensive Care Unit (ICU) for direct postoperative care, which is related to the type of 
malignancy and the nature and extent of the surgical procedure. As cancer incidence is in-
creasing by age, also elderly patients are now subject to multimodality strategies with curative 
intent. These patients are more vulnerable to postoperative complications at least in part due 
to more comorbidity of cardiovascular, pulmonary and/or metabolic origin [3]. As such, there is 
a need to obtain insight into the incidence and extent of acute complications and into hospital 
outcomes after major elective cancer surgery requiring postoperative ICU care. 
 Although many studies have reported on postoperative morbidity and mortality in un-
selected patient populations [4-8], few previous investigations examined the specific charac-
teristics of cancer patients in the ICU after major elective surgery. In a large observational study 
evaluating the outcomes of 88,504 surgical patients admitted to the ICU in Austria during an 
11-year period, 9.8% were reported to have a malignant non-metastatic process as comorbid 
condition [8]. Of these, a total of 6,987 patients were admitted to the ICU after elective surgery. 
ICU and hospital mortality of all surgical patients were 7.6% and 11.8% respectively; logistic re-
gression analysis identified non-metastatic cancer as an independent risk factor for postopera-
tive hospital mortality (odds ratio 1.20), but this analysis did not discriminate between elective 
and emergency surgery or different types of surgical procedures [8].  Of importance, whereas 
postoperative mortality of elective cancer surgery has been the topic of many investigations, 
none specifically addressed postoperative care on the ICU in this patient group [9-15].  
 Considering the limited data on postoperative care of cancer patients in the ICU pub-
lished to date, we here sought to analyze  the characteristics and outcome of patients after 
ICU admission following elective cancer surgery.  For this we analyzed all ICU admissions in the 
Netherlands collected in the National Intensive Care Evaluation (NICE) registry [16] from Janu-
ary 2007 through January 2012 and extracted data from all elective surgical cancer patients. 
Patients and Methods
Patient data and selection
The database of the Dutch National Intensive Care Evaluation (NICE) registry was used in this 
observational study [16]. The participating ICUs provide information on all ICU admissions. For 
each ICU admission variables are collected that among others describe patient characteris-
tics, severity of illness and acute comorbidities during the first 24 hours of ICU admission, and 
the ICU and in-hospital mortality and length of stay. The data are encrypted such that all pa-
tient-identifying information are untraceable. Since 2007 the recorded variables were used to 
calculate probabilities of death for each patient using the Acute Physiology and Chronic Health 
Evaluation (APACHE) IV prognostic model [17]. Data for the current study were collected from 
all consecutive admissions to 80 ICUs between January 2007 and January 2012. Patients for 
the present analysis were identified as having been subjected to elective surgery and having an 
APACHE IV reason for admission containing the term cancer, neoplasm or malignancy. ICU ad-
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mission after surgery was recorded as planned (as a consequence of the nature and/or extent 
of the surgical procedure) or unplanned (following unanticipated perioperative complications). 
Ethics
The NICE initiative is officially registered according to the Dutch Personal Data Protection Act. 
The need for ethical committee approval is waived by the Central Committee on Research 
Involving Human Subjects, because the study was purely observational and because only anon-
ymous patient data were used. 
Netherlands  Cancer Registry
Data on the total number of cancer diagnoses in the Netherlands in 2007 to 2010 were ob-
tained from the Netherlands Cancer Registry [18]; patient numbers  were divided by 4 to ob-
tain average annual numbers. To relate these numbers to the number of patients admitted to 
Dutch ICUs after elective cancer surgery, total patient numbers registered within NICE in 2007 
to 2011 were divided by 5 to obtain average annual numbers and subsequently multiplied by 
1.25 (considering that approximately 80% of all ICU’s in the Netherlands participate in NICE). 
Statistical analysis
Categorical variables are presented as percentages and continuous variables are presented as 
mean and standard deviation (SD), or in case of non-normally distributed variables as median 
and interquartile range (IQR). Standardized mortality ratios (SMRs) were calculated by dividing 
the actual in-hospital mortality by the expected mortality as calculated by the APACHE IV prog-
nostic model. The SMR is a mortality outcome indicator wherein  a SMR above the 1 indicates 
that mortality is higher than expected based on case-mix and a SMR below the 1 indicates that 
mortality is lower than expected.  
 type of malignancy and outcome: to assess the associations between the type of ma-
lignancy and in-hospital mortality multivariate logistic regression analyses were performed. 
In order to adjust for underlying case-mix differences ,the APACHE IV severity of illness score 
(consisting of the APACHE IV acute physiology score (APS) and comorbidities), age, and gender 
were included in the model as covariates [17, 19]. The two continuous nonlinear covariates (i.e. 
age and APACHE IV score) were included in the model using natural cubic regression splines. 
Regression splines allow accurate estimation of a nonlinear relationship between a covariate 
and an outcome variable. By univariate analyses, the number of knots (degrees of freedom) 
per spline was defined using the likelihood ratio test comparing linear, quadratic, cubic and 
higher-order splines. The resulting spline transformation orders were subsequently used in the 
final regression analysis.
 trends in mortality: to assess the associations between the period of admission (in 
trimesters during the study period) and in-hospital mortality, again multivariate logistic re-
gression analyses were performed. In-hospital mortality was the dependent variable and the 
trimester of admission per year the independent variable. In order to adjust for underlying 
case-mix differences, the APACHE IV severity of illness score, age, and gender were included in 
the model as covariate [17, 19]. The two continuous nonlinear covariates were again modeled 
using natural cubic regression splines. 
 trends in length of stay: to assess the associations between the period of admission 
(in trimesters during the study period) and ICU length of stay, multivariate linear regression 
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analyses were performed. The ICU length of stay calculated as fractional days based on ICU 
admission date and time and ICU discharge date and time was the dependent variable and 
the trimester of admission per year the independent variable.  We used the natural logarithm 
of length of stay because the distribution of length of stay was skewed to the right towards 
the longest length of stay. In order to adjust for underlying case-mix differences, the APACHE 
IV severity of illness score, age, and gender were included in the model as covariate [17, 19]. 
The two continuous nonlinear covariates were again modeled using natural cubic regression 
splines. For trends analyses we included only those ICUs that participated during the entire 
study period, i.e. between 2007 and 2012.  
 According to the APACHE IV exclusion criteria, patients younger than 16 years, patients 
whose ICU stay was less than 4 hours, patients who were admitted from or discharged to 
another ICU, patients with burns and, except for hepatic and renal transplantation, patients 
admitted after transplant operations were excluded for the multivariate logistic regression 
analyses and the calculation of SMRs [17]. Results were considered statistically significant if 
p-values were below 0.05.  All statistical analyses were performed using PASW statistics 18 
(SPSS, Chicago) and R 2.13.0.
results
Patients
321,493 patients were admitted to the participating ICUs between January 2007 and January 
2012. Of these, 28,973 patients (9.0%) were admitted after a planned surgical procedure for 
cancer (Table 1).  Overall, 77% of ICU admissions after elective cancer surgery were planned 
before the start of surgery; in 23% of cases the decision for ICU admission was made during 
or directly after surgery. The most frequent operated malignancies were colorectal carcinoma, 
followed by lung carcinoma  and tumors of the central nervous system.  Patients admitted to 
the ICU after colorectal surgery were relatively old (median age 74 years), whereas patients 
operated for central nervous system tumors were relatively young (median age 57 years); pa-
tients admitted to the ICU for postoperative care for other types of cancer surgery were within 
the same age range (median age between 64 and 68 years). In all patient groups the most prev-
alent chronic comorbidities were diabetes and chronic obstructive pulmonary disease. Diabe-
tes was most prevalent in patients undergoing surgery for pancreatic and cholangiocarcinoma, 
whereas chronic obstructive pulmonary disease was most prevalent in patients admitted after 
surgery for lung carcinoma. Almost one tenth of patients were considered immune compro-
mised based on use of immune suppressive medication and/or receipt of chemotherapy or 
radiation therapy in the year before ICU admission. 
Acute postoperative morbidity and care
Table 2 lists acute postoperative events on the ICU in all patient groups. Almost one in four 
patients received mechanical ventilation postoperatively. Surgical procedures that required 
mechanical ventilation in the acute postoperative phase most frequently were operations for 
esophageal cancer and head and neck cancer. One of five patients was treated with vasopres-
sors in the acute postoperative phase, in particular patients after surgery for esophageal can-
cer. Cardiac dysrhythmia was the most frequent postoperative comorbidity. Infections were 
relatively rare; these were most prevalent in patients after surgery for gastrointestinal cancer. 
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Length of stay and mortality
Table 2 lists ICU and hospital lengths of stay and mortality in all patient groups. The median 
length of stay on the ICU for the entire patient group was 0.9 days; surgery for esophageal 
carcinoma was associated with the longest ICU length of stay (median 2.0 days) and with the 
largest variation. The median hospital length of stay was 12.0 days for all patients combined; 
patients stayed in the hospital longest after surgery for pancreatico-cholangiocarcinoma, head 
and neck cancer and bladder cancer. Patients whose ICU admission was not already planned at 
the start of surgery had a slightly longer ICU length of stay (0.94 days (IQR 0.79 – 1.98 days) vs. 
0.90 days (IQR 0.79 – 1.10 days) in planned patients) (P<0.01). For all patient groups combined 
ICU and hospital mortalities were 1.4% and 4.7% respectively. Surgery for gastrointestinal can-
cer was associated with the highest ICU and hospital mortality. In accordance, multivariate 
logistic regression analysis assessing the associations between the type of malignancy and 
in-hospital mortality showed that surgery for pancreatico-cholangiocarcinoma (OR 1.56) and 
colorectal carcinoma (OR 1.41) were associated with a significantly increased risk for mortality 
(Table 3). SMRs were < 1.0 for most types of cancer surgery (except for bladder cancer, head 
and neck cancer, and male cancer surgery), indicating a lower mortality than expected based 
on the APACHE IV prognostic model (Table 3). 
Trends in length of stay and mortality
We performed multivariate linear regression analysis to assess the associations between the 
period of admission (in trimesters) and ICU  length of stay; for this analysis we studied the 
main four surgical categories and only included the 46 ICUs that participated during the entire 
five-year study period.  ICU length of stay changed only modestly over time for all  patients 
undergoing cancer surgery combined and when divided in surgical procedures by organ system 
(data not shown). In contrast, hospital mortality showed a significant decrease in time (from 
5.7% in 2007 to 4.1% in 2011, P < 0.05; Figure 1).  When analyzed for different types of cancer 
surgery, only hospital mortality after surgery for gastrointestinal cancer (but not for lung or 
urinary tract cancer) demonstrated a significant decline in time (from 8.0% in 2007 to 5.2 % in 
2011, P < 0.05; Figure 1). 
Table 3: Mortality risk by type of cancer surgery (multivariate analysis)
 Odds ratio (SD)1
Colorectal cancer surgery 1.41 (1.23-1.60) *
Thoracotomy for lung cancer 0.82 (0.69-0.98) *
Central Nervous System surgery for neoplasm 0.86 (0.68-1.09)
Bladder cancer surgery 0.57 (0.44-0.74) *
Esophageal cancer surgery 1.14 (0.91-1.43)
Renal cancer surgery 0.61 (0.45-0.83) *
Pancreatic - Cholangio cancer surgery 1.60 (1.20-2.04) *
Head and Neck  cancer surgery 0.84 (0.56-1.26)
Female cancer surgery 0.60 (0.36-1.01)
Male cancer surgery 0.27 (0.14-0.53) *
Other types of cancer 1.24 (1.03-1.47) *
Odds ratio for mor-
tality risk by type of 
cancer surgery as 
compared with can-
cer patients with oth-
er types of surgery. 
Multivariate analysis 
including age, gender 
and APACHE IV score.
 *  P < 0.05. 1Standard 
Deviation
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Total number of cancer diagnoses in the Netherlands during study period
To obtain insight in the proportion of patients per cancer diagnosis admitted to the ICU after 
elective surgery, we analyzed data provided by the Netherlands Cancer Registry. Table 4 lists 
the total number of cancer diagnoses registered herein during the study period (2007-2010). 
Furthermore, Table 4 shows estimates of the proportion of patients diagnosed with cancer in 
the Netherlands that was admitted to the ICU after elective surgery, stratified according to the 
type of malignancy.
discussion
Background and main results
Knowledge of the specific characteristics of cancer patients in the ICU after major elective 
surgery is limited. As a consequence of advances in cancer treatment, ICU physicians can be 
expected to be confronted with increasing numbers of oncology patients directly following ag-
gressive surgical treatments. Surgical procedures for different malignancies vary considerably, 
each carrying their own specific risks during the acute postoperative care.  
 This study focused on the acute postoperative ICU care and morbidity after major elec-
tive cancer surgery. Our survey comprised 28,973 elective surgical cancer patients admitted to 
80 ICUs during a five-year period, providing information on acute morbidity, as well as ICU and 
hospital length of stay and mortality across distinct cancer diagnoses. These patients repre-
sented 9.0% of all ICU admissions (Table 1) and approximately 16% of all surgical and 22% of all 
elective surgical admissions (data not shown). Overall, ICU length of stay was short (median 0.9 
Table 4: Annual number of patients per cancer diagnosis and proportion admitted 
to the iCu
Average number of patients 
per year diagnosed with 
different types of cancer in 
the Netherlands between 
2007-2010 (ref. 18)
Patients admitted to the ICU 
for post-operative care per 
year (%)1
Colorectal Cancer 12,296 1,851 (15.1)
Lung Cancer 11,612 1,340 (11.5)
Central Nervous System Neoplasm 1,167 1,039 (89.0)
Bladder Cancer 3,208 565 (17.6)
Esophageal Cancer 2,403 504 (20.1)
Renal Cancer 2,079 337 (16.2)
Pancreatic - Cholangio Cancer 2,520 247 (9.8)
Head and Neck  Cancer 2,815 222 (7.9)
Female Cancer 4,362 148 (3.4)
Male Cancer 10,838 177 (1.6)
All types of cancer 91,428 7,243 (7.9)
1 Based on 80% of the ICU-beds participating in the NICE registry
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figure 1: hospital mortality 
and standardized mortali-
ty ratios per quartile from 
January 2007 to January 
2012 
Hospital mortality is shown as per-
centage of the total number of pa-
tients within that category (left X 
axis). Standardized mortality ratios 
(SMR) are shown as medians with 
95% confidence intervals (right X 
axis). Data are shown for all cancer 
patients undergoing elective sur-
gery and for patients operated for 
lung cancer, gastrointestinal cancer 
(colorectal, esophageal and pancre-
atico-cholangio cancer) or urinary 
tract cancer (renal and bladder can-
cer).  Hospital mortality and SMR’s 
amongst all cancer patients com-
bined showed significant decreases 
in time (P < 0.05); when analyzed 
for different types of cancer surgery, 
only hospital mortality and SMR’s 
after surgery for gastrointestinal 
cancer (but not for lung or urinary 
tract cancer) demonstrated signifi-
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days) with mechanical ventilation (one of four patients) and vasopressor use (one of five pa-
tients) as the most prevalent supportive measures. ICU and hospital mortality were 1.4% and 
4.7% respectively. During the study period hospital mortality showed a significant decrease in 
time from 5.7% in 2007 to 4.1% in 2011.
Previous studies reporting on cancer patients in the ICU
The current study used data from the Dutch National Intensive Care Evaluation (NICE) database 
to obtain insight in the epidemiology and short-term outcome of cancer patients admitted 
to general ICUs after elective cancer surgery. Although knowledge of long-term outcomes of 
cancer surgery is essential, awareness of the facts on the duration of ICU admission, comor-
bidity and mortality in the ICU after major elective operations for malignancies is important for 
optimal delivery of acute care and in light of the high costs of the use of ICU amenities. Most 
patients in this analysis left the ICU within a day, with patients operated for esophageal cancer 
as the only exception (median ICU length of stay 2 days with a large interindividual variation). 
Several earlier studies reported on the outcome of cancer patients in the ICU [20]. One inves-
tigation specifically addressed cancer patients admitted to the ICU after elective surgery; this 
study encompassed 381 patients who had a median length of stay on the ICU of 2 days and 
an ICU mortality of 6%  [1]. This relatively small study is difficult to compare with our current 
results since the type of surgery was not specified.  
Estimation of proportion of patients per cancer diagnosis admitted to ICU after elective surgery
One of four patients admitted to the ICU after elective cancer surgery was operated for col-
orectal carcinoma. This patient group had the highest ICU and hospital mortality (2.2% and 
8.0% respectively). Our investigation does not provide insight into how many patients were 
operated for colorectal carcinoma in total. Indeed, many patients are transferred to a general 
surgical ward after elective colorectal cancer surgery. Comparing data from the Netherlands 
Cancer Registry, which provides data on all new cancer diagnoses in the country [18], with the 
data from the NICE registry, we estimate that approximately 15% of all patients with colorectal 
carcinoma were admitted to the ICU after surgery (considering that approximately 80% of all 
ICU beds in the Netherlands are included in the NICE registry); the remaining 85% of patients 
was either not operated or received postoperative care outside the ICU.  Lung cancer was 
the second most prevalent diagnosis in our elective surgical ICU cohort; the ICU and hospital 
mortality of this group was relatively low (0.8% and 3.0% respectively). Based on data from the 
Netherlands Cancer Registry [18], we estimate [18]that 12% of all patients with this malignancy 
(irrespective of type of therapy) received ICU care after surgery. Along the same lines, the per-
centage of all patients diagnosed with a specific cancer that is admitted to the ICU after elec-
tive surgery can be estimated: esophageal cancer 21%, pancreatic-cholangiocarcinoma 12%, 
renal carcinoma 16%, bladder cancer 20%, male cancer 8%, female cancer 4%, head and neck 
cancer 80% and CNS tumors 89%. Altogether, these estimates demonstrate that many cancer 
patients receive postoperative ICU care and emphasize the importance of analyzing clinical 
outcome data of ICU admissions after cancer surgery. 
Limitations
Our study has several limitations. The present study specifically focused on the epidemiolo-
gy and short-term outcome of cancer patients admitted to general ICUs after elective cancer 
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surgery. Thus, this survey involves a selected population and does not provide information on 
in-hospital outcomes of cancer patients who were not admitted to the ICU postoperatively. Our 
study has several limitations. The present study specifically focused on the epidemiology and 
short-term outcome of cancer patients admitted to general ICUs after elective cancer surgery. 
The decision to electively admit these patients to the ICU is subjective. Major differences in the 
indications for post-operative ICU care after cancer surgery may exist between different hos-
pitals and may influence outcome. Follow up of our patients was limited to hospital discharge; 
we cannot exclude that some patients may have died soon after hospital discharge. Moreover, 
NICE does not contain data on the stage of cancer and/or details about previous cancer treat-
ments; this is caused by the fact that data collection within the NICE registry does not focus 
specifically on cancer patients. Finally, information about specific postoperative complications, 
such as thrombosis and bleeding, is not available. 
 
Hospital mortality
In our cohort of patients who required postoperative care in the ICU, hospital mortality was 
4.7%, a percentage that significantly decreased in time from 2007 to 2012.  For the majority of 
different types of cancer surgeries, hospital mortality rates were in the same range as published 
previously for patients subjected to elective surgery for cancer of the lung [21], esophagus [22, 
23], pancreas [24], female genital tract [25], bladder [26] and head and neck [27, 28]. In con-
trast, hospital mortality amongst patients with colorectal carcinoma was higher than  reported 
earlier for elective surgery in this group [9, 29, 30], which can be explained, at least in part, by 
the fact that patients selected for postoperative ICU care likely represent a high-risk subgroup. 
In addition, in a relatively high proportion of this group ICU admission was not planned prior to 
surgery (in 32% of cases), indicative of unanticipated perioperative complications. Moreover, 
the median age  was high (74 years) in our cohort of patients with colorectal carcinoma and 
postoperative mortality after colorectal surgery is known to increase with age [31]. 
Conclusion
This multicenter five-year observational study conducted in 80 general ICUs shows that the 
most frequent cancer types admitted to the ICU after elective surgery are colorectal carcinoma, 
lung carcinoma and head and neck carcinoma. The median length of stay in the ICU was less 
than one day for almost all cancers, while postoperative care for esophageal carcinoma typi-
cally is longer (median two days). In addition, overall ICU mortality was low in this patient pop-
ulation, with highest mortality (2.2%) found in patients operated for esophageal carcinoma. 
The present study is the first to report on acute care, morbidities and outcome of admissions 
to general ICUs after major elective cancer surgery, revealing that the vast majority of patients 
demonstrate a favorable outcome. 
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Abstract 
Background: Emergency presentation of colorectal carcinoma (CRC) is associated with a high 
morbidity and mortality, frequently requiring postoperative care on the intensive care unit 
(ICU). We here sought to determine whether CRC influences the short-term outcome of pa-
tients admitted to the ICU after emergency colorectal surgery. 
Methods: We compared CRC patients who were admitted to the ICU after emergency col-
orectal surgery with a defined group of patients undergoing acute surgery for other colorectal 
diseases. We used the National Intensive Care Evaluation registry to identify all patients with 
unplanned admission to the ICU after emergency colorectal surgery between January 2007 and 
August 2012 in the Netherlands.  
results: 11,495 patients were admitted to the ICU after emergency colorectal surgery, of whom 
13.7% had CRC. On ICU admission, CRC patients had a lower prevalence of confirmed infection 
(22.3%) than patients with non-malignant disease (41.0%). Patients with CRC had a shorter ICU 
length of stay (median 2.3 days) than patients without CRC (median 2.8 days). In addition, CRC 
patients had a lower ICU mortality (10.3 versus 12.9%). Hospital length of stay and mortality 
did not differ between groups. In a multivariate analysis in-hospital mortality was associated 
with high age, low body weight, high severity of illness at ICU admission, chronic comorbidities 
and metastasized carcinoma. CRC as reason for surgery, gender and organizational level of ICU 
were not associated with mortality. 
Conclusion: The diagnosis of CRC does not influence in-hospital mortality of patients admitted 
to the ICU after emergency colorectal surgery. 
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Introduction
Colorectal cancer (CRC) is a common disease worldwide. In the United States CRC is the third 
most frequently diagnosed cancer and the second leading cause of cancer-related death [1]. In 
the Netherlands CRC is the second most common malignancy with an incidence of more than 
57 per 100,000 population per year [2]. A subset of patients with CRC require acute surgery, 
e.g. after intestinal obstruction and/or perforation; the proportion of CRC patients with an 
acute presentation varied between 8-25% in different studies [3-6]. Acute presentation of CRC 
is associated with higher postoperative morbidity and mortality [5-9]. As a consequence, unlike 
after elective CRC operations, postoperative care after emergency CRC surgery is frequently 
provided on Intensive Care Units (ICUs). 
 We recently used the National Intensive Care Evaluation (NICE) registry, which prospec-
tively collects data from all ICU admissions in 80 Dutch ICUs [10], to study the outcome of un-
planned ICU admissions of 15,211 cancer patients in these ICUs during a four-year period [11]. 
In unplanned non-surgical cancer patients both ICU mortality and in-hospital mortality were 
almost twice as high as in unplanned non-surgical patients without cancer. In contrast, ICU 
mortality did not differ between unplanned surgical cancer patients and unplanned surgical 
non-cancer patients (9.0% and 8.9% respectively). In-hospital mortality was slightly higher in 
unplanned surgical cancer patients (17.4% and 14.6% respectively). This previous investigation 
did not stratify patients according to type of cancer or type of surgery [11]. 
 Gender has been reported to influence treatments and outcome of patients with CRC 
[12]. Several studies have reported a longer survival of women after CRC resection when com-
pared to men [12-15]. On the other hand, females with CRC more often present with an emer-
gency, possibly because women undergo endoscopic screening less frequently than men [12, 
15]. A possible gender effect on postoperative survival after emergency CRC surgery has not 
been studied thus far. Notably, gender may impact on the occurrence of complications and the 
type of therapeutic interventions while on the ICU. Although overall ICU mortality does not 
seem to differ between sexes [16, 17], men are more likely to develop sepsis [17-19]. Addition-
ally, men are more likely to receive invasive therapeutic procedures while on the ICU [16, 20]. 
 Knowledge of the short-term outcome of patients admitted to the ICU after emergency 
CRC surgery and how this relates to the outcome of patients receiving postoperative ICU care 
after unforeseen colorectal surgery for reasons not related to cancer is limited. We here sought 
to determine whether CRC is an important factor in the short-term outcome of patients admit-
ted to the ICU after emergency colorectal surgery. Therefore, the specific aims of the present 
study were (1) to compare short-term outcomes of unplanned ICU admissions after emergency 
surgery for CRC with those in unplanned ICU admissions after emergency colorectal surgery for 
other reasons, and (2) to study factors that influence short-term outcomes in this acute CRC 
surgical population. For this we analyzed all ICU admissions in the Netherlands collected in the 
NICE registry from January 2007 through August 2012.
Methods
Ethics statement
The Dutch National Intensive Care Evaluation  (NICE) initiative is officially registered according 
to the Dutch Personal Data Protection Act. The need for ethical committee approval is waived 
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by the Central Committee on Research Involving Human Subjects, because the study was pure-
ly observational and because only anonymous patient data were used. 
Patient data
The database of the NICE registry was used in this observational study [10]. In 1996 the NICE 
foundation started collecting data on patients admitted to Dutch ICUs. The participating ICUs 
(covering 80% of Dutch ICUs)  provide information on all ICU admissions with the aim to as-
sess and compare the performance of the ICUs and to improve the quality of care. For each 
ICU admission variables are collected that describe patient characteristics, severity of illness 
during the first 24 hours of ICU admission, and the ICU and in-hospital mortality and length 
of stay [10]. The data are encrypted such that all patient-identifying information, including 
name and patient identification number, are untraceable. The recorded variables are used to 
calculate probabilities of death for each patient using the Acute Physiology and Chronic Health 
Evaluation (APACHE) IV prognostic model [21]. Data for the current study were collected from 
all consecutive admissions to the 80 ICUs between January 1st 2007 and August 1st  2012. In the 
Netherlands, ICUs are categorized by organizational level 1, 2 or 3. Medical care is covered by 
certified intensivists for 24 hours per day, seven days per week in level 2 and 3 ICUs. The mini-
mal volume of care per year is 3000 treatment days in level 3 and 1500 treatment days in level 
2 ICUs. In level 1 ICUs, medical care is offered by intensivists at daytimes, while other medical 
specialists may be responsible at night and during weekends. 
Selection of patients
Patient selection was done according to Figure 1. Patients admitted to the ICU for emergency 
colorectal surgery were identified by selecting for (a) admission type (surgical and unplanned), 
(b) type of surgery (colorectal) and (c) indication (CRC or non-malignant disease, i.e. divertic-
ular disease, fistula or abscess, gastrointestinal obstruction, perforation or rupture, or peri-
tonitis). Patients with inflammatory bowel disease were excluded from the current analysis 
because they are likely to be younger and to use immune suppressive medication [22-24]; 
patients with gastrointestinal vascular ischemia were excluded because they are more likely 
to have significant comorbidities  and a grim prognosis if acute surgery is needed [25-28]. In 
addition, surgery for complications of previous surgical procedures were excluded. According 
to the APACHE IV exclusion criteria, patients younger than 16 years, patients whose ICU stay 
was less than 4 hours, patients who were admitted from or discharged to another ICU, patients 
with burns and, patients admitted after transplant operations (except for hepatic and renal 
transplantation) were excluded from the multivariate logistic regression analyses [21].
 
Statistical analysis
Categorical variables are presented as percentages and continuous variables are presented as 
mean and standard deviation (SD), or in case of non-normally distributed variables as median 
and interquartile range (IQR). Standardized mortality ratios (SMRs) were calculated by dividing 
the actual in-hospital mortality by the expected mortality as calculated by the APACHE IV prog-
nostic model.  The chi-squared test was used to compare categorical data, and the student’s 
T test (for normally distributed variable) or Mann-Whitney U-test (non-normally distributed 
variables) were used for other variables when comparing two groups.
 Type of colorectal surgery and outcome: to assess the associations between the type 
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of colorectal surgery, i.e. cancer vs. non-cancer, and in-hospital mortality multivariate logistic 
regression analyses were performed. In order to adjust for underlying case-mix differences ,the 
APACHE IV severity of illness score (consisting of the APACHE IV acute physiology score (APS) 
and comorbidities), gender, age (dichotomized as below or above 70 years), level of ICU, BMI 
(i.e. categorized as normal range, underweight and overweight), chronic comorbidities (i.e. 
Figure 1: Patient selection
Data were collected from all consecutive admission to 80 ICUs between January 1st 2007 and August 1st 2012. 
1  Excluded because ICU admission was done for logistical reasons (NICE registry definition: admission could have 
been postponed for 12 hours). 
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COPD, Heart failure, neurologic disorder, neoplasm, and hematological malignancy), and acute 
comorbidities (i.e. confirmed infection, mechanical ventilation, vasopressors, and acute renal 
failure)  were included in the model as covariates [21, 29]. 
 Results were considered statistically significant if p-values were below 0.05.  All statisti-
cal analyses were performed using PASW statistics 19 (SPSS, Chicago).
results
Patients
From January 2007 to August 2012, 11,495 patients were admitted to the participating ICUs 
after unplanned colorectal surgery (Figure 1, Table 1a).  Of these, 1,575 (13.7%) had a diag-
Table 1a: Patients admitted in the ICU after emergency colorectal surgery
Colorectal Cancer surgery 
1,575 (13.7%)





Interquartile Ranges 65-81 59-79 <0.001
<70 y (%) 37.6 46.3 <0.001
≥70 y (%) 62.4 53.7 <0.001
Mean BMI (SD) 25.6 (8.3) 25.6 (6.1) 0.862
Underweight (BMI <18.5) (%) 4.3 5.4
Normal range (BMI 18.5-25.0) (%) 47.6 47.7
Overweight (≥25.00) (%) 48.1 46.9
Chronic comorbidity (%)
Chronic renal failure1 4.1 7.2 <0.001
COPD 10.9 10.5 0.456
Heart failure 4.3 3.6 0.088
Diabetes 14.2 12.5 0.031
Neurologic disorder2 1.5 1.4 0.655
Cirrhosis 0.26 1.2 <0.001
Metastasized neoplasm 28.7 8.6 <0.001
Hematological malignancy 1.2 1.7 0.085
level of iCu3 (%) <0.001
level 1 35.8 26.8
level2 48.6 50.4
level3 14.5 21.8
admission source4 (%) <0.001
Same Hospital 91.7 84.0
Other hospital 6.8 14.3
CRC = Colorectal cancer,  `1 Includes chronic dialysis, 2 Includes previous cerebrovascular accident,
3 Level one being lowest level and level three the highest level of ICU in the Netherlands, 4 Rest is missing.
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nosis of CRC. Patients with CRC were older (median age 74 years) than patients admitted for 
unplanned colorectal surgery for non-malignant disease (median age 71 years) (p<0.001) and 
there were slightly more men in the former group (51.4% and 49.9% respectively, Table 1b). 
With regard to chronic comorbidity, differences between both patient groups were modest, 
with the CRC group harboring more patients with diabetes and fewer patients with chronic 
renal failure and cirrhosis. Of patients with CRC 28.7% had metastasized disease; notably, 8.6% 
of the unplanned colorectal surgical patients without CRC had a metastasized malignancy from 
another (not colorectal) origin. Patients with benign colorectal disease were more often admit-
ted to the ICU from another hospital (14.3% versus 6.8% of patients with CRC, p<0.001). Both 
patient groups were predominantly admitted to a level 2 ICU; however, patients with benign 
colorectal disease more often were admitted to a level 3 ICU when compared with patients 
with CRC.     
Acute comorbidity and admission laboratory results
Clear differences existed between patient groups with regard to acute comorbidity (Table 2a). 
Patients undergoing emergency surgery for other reasons than CRC  had a higher prevalence 
of confirmed infection and sepsis (both p<0.001 versus CRC patients), more frequently had 
acute renal failure (p<0.001), and more often required mechanical ventilation (p<0.001) and 
vasopressors (p=0.007). APACHE IV scores were similar in both patient-groups (Table 2a).  With 
regard to laboratory results on the first day after admission, differences between groups were 
Figure 2: ICU and hospital length of stay for unplanned CRC patients admitted to 
the ICU for emergency colorectal surgery stratified according the age (< 70 and > 70 
years) and gender
Data are expressed as box-and-whisker diagrams depicting the smallest observation, lower quartile, median, 
upper quartile and largest observation.  
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modest at best and clinically not relevant (Table 2a). In accordance with the higher prevalence 
of acute renal failure in patients undergoing emergency surgery for other reasons than CRC, 
peak plasma creatinin levels were higher in this group than in patients with CRC (Table 2a, 
p<0.001).
Length of stay and mortality
Patients with CRC had a shorter length of stay on the ICU (median 2.1 days) than patients with 
benign colorectal disease (median 2.8 days)( p<0.001), while hospital length of stay did not 
Table 1b: Patients admitted in the ICU after emergency colorectal surgery  separated 
by gender
1 Includes chronic dialysis, 2 Includes previous cerebrovascular accident, 3 Level one being lowest level and level 
three the highest level of ICU in the Netherlands, 4 Rest is missing.















Median 76 72 <0.001 74 69 <0.001
Interquartile Ranges 66-83 64-80 61-81 58-77
<70 y (%) 32.4 42.8 <0.001 40.4 52.2 <0.001
≥70 y (%) 67.6 57.2 <0.001 59.6 47.8 <0.001
Mean BMI (SD) 25.5 (6.7) 25.7 (9.7) 0.831 25.8 (6.5) 25.5 (5.6) 0.614
Underweight (BMI <18.5) (%) 6.3 2.5 6.7 4.1
Normal range (BMI 18.5-25.0) (%) 46.6 48.5 45.8 49.7
Overweight (≥25.00) (%) 47.1 49.0 47.5 46.2
Chronic comorbidity (%)
Chronic renal failure1 3.2 4.9 0.138 6.1 8.2 <0.001
COPD 9.2 12.5 0.035 10.0 11.0 0.001
Heart failure 3.5 5.1 0.139 3.4 3.8 0.171
Diabetes 13.5 14.9 0.428 13.7 11.3 <0.001
Neurologic disorder2 1.6 1.5 0.525 1.3 1.5 0.494
Cirrhosis 0.1 0.4 0.625 1.0 1.3 0.103
Metastasized neoplasm 28.8 28.6 1.000 7.8 9.4 0.002
Hematological malignancy 0.8 1.5 0.239 1.3 2.0 0.003
level of iCu3 (%) 0.066 0.010
level 1 35.8 35.7 28.4 25.1
level2 47.5 49.6 50.3 50.5
level3 16.3 13.3 20.5 23.2
admission source4 (%) 0.165 0.398
Same Hospital 91.4 92.0 84.3 83.7
Other hospital 7.6 6.0 13.8 14.7
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differ between patient groups (median 19 days, Table 2a). Similarly, patients with CRC  had a 
lower  ICU mortality (10.3% vs 12.9%, p=0.004), whereas in-hospital mortality was not differ-
ent between groups (22.5 and 21.7% respectively, p=0.523). Multivariate analysis showed that 
high APACHE IV score, high age, low body weight, COPD, chronic heart failure, metastasized 
carcinoma, hematologic malignancy, mechanical ventilation, treatment with vasopressors and 
acute renal insufficiency were all independently associated with in-hospital mortality (Table 
3). On the other hand, surgery for CRC and organizational level of the ICU were not associated 
with in-hospital mortality.
Influence of gender
To obtain insight into a possible influence of gender on the outcome of emergency colorectal 
surgery in cancer patients, we studied differences between males and females in this group 
and (as a reference) in the group of non-CRC unplanned surgery (Tables 1b, 2b). Severity of 
illness, age, body weight index and acute and chronic co-morbidities were comparable in male 
and female patients. In patients without cancer, but not in CRC patients, ICU mortality and 
in-hospital mortality were higher in female patients. In the multivariate analysis, gender was 
not associated with in-hospital mortality (Table 3). Considering that women were relatively 
older than men in both patient groups (Table 1b), we also determined ICU and hospital length 
of stay in men and women with CRC aged below or above 70 years admitted for unplanned col-
orectal surgery (Figure 2). Clearly, gender did not influence length of stay in either age cohort. 
Finally, we assessed the impact of gender on ICU and hospital mortality in CRC patients strati-
fied according to age (below or above the age of 70; Figure 3). This analysis showed that older 
Figure 3: ICU and hospital mortality of unplanned CRC patients admitted to the ICU 
for emergency colorectal surgery stratified according the age (< 70 and > 70 years) 
and gender
CRC = Colorectal cancer. Bars indicate hospital mortality (dark green) and ICU mortality (light green). Triangles 
indicate SMR  (standardized mortality ratio) with 95% confidence intervals. 
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patients of both genders had a significantly higher ICU and hospital mortality. Most notably, 
whereas ICU mortality was similar in men and women in both age cohorts, hospital mortality 
was lower in men aged below 70 years but higher above 70 years when compared to women 
within the respective age cohorts.   
discussion
To the best of our knowledge our study is the first to specifically address postoperative care 
and outcome of CRC patients who are admitted to the ICU after emergency colorectal surgery. 
Our survey comprised 1,575 CRC patients who received postoperative care in one of 80 partici-
Table 2a: Admission parameters, severity of illness and mortality for patients 
admitted in the ICU after emergency colorectal surgery
Colorectal Cancer surgery 
(1,575)




GI bleeding 1.7 1.2 0.098
Confirmed infections 22.3 41.0 <0.001
Pneumonia 1.4 1.2 0.333
Sepsis 9.2 19.6 <0.001
CPR 0.8 0.8 0.515
Cardiac dysrhythmia 8.2 8.4 0.437
Vasopressors 42.8 46.1 0.007
Immunodeficiency 4.7 8.2 <0.001
Mechanical ventilation 24hrs 51.8 61.3 <0.001
Acute renal failure 7.3 12.2 <0.001
Laboratory results day 1 (Median and IQR)
Hematocrit (lowest, liter/liter) 0.29 (0.25-0.34) 0.30 (0.25-0.34) 0.797
Leukocytes (highest x109/liter) 11.5 (11.9-17) 11.6 (7.4-17) 0.902
Leukocytes (lowest x109/liter) 8.2 (4-12.5) 8.4 (4.4-13.1) 0.003
Thrombocytes (lowest x109/liter) 230 (157-299) 204 (141-292) <0.001
Albumen (lowest gram/liter) 17 (12-22) 18 (12-23) 0.566
Creatinin (max, micromole/liter) 87 (66-126) 99 (70-152) <0.001
PaO2/FiO2 ratio 254 (186-337) 236 (168-320) <0.001
severity of illness and mortality
APACHE IV score (IQR) 70 (54-88) 69 (57-87) 0.616
ICU lengths of stay (IQR) 2.1(0.9-5.7) 2.8 (1.1-7.4) <0.001
Hospital length of stay (IQR) 19 (12-32) 19 (11-35) 0.359
ICU mortality (%) 10.3 12.9 0.004
Hospital mortality (%) 21.7 22.5 0.523
APACHE IV SMR (±95% CI) 0.69 (0.57-0.81) 0.91(0.81-1.01) <0.001
IQR = Interquartile ranges
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pating ICUs after unplanned surgery during a five-year and seven-month period, and who were 
compared with 9,920 patients who received postoperative care after unplanned colorectal sur-
gery for other reasons during the same period in the same ICUs. Our main findings are that 
CRC patients had fewer acute comorbidities, fewer infections, a shorter length of ICU stay and 
a lower ICU mortality, while hospital length of stay and mortality did not differ between groups. 
In accordance, in a multivariate analysis, low body weight, high age, chronic comorbidities and 
high severity of illness at ICU admission, but not CRC, gender or organizational level of ICU 
were associated with in-hospital mortality. 
 In spite of improved surgical techniques and perioperative care colorectal surgery re-
mains to account for the greatest share of adverse events in general surgical patients, con-
tributing a disproportionate part of morbidity, mortality and length of stay in this group [30]. 
Postoperative complication rates and mortality after CRC surgery are as high as 20-40% and 5% 
respectively [31-34]. Emergency surgery for CRC bears an even greater risk for postoperative 
complications and mortality. In a Dutch study, the risk of developing any postoperative com-
plication among colon cancer patients was significantly higher for those undergoing emergen-
cy surgery (odds ratio 3.6) [35]. Similarly, emergency surgery was identified as an important 
risk factor for mortality amongst CRC patients, bearing a 2.5-fold increased risk of death [34]. 
Moreover, in an investigation that examined > 30,000 colorectal resections in 142 US hospi-
tals mortality was 1.9% after nonemergency surgery versus 15.3% after emergency operations 
[36]. In accordance, in our cohort of patients after unplanned CRC surgery, we found high ICU 
mortality and in-hospital mortality of 10% and 22% respectively. Importantly, the high mortal-
ity was also found in patients after unplanned colorectal surgery for non-cancer diagnoses. 
 Our findings differ from a previous study comparing outcome of Dutch patients after 
unplanned ICU admission for cancer versus non-cancer reasons [11]. In that study medical can-
cer patients had a strongly increased hospital mortality (40.6%) when compared with medical 
non-cancer patients (23.7%); mortality was also higher in unplanned surgical patients with can-
cer compared with surgical patients without cancer (17.4% vs. 14.6%) [11]. This earlier study 
contained all types of cancer [11]. In the current analysis in patients with CRC only, the risk of 
mortality was not higher in patients with cancer as compared with patients with non-cancer 
reasons for colorectal surgery requiring ICU admission, such as treatment for diverticular dis-
ease, fistula, abscesses, gastrointestinal obstruction, perforation or rupture. Interestingly, ICU 
mortality was even lower in patients with CRC compared with patients after colorectal surgery 
for other reasons. This lower mortality may be explained by higher acute comorbidities, such 
as infections and renal failure, in patients admitted to the ICU after non-cancer surgery. 
Based on earlier studies, we hypothesized that gender could have an important influence on 
outcome after CRC surgery [12-15]. Also, gender has been shown to affect ICU care [16, 20, 37]. 
A large population-based study conducted in Canada demonstrated that older women with 
critical illness were less likely than critically ill men to be admitted to an ICU and were more 
likely to die in the ICU or hospital [20]. A prospective study involving 25,998 adult patients ad-
mitted to 31 ICUs in Austria also documented gender-related differences in ICU care, with male 
patients  - despite presenting with a lower severity of illness - more likely than female patients 
to receive a high level of care, as defined by the number of invasive procedures [16]. Although 
in this investigation women had a higher observed mortality rate than men, there was no dif-
ference in outcome after adjustment for the severity of illness [16]. Overall ICU mortality did 
not differ between sexes in another study [17]. In our current study gender did not impact on 
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Table 2b: Admission parameters, severity of illness and mortality for patients 
 admitted in the ICU after emergency colorectal surgery separated by gender
IQR = Interquartile ranges, l.o.s. = length of stay, SMR = standardized mortality ratio











GI bleeding 1.4 1.9 0.558 0.7 1.7 <0.001
Confirmed infections 23.0 21.7 0.546 41.1 41.0 0.439
Pneumonia 1.2 1.6 0.524 1.0 1.4 0.058
Sepsis 9.0 9.4 0.862 19.6 19.5 0.501
CPR 1.0 0.6 0.411 0.8 0.8 0.539
Cardiac dysrhythmia 8.0 8.4 0.783 8.2 8.5 0.301
Vasopressors 43.7 41.9 0.476 46.1 46.1 0.489
Immunodeficiency 4.1 5.3 0.284 8.0 8.4 0.240
Mechanical ventilation 
24hrs
51.2 52.3 0.687 61.0 61.5 0.297
Acute renal failure 7.1 7.4 0.846 11.9 12.5 0.179












































































severity of illness and mortality
APACHE IV score (IQR) 72 (58-88) 67 (56-83) 0.373 70 (55-89) 69 (53-86) 0.023






















ICU mortality (%) 10.8 9.8 0.507 14.4 11.4 <0.001
Hospital mortality (%) 22.1 21.3 0.706 24.5 20.4 <0.001
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ICU or hospital mortality after unplanned ICU admission following emergency CRC surgery. 
Our study has some limitations. We extracted data from the NICE registry, which collects data 
from all ICU admissions to 80 general ICUs in the Netherlands. NICE primarily monitors the 
performance of ICUs and does not focus specifically on cancer patients. As a consequence 
thereof, the type of malignancy is only recorded when cancer is the main reason for admission 
to the ICU; otherwise malignancy is scored as hematological malignancy or metastasized carci-
noma without further specification. Hence, the current analysis involves patients of whom CRC 
was considered one of the maximal two recorded main admission diagnosis by the treating 
ICU physician. Our study is  also limited by the fact that we cannot evaluate the impact of the 
stage of CRC, which is a major denominator of one-year mortality after colorectal surgery [34], 
on immediate postoperative outcome, since this information is not collected in the NICE data 
base. In addition, our survey is limited in that patient follow up was restricted to hospital dis-
charge. Of note, however, the objective of our study was to evaluate the direct outcome of ICU 
postoperative care after emergency colorectal surgery (i.e. not the impact of emergency CRC 
surgery on cancer progression and outcome); hence, although we cannot exclude that some 
Table 3: Multivariate analysis for hospital mortality
Odds ratio (CI)
Colorectal Cancer admission 0.87 (0.73-1.03)
Male 1.08 (0.96-1.22)
Age ≥ 70 years 2.41 (2.11-2.74)
APACHE IV score 1.03 (1.02-1.04)
level of iCu
Level 1 1.00
Level 2 0.89 (0.75-1.05)
Level 3 1.05 (0.91-1.22)
BMi
Underweight (BMI <18.5) 1.36 (1.22-1.55)
Normal range (BMI 18.5-25.0) 1.00
Overweight (≥25.00) 0.84 (0.75-0.99)
Chronic comorbidities
COPD 1.52 (1.29-1.80)
Heart failure 1.74 (1.33-2.30)
Neurologic disorder 1.42 (0.91-2.15)
Metastasized neoplasm 1.94 (1.65-2.29)
Hematological  malignancy 1.67 (1.14-2.43)
Acute comorbidities
Confirmed infection 1.03 (0.93-1.18)
Mechanical ventilation 24hrs 1.39 (1.25-1.66)
Vasopressors 1.31 (1.15-1.50)
Acute renal failure 1.47 (1.25-1.73)
CI = 95% Confidence Interval
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patients died soon after hospital discharge, this limitation in follow up is unlikely to influence 
our results to an important extent.  Finally, a limitation of our study is that we only analyzed 
the outcome of patients after emergency colorectal surgery who received postoperative care 
on the ICU. Mortality may differ in patients after unplanned colorectal surgery for CRC or other 
types of colorectal surgery not requiring ICU admission. 
 We excluded patients with IBD or ischemic colitis from the reference group receiving 
postoperative care after emergency colorectal surgery for benign disease, since they differ 
considerably from CRC patients in various aspects. The proportion of IBD patients going to the 
ICU is low, many use immune suppressive therapy and the age-peak of incidence of IBD differs 
strongly from the average age of CRC patients [22-24]. Patients with ischemic colitis have signif-
icant comorbidities and are usually treated in a conservative way; if surgery is deemed neces-
sary the outcome is poor with postoperative mortality rates of 37-47%, which at least in part is 
caused by the underlying widespread vascular occlusive disease rather than by the extent and 
the complexity of the surgical procedure [25-28]. As such, patients undergoing emergency col-
orectal surgery for IBD or ischemic colitis are not suitable comparators for patients undergoing 
unforeseen colorectal surgery for CRC.  
 In conclusion, we here report that ICU and hospital mortality amongst CRC patients ad-
mitted to the ICU after emergency colorectal surgery for all causes is 10.3% and 21.7% respec-
tively.  While ICU mortality is slightly lower amongst CRC patients when compared to patients 
after emergency colorectal surgery for non-malignant disease, hospital mortality is similar in 
both groups. Factors associated with mortality include high age, low body weight, high severity 
of illness at ICU admission, chronic comorbidities and metastasized carcinoma.  In addition, we 
show that gender does not influence postoperative outcome after unplanned ICU admission 
for emergency colorectal surgery. While in the early 1980s the presence of a malignancy was 
considered a contraindication for admission to an ICU, the success of anti-cancer therapies has 
created a mind switch amongst clinicians with regard to the use of aggressive supportive ther-
apy in cancer patients [38, 39]. The current study adds to this growing evidence, showing that 
the diagnosis of CRC should not influence the decision whether or not to provide postoperative 
ICU care after emergency colorectal surgery.  
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Abstract 
Purpose: Cancer is associated with an increased risk to acquire bloodstream infection (BSIs). 
Most knowledge on pathogens and outcome of are derived from specialized cancer centres. 
We here sought to compare causative microorganisms in BSIs in patients with or without can-
cer in a 600-bed teaching community hospital. 
Methods: We analysed all positive blood cultures from adult patients between January 2005 
and January 2011.
Results: 4,918 episodes of BSI occurred in 2,891 patients, of whom 13.4% had a diagnosis of 
cancer (85.5% with a solid tumour). In both patient groups Gram-positive isolates were more 
prevalent (58.7 and 61.4% in patients with and without cancer respectively)  than Gram-nega-
tive isolates (31.8 and 32.3% respectively). Amongst Gram-positive organisms, coagulase neg-
ative staphylococci, Staphylococcus (S.) aureus and enterococci were most frequently isolated 
in both patient groups; in cancer patients twice as many BSIs were caused by Enterococcus (E.) 
faecalis and E. faecium. Amongst Gram-negative organisms, Escherichia (E.) coli was the most 
common isolate; in cancer patients twice as many BSIs were caused by Pseudomonas aerugi-
nosa and Enterobacter cloacae. Yeasts were grown from 3.0% of blood cultures from cancer 
patients versus 1.5% of cultures from non-cancer patients. Cancer patients had a 90-day mor-
tality of 35.8% following BSI versus 23.5% in patients without cancer. 
Conclusion: These data demonstrate distinct BSI pathogens and impaired outcomes in patients 
with cancer in the setting of a large community teaching hospital. 
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Introduction
Bloodstream infections (BSIs) represent a major cause of morbidity and mortality in cancer 
patients [1-3]. Cancer is associated with a strongly increased risk to acquire BSI [4-6]. In ac-
cordance, cancer is the most common comorbid condition in patients with sepsis, reported to 
be present in approximately 17% of cases [7, 8]. Cancer patients are more vulnerable to de-
velop invasive infection due to various reasons, including an often progressive catabolic state, 
ulcerating lesions in mucosal surfaces and immune suppression secondary to chemotherapy, 
radiation, immune modulating therapeutics and/or the malignancy itself [9]. Patients with 
neutropenia are particularly prone to develop BSI, with the highest risk for patients who have 
undergone bone marrow transplantation [3, 10-12]. BSIs not only cause considerable mortali-
ty, but also prolong hospital stay and increase patient care costs [13]. 
 Until the 80s, Gram-negative bacteria were the most common cause of BSIs in the west-
ern world. Since then, Gram-positive organisms have become increasingly frequent as caus-
ative agents of BSIs [5, 8, 14]. In addition, the proportion of Candida species among BSI isolates 
has increased in recent decades [5, 8]. In a large survey involving 2,340 cancer patients studied 
between 1995 and 2001 Gram-positive organisms accounted for 62% of all nosocomial BSIs 
in 1995 and for 76% in 2000, whereas Gram-negative organisms accounted for 22% and 14% 
of all BSIs for these years, respectively; the predominant pathogens were coagulase-negative 
staphylococci [12]. Other investigations have examined the causative agents implicated in BSIs 
in cancer patients in specialized cancer centres and/or specific cancer populations, such as 
patients with haematological malignancies, neutropenia and/or after bone marrow transplan-
tation [3, 15-18]. In the Netherlands most cancer patients are treated in community hospi-
tals. The primary objective of the current study was to obtain insight into the distribution of 
pathogens causing BSI in cancer patients (as compared with patient without malignancy) in the 
setting of a community teaching hospital. For this we analysed all positive blood culture results 
obtained in our institution from adult patients between January 2005 and January 2011.  We 
report blood culture isolates, resistance patterns, demographics , referring specialties, type of 
cancer, cancer treatments and outcome.
Materials and Methods
Patient and design
This study is a single centre retrospective analysis of all positive blood culture results obtained 
from adult patients (> 16 years of age) between January 2005 and January 2011 registered in 
a 600-bed community teaching hospital in the Netherlands (Reinier de Graaf Hospital, Delft). 
For this study, BSIs were diagnosed solely on the basis of at least one positive blood culture 
irrespective of the causative microorganism. Multiple positive blood cultures with the same 
microorganism in the same patient within a 24-hour time frame were considered as a sin-
gle positive blood culture. Positive blood cultures were identified in the hospital microbiolo-
gy information system (General Laboratory Information Management System, GLIMS®, MIPS 
Diagnostics Intelligence, Gent, Belgium). Identification numbers  of patients with a positive 
blood culture were linked with (a) the hospital patient registration system containing encoded 
“diagnosis and treatment combinations” (a nationwide coding and registration system for all 
patients entering a hospital, either as outpatient or inpatient, providing information about the 
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diagnosis and treatment specified by the attending physician), and (b) the hospital laboratory 
information system (GLIMS), containing data on routine laboratory tests. Laboratory test re-
sults were included in the analysis if obtained in the period from 24 hours before to 48 hours 
after the blood culture was taken. Information about  all-cause mortality, also after hospital 
discharge, was collected from the hospital information system. 
Blood cultures
Blood was routinely inoculated into two separate bottles for aerobic and anaerobic culture 
respectively (Becton-Dickinson, Breda, the Netherlands; 10 mL each). All cultures were pro-
cessed in a Bactec 9000-seriescontinuous monitoring system (Becton-Dickinson) and incubat-
ed until microbial growth was detected or for four days; incubation periods were longer in case 
of suspected endocarditis or infection with Legionella or yeasts. Isolates from positive bottles 
were mostly identified by standard methods using the Phoenix 100 system(Becton-Dickinson) 
or API-methodology (bioMérieux, Lyon, France). Antimicrobial susceptibility testing was done 
with a Phoenix Automated Microbiology System (BD Diagnostics, USA) or disk diffusion with 
breakpoint criteria according to Clinical and  Laboratory Standards Institute (CLSI)  guidelines.
Statistical analysis
Data are shown as medians with interquartile ranges unless indicated otherwise.  Differences 
between groups were analysed by Mann-Whitney U tests. Survival data were analysed by log-
rank (Mantel Cox) and Chi-square tests. A p value < 0.05 was considered statistically significant. 




In the six-year study period, 4,918 microorganisms were cultured from a total of 4,196 posi-
tive blood cultures in 2,891 patients (Table 1). Of these 386 patients (13.4%) had a diagnosis 
of cancer. The vast majority of cancer patients had a solid tumour (330 or 85.5%, versus 56 
or 14.5% with a hematologic malignancy, Table 2). When compared with patients without a 
malignancy, cancer patients were more frequently male (61.4% versus 51.8%); the age distri-
bution was similar between groups. The hospital locations where positive blood cultures were 
obtained differed considerably between cancer and non-cancer patients, although in both pa-
tient groups most cultures were  acquired in non-surgical departments (31.1% and 43.1% in 
cancer and non-cancer patients respectively, Table 1). The proportion of (positive) blood cul-
tures taken in the emergency room or non-surgical departments was higher in patients without 
cancer, whereas the  fraction of blood cultures drawn in the intensive care unit and surgical 
departments was higher in patients with cancer.
Pathogens
Table 3 shows blood culture isolates in patients with and without cancer. In both patient 
groups Gram-positive isolates were more prevalent (58.7 and 61.4% in patients with and with-
out cancer respectively)  than Gram-negative isolates (31.8 and 32.3% respectively). Amongst 
Gram-positive organisms, coagulase negative staphylococci Staphylococcus (S.) aureus and en-
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terococci were most frequently isolated in both patient groups. However, within the group of 
Gram-positive isolates differences existed between patients with and without malignancy: in 
cancer patients with positive blood cultures, Enterococcus (E.) faecalis and E. faecium were 
twice as common when compared with non-cancer patients, while patients without malig-
nancy had almost five times as many positive cultures for haemolytic streptococci. Amongst 
Gram-negative organisms, Escherichia (E.) coli was the most common isolate in both patient 
groups. Notably, Pseudomonas (P.) aeruginosa and Enterobacter (E.) cloacae were twice as 
common in patients with cancer whereas E. coli was cultured more frequently from patients 
without cancer. Yeasts were grown from 3.0% of positive blood cultures from cancer patients 
Table 1: Demographic characteristics of all patients with blood stream infections
Cancer non-cancer p
Number of patients (%) 386 (13.4) 2,505 (86.4) -
Number of positive cultures 765 4,153 -
Mean age in years  (IQR1) 69 (61-76) 70 (52-80) ns
Male (%) 237 (61.4) 1,299 (51.8) <0.01 
Number of CVC2 with positive cultures (%) 119 (30.8)  382 (15.2) <0.01
Location cultures were drawn (%)
Emergency Room 121 (15.8) 1,047 (25.2) <0.01 
Intensive Care Unit 100 (13.1) 257 (6.2) <0.01
Surgical departments3  168 (22.0) 500 (12.0) <0.01
Non-surgical departments4  238 (31.1) 1,789 (43.1) <0.01
Other 138 (18.0) 560 (13.5) <0.01
Laboratory results †, data are given as median (IQR1)
Data are given as median (IQR1) # #
Hemoglobin (mmol per liter) 286 6.2 (5.5-7.1) 1,579 7.0 (5.9-8.1) <0.01
White blood count (x 109 per liter) 278 11.4 (5.8-16.2) 1,575 12.2 (8.7-17.2) 0.02
Neutrophils (x 109 per liter) 205 10.0 (6.8-14.2) 1,357 9.9 (6.7-14.4) 0.90
Absolute neutrophil count < 1x109 per liter 196 9 (4.6%) 1,357 26 (1.9%) 0.03*
Thrombocytes (x 109 per liter) 270 200 (99-326) 1,520 209 (144-280) 0.40
Creatinin (micromole per liter) 273 85 (65-112) 1,487 100 (76-158) <0.01
Prothrombin Time (seconds) 126 16.0 (15.2-17.1) 614 16.3 (14.9-18.4) 0.40
C-Reactive Protein (milligram per liter) 238 143 (76-219) 1,379 128 (61-208) 0.20
Albumin (gram/liter) 212 22 (17-30) 1,180 27 (21-34) <0.01
Glucose (mmol/liter) 105 7.4 (6.1-8.6) 774 7.1 (6.0-8.9) 0.20
1 Interquartile range
2 Central Venous Catheter
3 Including department of surgery, gynecology, urology, ENT, and orthopedics
4 Including department of medicine, gastro-enterology, pulmonology, neurology, cardiology
# Number of samples tested
* By Chi-square
† Laboratory results drawn minus 24 hours or plus 48 hours after blood culture was taken
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versus 1.5% of cultures from non-cancer patients; this difference was caused by a higher incidence 
of Candida non-albicans species in cancer patients. In 502 patients who had a central venous cath-
eter (119 patients with cancer and 382 non-cancer patients), 919 pathogens were cultured (Table 
4); in patients with cancer, positive blood cultures more often yielded Gram-negative bacteria, in 
particular P.aeruginosa, while coagulase negative staphylococci were more common in non-cancer 
patients.  In Table 5 susceptibility patterns for the most relevant micro-organisms are enlisted. Only 
meropenem resistance of P.aeruginosa was higher in cancer patients. All other antimicrobial resis-
tance patterns did not significantly differ between  cancer and non-cancer patients.
Laboratory results
Laboratory results at the time of blood cultures are shown in Table 1. Cancer patients had 
lower haemoglobin  levels and white blood cell counts; Cancer patients also had lower plasma 
creatinin and albumin concentrations. C-reactive protein levels did not differ between groups. 
Blood culture isolates in neutropenic patients are shown in Table 6.
Table 2: Type of malignancy and treatment in cancer patients with positive blood 
cultures
1 Includes  acute and chronic leukemia
2 Includes tamoxifen, aromatase-inhibitors, LH-RH and anti-androgenic therapy
3 includes cystoscopy, hysteroscopy, colonoscopy, gastroscopy, and bronchoscopy.
type of cancer patients (%) 
n=386
Lung cancer 28 (7.3)
Colorectal cancer 74 (19.2)
Pancreaticobilliary cancer 63 (16.3)
Esophageal/Gastric cancer 35 (9.1)
Prostate cancer 23 (6.0)
Other urinary tract cancer 53 (13.7)
Breast cancer 31 (8.0)
Gyneacological cancer 11 (2.8)
Melanoma 3 (0.8)
Head and Neck cancer 3 (0.8)
CNS malignancy 3 (0.8)
Other 3 (0.8)
Leukemia1 24 (6.2)
Malignant lymphoma 32 (8.3)
type of treatment
Surgery 56 (14.5)
Radiation therapy 9 (2.3)
Chemotherapy 99 (25.6)
Hormonal Therapy2 10 (2.6)
Endoscopic procedures3 120 (31.1)
Other /no treatment 92 (23.8)
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Figure 1: Survival for cancer and non-cancer patients
Kaplan-Meier curves and proportion survivors of patients with or without cancer with bloodstream infection 
caused by any pathogen (upper panels), a Gram-positive micro-organism (middle panels) or a Gram-negative 
micro-organism (lower panels). Dotted lines represent patients with cancer, solid lines represent patients with-
out cancer. 
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Table 3: Blood culture isolates
Cancer non-cancer
 n=765 (%) n=4,153 (%) p
Gram-positive 449 (58.7) 2,551 (61.4) 0.17
Staphylococcus aureus 45 (5.9) 345 (8.3) 0.03
Coagulase negative Staphylococci1 212 (27.7) 1,217 (29.3) 0.30
Streptococcus pneumoniae 25 (3.3) 200 (4.8) 0.07
Hemolytic Streptococci (A,B,C,F,G) 5 (0.7) 135 (3.3) <0.01
Other Streptococcus species2 20 (2.6) 169 (4.1) 0.07
Enterococcus faecalis 59 (7.7) 196 (4.7) <0.01
Enterococcus faecium 33 (4.3) 82 (2.0) <0.01
Other Enterococcus species3 5 (0.7) 28 (0.7) 0.80
Other gram-positive organism4 45 (5.9) 179 (4.3) 0.07
Gram-negative 243 (31.8) 1,342 (32.3) 0.65
Escherichia coli 100 (13.1) 758 (18.3) <0.01
Pseudomonas aeruginosa 36 (4.7) 91 (2.2) <0.01
Haemophilus (para-)influenzae 1 (0.1) 17 (0.4) 0.40
Klebsiella pneumoniae 25 (3.3) 108 (2.6) 0.40
Other Klebsiella species5 15 (2.0) 50 (1.2) 0.10
Proteus6 7 (0.9) 89 (2.1) 0.03
Serratia7 11 (1.4) 34 (0.8) 0.10
Enterobacter cloacae 19 (2.5) 42 (1.0) <0.01
Other Enterobacter species8 3 (0.4) 15 (0.4) 0.80
Citrobacter9 9 (1.2) 26 (0.6) 0.20
Fermentative gram-negative rods10 10 (1.3) 21 (0.5) 0.02
Non- fermentative Gram-negative rods11 3 (0.4) 45 (1.1) 0.10
Other gram-negative organisms12 4 (0.5) 46 (1.1) 0.20
Anaerobes13 39 (5.1) 132 (3.2) 0.02
enteropathogens 3 (0.4) 28 (0.6) 0.60
Salmonella species14 3 (0.4) 26 (0.6) 0.60
Other enteropathogens15 2 (0)
yeast 23 (3.0) 63 (1.5) 0.03
Candida albicans 10 (1.3) 32 (0.8) 0.20
Other Candida and yeast species16 13 (1.7) 31 (0.7) 0.02
other micro-organism 5 (0.7) 11 (0.3) 0.20
Missing 3 (0.4) 26 (0.6) 0.60
1  Includes Staphylococcus epidermidis, haemolyticus, hominis, hyicus, lentus, lugdunensis, pasteuri,  saprophyt-
icus, schleiferi, simulans, warneri, xylosus, carnosus, cohnii, urealyticum, capitis. Dermacoccus nishinomly-
aensis, Micrococcus luteus, Stomatococcus mucilaginosus.
2  Includes Streptococcus mitis, bovis (1&2), sanguis, salivarius, mutans, oralis, parasanguinis, sobrinus, ves-
tibularis, acidominimus, anginosusm, constellatusm, cristatus, dysgalactiae, equisimillis, equinus, gallolyticus.
3  Includes Enterococcus casseliflavus, gallinarum, durans. 
4  Includes Difteroid rods, Bacillus cereus, circulans, Corynebacterium accolens, amycolatum, minitissimum, stri-
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atum, jeikeium, propinquum, Leuconostoc species, Propionibacterium acnes, Rothia mucilaginosa, Aerococcus, 
Lactococcus and unspecified Gram-positive bacteria.
5  Includes Klebsiella oxytoca, ozaenae.
6  Includes Proteus mirabilis, vulgaris.
7  Includes Serratia marcescens,liquefaciens, odorifera, plymuthica.
8 Includes Enterobacter aerogenes, sakazakii, hermannii.
9 Includes Citrobacter freundii, koseri, werkmanii, amalonaticus, braakii, farmer.
10  Includes Morganella morganii, Aeromonas caviae, hydrophila, sobria, Eubacterium aerofaciens, Hafnia alvei, 
Providencia rettgeri,stuartii, Raoultella terrigena.
11  Includes Acinetobacter baumannii, calcoaceticus-baumannii complex, lwoffii, haemolyticus. Alcaligenes fae-
calis, Chryseobacterium indologenes, meningosepticum, Metylobacterium mesophilicum, Rhizobium radio-
bacter, Stenotrophomonas maltophilia, Achromobacter xylosoxidans.
12  Includes Neisseria species, Moraxella catarrhalis, Listeria monocytogenes.
13  Includes Bacteroides fragilis,Clostridium paraputrificium, perfringens (welchii), septicum, tertium, Fusobacte-
rium necrophorum, nucleatum, Pasteurella multocida, Bifidobacterium species, Gemella morbillorum, -Pep-
to-streptococcus saccharolyticus, Prevotella loescheii, oralis.
14  Includes Salmonella group B, C, D, paratyphi A, typhi. Typhimurium
15  Shigella sonnei, Campylobacter jejuni.
16  Includes Candida  glabrata, intermedia, krusei, parapsilosis, tropicalis, and other types of yeast.
Table 4: Blood culture isolates in patients with a central venous catheter
Cancer non-cancer
 n=219 (%) n=700 (%) p
Gram-positive 156 (71.2) 564 (80.6) <0.01
Staphylococcus aureus 8 (3.7) 27 (3.9) 0.90
Coagulase negative Staphylococci 91 (41.6) 346 (49.4) 0.05
Streptococci 1 (0.5) 7 (1.0) 0.70
Enterococci 26 (11.9) 99 (14.1) 0.50
Other Gram-positive organisms 30 (13.7) 85 (12.1) 0.60
Gram-negative 48 (21.9) 98 (14.0) <0.01
Escherichia coli 3 (1.4) 8 (1.1) 0.90
Pseudomonas aeruginosa 16 (7.3) 22 (3.1) 0.01
Klebsiella 8 (3.7) 12 (1.7) 0.10
Proteus 2 (0.9) 7 (1.0) 0.80
Serratia 6 (2.7) 8 (1.1) 0.07
Enterobacter 3 (1.4) 11 (1.6) 0.90
Citrobacter 2 (0.9) 4 (0.6) 0.90
Other Gram-negative organisms 8 (3.7) 26 (3.7) 0.80
yeast 10 (4.6) 28 (4.0) 0.90
Candida albicans 5 (2.3) 17 (2.4) 0.90
Other yeast species 5 (2.3) 11 (1.6) 0.70
other micro-organisms 5 (2.3) 10 (1.4) 0.60
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Survival
To obtain insight into the impact of documented BSI on outcome we determined 30-, 60 and 
90-day all-cause mortality following blood culture positivity in both patient groups (Figure 1). 
Cancer patients with BSI had a significantly increased crude mortality when compared to pa-
tients without cancer. Differences between cancer and non-cancer patients were present in 
both Gram-positive and Gram-negative BSI, albeit to a larger extent in the latter group. 
Table 5: Antimicrobial resistance in cultured isolates in patients with cancer and 
non-cancer patients
Cancer patients Non-cancer patients
# Resistant (%) # Resistant (%) p
Staphylococcus aureus
oxacillin 45 0 (0) 345 5 (1.4) 0.90
erytromycin 33 3 (9.1) 233 34 (14.6) 0.60
vancomycin 37 0 (0) 315 1 (0.03) 0.20
Streptococcus pneumoniae
penicillin 24 0 (0) 190 4 (2.1) 0.90
erytromycin 24 2 (8.3) 184 22 (12.0) 0.90
Enterococcus faecalis
ampicillin 55 0 (0) 159 0 (0) -
vancomycin 55 1 (1.8) 177 4 (2.3) 0.70
Enterococcus faecium
ampicillin 27 19 (70.4) 76 59 (77.6) 0.60
vancomycin 27 0 (0) 79 7 (8.9) 0.20
Escherichia coli
ampicillin 95 46 703 302 0.40
ciprofloxacin 93 5 (5.4) 707 74 (10.5) 0.20
cefuroxim 94 8 (8.5) 692 44 (6.4) 0.60
ceftazidime 92 4 (4.3) 699 23 (3.3) 0.80
meropenem 63 0 (0) 557 0 (0) -
Klebsiella pneumoniae
ampicillin 23 22 (95.7) 103 101 (98.1) 0.90
ciprofloxacin 23 1 (4.3) 100 7 (7.0) 0.90
cefuroxim 23 2 (8.7) 99 8 (8.1) 0.70
ceftazidime 23 2 (8.7) 103 7 (6.8) 0.90
meropenem 15 0 (0) 98 0 (0) -
Pseudomonas aeruginosa
ciprofloxacin 30 6 (20) 81 5 (6.2) 0.07
ceftazidime 25 1 (4) 75 3 (4) 0.60
meropenem 24 5 (20.8) 70 0 (0) <0.01
# Number of samples tested
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discussion
Current knowledge of causative organisms in BSI in patients with cancer is predominantly 
derived from investigations performed in specialized cancer treatment centres. The primary 
objective of the current study was to obtain insight into the distribution of pathogens caus-
ing BSI in cancer patients (as compared with patient without malignancy) in the setting of a 
community teaching hospital. For this we analysed all positive blood culture results obtained 
in our institution from adult patients between January 2005 and January 2011. We found a 
predominance of Gram-positive isolates in both patients with and patients without cancer. 
Positive blood cultures in cancer patients were caused more often by enterococci, P. aerugi-
nosa, E. cloacae and yeasts when compared with non-cancer patients, while patients without 
malignancy had more positive blood cultures for haemolytic streptococci and E. coli.  Mortality 
rates were much higher in patients with cancer.  With the exception of meropenem resistance 
by P. aeruginosa  no difference in antimicrobial resistance patterns were found between bacte-
ria cultured in cancer and  non-cancer patients. The difference in meropenem resistance might 
be related to local transmission of a Pseudomonas strain in the oncology unit as has been de-
scribed in nosocomial outbreaks [19].  
 The current cohort of cancer patients with BSI predominantly consisted of patients with 
solid tumours (85.5%). As such, our result predominantly apply to this group of cancer patients. 
Previous studies have documented differences in causative BSI pathogens in patients with solid 
tumours and haematological malignancies, with a higher incidence of E. coli and Klebsiella spp. 
in the latter group [20]. 
 Our study comprised all BSI irrespective of place of acquisition or hospital location. We 
found a marked predominance of Gram-positive organisms in both patients with and without 
cancer (58.7 and 61.4% respectively). Similarly, in a cohort of 2,340 cancer patients with nos-






Gram-positive 4 (44.4) 16 (61.5)
Staphylococcus aureus 2 (7.7)
Coagulase negative Staphylococci 2 (22.2) 6 (23.1)
Streptococcus pneumoniae 5 (19.2)
Other Streptococci 1 (11.1) 3 (11.4)
Other Gram-positive organism 1 (11.1)
Gram-negative 5 (55.5) 10 (38.5)
Escherichia coli 3 (33.3) 5 (19.2)
Pseudomonas aeruginosa 1 (11.1) 1 (3.8)
Haemophilus (para-) influenzae 2 (7.7)
Proteus mirabilis 1 (3.8)
other micro-organisms 1 (11.1) 1 (3.8)
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ocomial BSI 61% of all episodes were caused by Gram-positive organisms [12]. The most fre-
quently isolated pathogens in our investigation were coagulase negative staphylococci, E. coli, 
S. aureus and enterococci, which resembles the data obtained from nosocomial blood cultured 
isolates in cancer patients in the United States [12]. Similarly, coagulase negative staphylococci, 
S. aureus and  E. coli were reported as most frequent BSI pathogens in various rank orders in 
patients with haematological malignancies or solid tumours [15, 21, 22]. The current results 
in addition show that among these common BSI pathogens, enterococci were more prevalent 
in cancer patients and E. coli in non-cancer patients. E. faecalis was more common than E. 
faecium in our study (7.7 and 4.3% of all isolates respectively), whereas in the United States 
nosocomial BSI were caused more often by E. faecium (5.2%) than E. faecalis (4.6%) [12]. Can-
cer has been implicated as a risk factor for BSI by a number of specific pathogens, including S. 
aureus [23], E. coli [24], K. pneumoniae [25] and P. aeruginosa [26]. However, we only found an 
increased incidence of P. aeruginosa in cancer patients, whereas S. aureus and K. pneumoniae 
were equally common in both patient groups and E. coli was more frequent in patients without 
cancer. Fungi accounted for 10% of BSI isolates in hospitalized cancer patients in the United 
States [12] versus only 3% in the current study, which at least partially can be explained by 
differences in the populations studied (i.e. restricted to nosocomial BSI in the earlier investiga-
tion) [12]. 
 In the subgroup of patients in whom neutrophil counts were measured, cancer patients 
had absolute neutropenia in < 5% of cases versus < 2% of non-cancer patients; this group was 
too small to adequately investigate the impact of neutropenia on BSI pathogens. Of note, how-
ever, in the largest study performed to date neutropenia only modestly influenced the distribu-
tion of specific causative organisms of BSI in cancer patients, with a slightly altered incidence of 
viridans group streptococci (increased) and E. faecium (reduced) in neutropenic patients; the 
incidence of the most common BSI pathogens was not influenced by the presence or absence 
of neutropenia [12].  Another smaller study conducted in a tertiary oncology care center with a 
mixed solid tumor and hematological malignancy population reported higher incidences of BSI 
caused by E. coli, Klebsiella spp. and P. aeruginosa in neutropenic patients [20]. 
 The impact of BSI on outcome was evaluated by determining 30-, 60- and 90-day mor-
tality; we considered assessment of mortality beyond this time point of less relevance because 
late deaths are less likely to be related to the BSI and more likely to cancer. Nonetheless, the 
extent to which the cancer itself, more so than the BSI per se, contributed to short-term mor-
tality cannot be deducted from our study. Cancer patients had a 90-day mortality of 35.8% 
following BSI caused by any pathogen versus 23.5% in patients without cancer. In the largest 
survey conducted to date, in hospital mortality following nosocomial BSI was 36% for neutro-
penic patients and 31% for patients without neutropenia [12]. Earlier investigations reported 
mortality rates of 20-25% of BSI in patients with solid tumours [1, 27, 28]. In accordance with 
the current results, in ICU patients with documented infection cancer was associated with a 
greater risk of hospital death [6]. Notably, in cancer patients we found a considerably higher 
90-day mortality after Gram-negative BSI (41.4%) than after Gram-positive BSI (31.2%); this 
difference in 90-day mortality after Gram-negative and Gram-positive BSI was not present in 
patients without cancer (22.3 and 23.8% respectively). 
 We evaluated several laboratory results obtained in the period from 24 hours before to 
48 hours after blood culture positivity. We specifically chose for this time window in order to 
obtain insight in the systemic response to BSI in both patient groups. Based on C-reactive pro-
99
B S I s  I n  pat I e n t S  w I t h  o r  w I t h o u t  c a n c e r
tein levels (inflammatory response), platelet counts and prothrombin time (both indicative of 
coagulopathy) cancer patients did not differ from non-cancer patients. Patients with malignan-
cy did show lower albumin concentrations, which could have been caused by either a stron-
ger acute phase response (albumin is a negative acute phase protein) or a worse pre-existing 
nutritional status; the latter explanation may be more likely considering the similar C-reactive 
protein levels in both patient groups. Cancer patients did not show more evidence of renal 
insufficiency during BSI; on the contrary, plasma creatinin concentrations were even higher in 
patients without cancer. 
 There are some important limitations in this study. First, our survey represents a de-
scriptive retrospective evaluation using laboratory and hospital information systems data; clin-
ical data and bloodstream isolates were not prospectively collected. Second, no information 
is available regarding the source of infection in patients with bacteremia. We can not exclude 
that differences exist in the source of infection between cancer and non-cancer patients. Such 
differences could also influence the likelihood of survival in these patients. Furthermore, posi-
tive blood cultures not necessarily imply the presence of blood stream infections but could also 
result from skin contaminants. In this respect, it is important that coagulase negative staphy-
lococci represented almost 30% of cultured isolates. The clinical significance of these isolates 
remain unknown. However, as the proportion of coagulase negative staphylococci among bac-
teria from positive blood cultures was similar we can conclude that the presence of cancer 
has no important influence on the likelihood of coagulase negative staphylococci as causative 
microorganism in BSIs.  In this study, positive blood cultures with the same bacteria were con-
sidered as distinct cultures if taken more than 24 hours apart. Consequently, the number of 
positive cultures as reported here may be an overestimation of the true incidence. However, 
this limitation applies equally for both cancer and non-cancer patients.  Therefore, we consider 
it unlikely, that this definition could have an important influence on the comparisons between 
cancer and non-cancer patients made in this study. Finally, a limitation of our retrospective 
study is that in only one third of patients peripheral blood neutrophil counts were determined 
within the time window of 24 hours before to 48 hours after the positive blood culture.
 In conclusion, we here report that in a large community teaching hospital in the Neth-
erlands Gram-positive organisms are the most common isolates from blood cultures in both 
cancer and non-cancer patients. Specific pathogens were more present in cancer patients, 
in particular enterococci, P. aeruginosa, E. cloacae and yeasts. Mortality rates after BSI were 
much higher in cancer patients than in patients without cancer with the greatest difference in 
BSI caused by Gram-negative bacteria. 
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Abstract 
Background: Port-A-Caths (PACs) represent an important component of the care of cancer pa-
tients, in particular for administration of chemotherapy. We here sought to analyse the longev-
ity and complications of PACs in cancer patients in a large community hospital.
Methods: We retrospectively analysed the indications, duration of use, complications and rea-
sons for removal of PACs in cancer patients treated in our centre from January 2005 to Decem-
ber 2010, and compared these with findings in patients who received a PAC in the same period 
for reasons not related to cancer. 
Results: During the study period 152 cancer patients received a total of 170 PACs; in the same 
period, 21 patients received a total of 35 PACs for reasons unrelated to cancer. The total anal-
ysis comprised 70.919 days of PAC use. Most cancer patients had a solid tumour (97%). PACs 
were removed because of a complication in 25 cases in cancer patients (14.7%) versus 15 cases 
in non-cancer patients (42.9%, P < 0.01). Culture proven infection was the reason for PAC re-
moval in 16 cases in cancer patients (23.5%) versus 8 cases in non-cancer patients (42.1%; P 
=ns). The total number of PAC associated infections was 20 in cancer patients (0.35 infections 
per 1,000 PAC days) versus 19 in non-cancer patients (1.43 infections per 1,000 PAC days; P 
<0.01). No PAC associated thrombosis was found. 
Conclusion: In clinical practice the use of PACs in cancer patients is safe with lower complica-
tion rates when compared with PAC use in patients without malignancy. 
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Introduction
Venous access is problematic for oncology patients receiving repeated courses of cytotoxic 
therapy. Totally implantable ports connected with a central venous catheter were first intro-
duced in 1982 and soon replaced subcutaneously tunnelled catheters such as Hickman, Gro-
shong and Broviac lines [1, 2]. These totally implantable venous access ports (TIVAPs), among 
which Port-A-Caths (PACs), now represent an important component of the regular care of 
cancer patients by providing a simple way of accessing the venous system for administration 
of chemotherapy, antibiotics, analgesics, blood products and fluids, and for the collection of 
blood. Although in general these devices are safe, their use can be associated with significant 
complications, most notably infection and thrombosis. 
 Previous studies have examined complication rates of PAC use in cancer patients  [3-
11]. Such knowledge is significant considering the importance of PACs for the clinical care of 
cancer patients and for guiding preventive measures. This in particular holds true for the main 
complications described in literature, infection and thrombosis. In the current study we ret-
rospectively analysed the indications, duration of use, complications and reasons for removal 
of PACs in patients with malignancies treated in our centre (a large community hospital in the 
Netherlands) from January 2005 to December 2010. In addition, we analysed the microbial 
causes of PAC associated infections in these patients and their impact on PAC use and removal. 
In order to obtain insight into complications that may relate to cancer specifically, we com-
pared findings in cancer patients with those in patients who received a PAC in the same period 
for reasons not related to cancer.
Materials and Methods
Patients
We performed a retrospective analysis of 173 adult patients (> 18 years of age)  who received 
a total of 205 PACs between January 2005 and December 2010 in the Reinier de Graaf Hospital 
in Delft, the Netherlands. The analysis was approved by the institutional medical ethics com-
mittee. 
Study design
Porth-A-Cath removals within two days after implantation were excluded since these were 
considered related to the surgical procedure. A single type of PAC was used (DeltecTM, Smiths 
Medical). The PACs were placed by surgeons from the Department of Vascular Surgery in the 
operation room under general or local anaesthesia using a standardized surgical technique. 
The access route was chosen according to the patient’s anatomy, preferably the right subclavi-
an or external jugular vein. Prophylactic antibiotics were not routinely administered. The PACs 
were accessed and cared for by trained nursing staff. Lock with heparin solution was done 
after every PAC access and every four weeks if the PAC was not in use. Patients did not receive 
routine anticoagulant therapy. PAC associated infection was defined as (1) a positive culture of 
blood obtained from either a peripheral vein or from the port and (2) clinical suspicion of PAC 
infection as reflected by local symptoms or absence of another infectious source [12]. For the 
analysis of PAC associated infections, multiple positive blood cultures with a single pathogen in 
one clinical episode were counted as one PAC associated infection with this pathogen [12]. The 
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occurrence of a PAC associated infection was defined as a complication; other non-infection re-
lated complications were analysed by studying reasons for PAC removal making use of patient 
hospital records. Diagnostic procedures were done as ordered by the physician; systematic 
venographies were not done. Minor complications such as local pain, skin irritation and/or 
transient inability to draw blood from the PAC were not analysed.  
Statistical analysis
Data are expressed as means, medians, interquartile range and ranges as indicated. Differences 
between cancer patients and non-cancer patients were analysed by Mann-Whitney U test, Chi 
square test or Log Rank test. A p value below 0.05 was considered to be statistically significant. 
results
Patients
From January 2005 to December 2010 152 patients with a malignancy received a total of 170 
PACs; in the same period, 21 patients received a total of 35 PACs for reasons unrelated to can-
cer (Table 1). In both groups, more women than men received a PAC (73.7% amongst cancer 
patients and 61.9% amongst non-cancer patients). The vast majority of patients with a malig-
nancy suffered from a solid tumour, with breast and colorectal cancer as the predominant diag-
noses (47.4% and 32.9% respectively). In non-cancer patients neuromuscular disease was the 
most frequent diagnosis (57.1%). The total analysis comprised 70,919 days of PAC use, of which 
57,642 days in cancer patients and 13,277 days in non-cancer patients. In cancer patients all 
PACs were used for administration of chemotherapy. In 14 cases (9.2%) it was also used for 
immunotherapy. In non-cancer patients 10 PACs (47.6%) were placed for immunotherapy and 
8 PACs (38.1%) for chronic treatment with dopamine for heart failure (table 1). 
Longevity of PACs
Table 2 shows the longevity and reasons for removal of the inserted PACs. Twenty percent of 
PACs in cancer patients were in use at the end of follow-up, compared with 31.4% in non-can-
cer patients (p=ns). Figure 1 is a Kaplan Meier plot showing that the average survival of the 
PACs was similar in cancer and non-cancer patients (mean time to removal 927 days vs. 899 
days, p=0.9 by log rank test). The percentage of PACs removed during the follow-up period was 
40% in cancer patients and 51.5% in non-cancer patients (p=ns). The mean number of days 
a PAC was in situ at the time of removal was 309 days and 500 days in cancer and non-can-
cer patients respectively, p=ns). In cancer patients, most PACs were removed because therapy 
was completed (63.2% vs. 15.8% in non-cancer patients, p<0.01). Twenty-five (14.7%) and 15 
(42.9%) of PACs were removed for complications (infectious or non-infectious) in cancer and 
non-cancer patients respectively (p<0.01).
PAC associated infections
PAC associated blood stream infection occurred in 25 of 173 patients (14.4%) (Table 3). Amongst 
cancer patients, 18 (11.8%) were diagnosed with PAC associated infection during the study 
period, versus 7 (33.3%) non-cancer patients (P = 0.02). The total number of PAC associated 
infections was 21 in cancer patients (0.36 infections per 1,000 PAC days) versus 18 in non-can-
cer patients (1.4 infections per 1,000 PAC days; P < 0.01 versus cancer patients); Of interest, 
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the median time that a PAC was in situ before a blood stream infection occurred was shorter 
in cancer patients than in non-cancer patients (100 versus 414 days respectively, P = 0.01). The 
cumulative proportion of PACs removed for an infectious complication is shown in figure 2. 
Causative organisms did not differ between cancer and non-cancer patients (Table 3). In both 
groups, gram-positive pathogens, in particular Staphylococcus aureus and coagulase negative 
staphylococci, were most prevalent (more than two thirds of all blood stream infections).
discussion
In the last decades, much attention has been given to the achievement of an adequate means 
of venous access in cancer patients that is suitable for long-term use, in particular for repeated 
administration of chemotherapy and blood draw for testing. Totally implantable venous access 
Table 1: Patient characteristics and indications for PAC placement
total Cancer patients Non-cancer patients
Number of PACs (%) 205 170 (82.9) 35 (17.1)
Number of patients (%) 173 152 (87.9) 21 (12.1)
Female (%) 125 (72.3) 112 (73.7) 13 (61.9)
Male (%) 48 (27.7)   40 (26.3)    8 (38.1)
Mean age (range) at 
time of PAC placement
51.8 (18-80)  51.7 (26-77) 53.5 (18-80)
Diagnosis (%)
Breast cancer 72 (47.4) Neuromuscular disease1 12 (57.1)
Colorectal cancer 50 (32.9) Congestive heart failure 8 (38.1)
Upper GI cancer 9 (5.9) CIVD2 1 (4.8)




- Chemotherapy 152 (100) -
- Immunotherapy3 14 (9.2) 10 (47.6)
- Analgesics - 2 (9.5)
- Dopamine - 8 (38.1)
- Biphosponate (APD) - 1 (4.8)
Mean (range) number of days in situ 
- Total 70,919 57,642 13,277
- Per PAC 346 (9 - 2,064) 339 (9 - 2,064) 379 (13 - 1,839)
1 Dystrophia (N=4), Chronic inflammatory demyelinating polyneuropathy (N=6) and multiple sclerosis (N=2). 
2 Common variable immunodeficiency. 
3  Refers to monoclonal antibodies: in cancer patients trastuzumb (Herceptin®, antibody directed against epider-
mal growth factor receptor-2) or bevacizumab (Avastin®, antibody directed against the vascular endothelial 
growth factor receptor), in non-cancer patients gammaglobuline (Gammagard®).
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ports, such as PACs are preferred to other approaches for many different reasons, including 
a reduced risk for infection and thrombosis, less visibility and fewer restrictions on daily ac-
tivity [13]. We here report on our experience with PACs in a large community hospital in the 
Netherlands during a six-year period (January 2005 – December 2010), comparing indications, 
duration of use, complications and reasons for removal in 170 cancer patients and 35 patients 
without malignancy, comprising more than 70,000 days (which is almost 200 patient years) of 
PAC use. 
 The complication rate of PACs in cancer patients in part depends on the type of malig-
nant disease (solid tumour or haematological malignancy) and neutrophil counts in peripheral 
blood [13]. In the current analysis the vast majority of oncology patients had solid tumours, in 
particular breast and colorectal cancer (table 1) and only three patients had leucocytopenia at 
the time of PAC associated infection (data not shown). Hence, our results predominantly apply 
to patients with solid tumours and normal leucocyte counts. The current study excluded early 
complications of PAC placements, such as pneumothorax, primary malposition and arterial 
Table 2: Number and reasons for PAC removal
1 p=ns for difference between patients with cancer and non-cancer patients
2  PAC infection is defined as positive culture from blood obtained from the port or a peripheral vein and clinically 
suspicion of PAC as defined by symptoms or ruling out other foci.
3  Defined as inability to infuse fluids into the PAC system, confirmed by administration of radiological contrast 
fluid into the Port.
4 For example nicking of the line, Port moved away into deeper (breast-) tissue, Port turned away.








Number of PACs in situ at closure of data 
collection (%)
45 (22.0) 34 (20.0) 11 (31.4)
Number of PACs removed (%) 86 (41.9) 68 (40.0) 18 (51.5)
Number of days in situ1
- Mean 353 312 500
- Median 224 215 247
- Range 6-2,064 6-2,064 24 -1,809
Number of patients with PAC removed 77 64 13
- Female 60 51 9
- Male 17 13 4
Reason for removal (% of total removed)
- Treatment completed 46 (53.5) 43 (63.2) 3 (15.8)
- PAC infection2 24 (27.9) 16 (23.5) 8 (42.1)
- Occlusion3 4 (4.7) 2 (3.0) 2 (10.5)
- Malfunction4 9 (10.5) 4 (5.9) 5 (26.3)
- Other5 3 (3.5) 3 (4.5) 0
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Cancer patients are in green, non-cancer patients in dotted line. P=0.03 by log rank test for difference between 
PACs in patients with cancer and PACs in other patients.
Figure 1: Cumulative proportion of Porth-A-Caths (PACs) removed for any reason
Figure 2: Proportion of Porth-a-Caths (PACs) removed for infectious complications
Cases were censored at death or end of follow-up. Cancer patients are in green, non-cancer patients in dotted 
line. P=ns by log rank test for difference between PACs in patients with cancer and PACs in other patients.
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perforation, since these are related to the surgical procedure. The overall rate of removal of 
PACs for infectious or non-infectious complications was lower in cancer patients compared 
with non-cancer patients. Furthermore, the risk that a PAC will be removed for infectious rea-
sons is lower in cancer patients than in non-cancer patients. Although a definitive explanation 
for this difference is lacking, it may be related to a higher experience amongst oncology nurses 
in the management of PACs and/or differences in underlying diseases. For example insufficient 
hygienic precautions, inadequate flushing of the system after the introduction of fluids or a too 
Table 3: Porth-a-Caths (PACs) of patients with blood stream infections (BSI) and 
causative organisms
1 One blood culture per episode (i.e. if four blood cultures were positive for a particular pathogen during the 
same infection, only one culture was counted). 
all paCs Cancer non-cancer p
Number of PACs inserted 205 170 35
Number of patients with PAC and BSI (%) 25 (14.4) 18 (11.8) 7 (33.3) 0.02
Number PACs with BSI (% of total) 30 (14.6) 18 (10.6) 12 (34.3) < 0.01
Number of episodes of positive blood cultures1 39 21 18 < 0.01
Number of different organism in these cultures 43 21 22
Number of days PAC in situ prior to positive 
blood culture
0.01
Median 167 100 414
IQR 55-553 36-234 125-902
Causative organisms 
Gram-positive 29 14 15 ns
- Staphylococcus aureus 10 5 5
- Coagulase negative staphylococci 16 7 9
- Enterococcus 1 - 1
- Streptococcus pneumoniae 1 1 -
- Other streptococci 1 1 -
Gram-negative 13 6 7 ns
- Escherichia coli 2 1 1
- Pseudomonas aeruginosa 2 - 2
- Klebsiella oxytoca 1 - 1
- Klebsiella pneumoniae 1 1 -
- Serratia marcescens 1 1 -
- Rhizobacteria 1 - 1
- Stenotrophomonas maltophilia 1 - 1
- Enterobacter 2 1 1
- Acinetobacter 1 1 -
- Aeromonas hydrophilia 1 1 -
yeasts 1 1 - -
Candida glabratum 1 1 -
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long interval between usages of the Port make the system at risk for irreversible complications. 
Insufficient dosing of positive pressure leading to narrowing the lumen of the catheter due to 
deposits of fibrin or other substances will eventually obstruct the PAC [6]. Different infection 
rates in cancer and non-cancer patients could have been caused by differences in susceptibility 
for infection due to the underlying disease. However, although the most important indication 
for PAC use in non-cancer patients was immunotherapy in the form of infusion of gammaglob-
ulin, this therapy was provided for neuromuscular disease in all but one patient (who had a 
common variable immunodeficiency). As such, infection rates in non-cancer patients are not 
biased due to a large number of patients with primary immunodeficiency. 
 Although PACs are associated with much fewer infectious complications than other ap-
proaches to obtain prolonged access to the venous circulation, infection remains an issue of 
concern [7, 13]. In clinical practice, the diagnosis of PAC associated infection can be made 
with or without bacteriological confirmation [14, 15]. In the present analysis we only included 
culture proven infection: PAC associated infection was defined as a positive culture of blood 
obtained from either a peripheral vein or the port and clinical suspicion of PAC infection as 
reflected by local symptoms or absence of another infectious source [12]. The incidence of 
PAC associated infection amongst cancer patients found here (11.8%) is within the same range 
as that reported in previous studies: positive blood cultures associated with PACs have been 
reported to occur in 2.4–16.0% of patients [3, 4, 11], representing a major cause of hospi-
tal-acquired bacteraemia and the most frequent reason for catheter removal [4, 16]. The vast 
majority of PAC associated infections were caused by coagulase negative staphylococci and 
Staphylococcus aureus, which is in accordance with earlier investigations [11, 13]. 
 There are no standard criteria for catheter removal in PACs [12, 13]. In the presence of 
uncomplicated infection due to coagulase-negative staphylococci, the PAC may be retained if 
there is no evidence of persisting or relapsing bacteraemia. For PAC associated infection caused 
by pathogens other than coagulase-negative staphylococci, some physicians would retain the 
port, partially depending on the patient’s clinical status. In our analysis, most PAC associated 
infections resulted in PAC removal in cancer patients (80% of cases), but not in patients without 
cancer (42%). This difference was not related to a clear difference in causative pathogens. It is 
conceivable that medical oncologists are reluctant to continue chemotherapy through a PAC 
that has been infected and that as a consequence thereof PAC associated infection more often 
leads to PAC removal in cancer patients.  
 The reported incidence of venous thrombosis as a PAC associated complication varies 
between zero and 10% [13]. In our centre, thrombosis was never the cause of PAC removal 
during the six-year study period. Notably, since most cases of catheter-related thrombosis are 
asymptomatic [13], this does not exclude that thrombosis did occur in our population. Data on 
prophylactic anti-coagulant therapy are not available for the studied population, but this is not 
a routine policy in our hospital.  
 Several earlier investigations examined the complication rate of PACs in a single centre 
setting. No device related deaths were observed and complications as infection and thrombo-
sis were rare for all type of patients [5, 9, 11] In a Dutch retrospective analysis encompassing 
a  period of 7,5 years (1992 – 1999) involving 38 PACs, the most prevalent complications were 
infection (two cases or 5.3%) and thrombosis (three cases or 7.9%) [5]. Although the number 
of PACs studied was relatively low, these data suggest that the incidence of PAC associated 
thrombosis may have decreased in more recent years, probably at least in part as a result of 
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better preventive care by the nursing staff.
 Our study has several limitations. Firstly, the study has a low sample size relative to the 
low incidence of PAC related problems, which in particular is true for  thrombosis.  Second-
ly, the study groups were not comparable with respect to baseline and prognostic variables, 
which may hamper appropriate comparisons. 
 The use of PACs is widely implemented in the clinical care of patients with cancer. These 
devices have a high acceptance among patients, nurses and doctors. The current analysis illus-
trates the low rate of complications associated with the use of PACs in the setting of a large 
community hospital in the Netherlands. 
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summary
The number of patients living with cancer has increased steadily and it has been estimated 
that close to two-thirds of patients with cancer are long term survivors [1, 2].  This information, 
paired with the fact that antineoplastic therapies have become more aggressive to accom-
plish this success, indicates that selective use of critical care for cancer patients not only is 
reasonable but also necessary. Certainly, the care for acute complications occurring in cancer 
patients has changed dramatically in recent decades,  not only for direct post-operative care 
following major cancer surgery, but also for cancer patients in need of organ function replace-
ment due to the manifestation of their malignancy or toxicity of the therapies provided. This 
thesis studies the epidemiology and outcome of critical illness associated with cancer and/or 
its treatment. Chapters 2-5 describe the proportion of cancer patients that requires admission 
to an Intensive Care Unit (ICU) during the course of their disease and their characteristics and 
outcome once in the ICU. Chapters 6 and 7 focus on infectious complications in cancer patients. 
 Chapter 2 sought to obtain insight into how many cancer patients, stratified according 
to cancer diagnosis, need ICU care during the course of their disease. This chapter describes a 
retrospective study in which we collected data from adult cancer patients registered between 
January 1 2006 and January 1 2011 in four hospitals in four major cities in the Netherlands. 
Patients were selected based on the hospital patient registration systems containing encoded 
“Diagnosis Treatment Combinations”,  a nationwide coding and registration system for all pa-
tients entering a hospital, providing information about the type of care, diagnosis and treat-
ment specified by the attending physician [3, 4]. To identify patients from this cohort who 
were admitted to an ICU during the study period, data were linked with the database of the 
Dutch National Intensive Care Evaluation (NICE) registry, which  contains information on all 
admissions to the ICUs of 84 hospitals in the country (i.e. approximately 90% of all ICUs in the 
Netherlands) [5]. Of 36,860 patients registered with at least one cancer diagnosis 6.4% was 
admitted to the ICU during the six-year study period. Surgery was the most common treatment 
associated with ICU admission: of all cancers treated solely or partially with surgery 11.8% 
resulted in ICU admission. The fraction of patients that received active treatment with curative 
intent for a solid tumor was much greater in the ICU group (42.2%) than in the non-ICU group 
(17.6%). Esophageal cancer most commonly lead to ICU admission (27.3% of patients with this 
diagnosis); patients with other types of gastrointestinal cancer, including colorectal (10.4%) 
and pancreatic and biliary cancer (9.4%) also were relatively frequently admitted to the ICU. 
Although in the general population of cancer patients women (54.0%) were more prevalent 
than men, the proportion of men that entered the ICU was twice as large when compared with 
women (9.3 versus 4.0%). Long term survival of cancer patients admitted to the ICU was much 
lower (median survival time 771 days) than in patients not admitted to the ICU (median surviv-
al time not reached). Nonetheless, long-term survival after ICU admission stratified according 
to cancer diagnosis was substantial. 
 In Chapters 3 to 5 the NICE registry was further used to study specific subgroups of 
cancer patients admitted to the ICU: while Chapter 3 focuses on cancer patients with unfore-
seen ICU admissions, Chapters 4 and 5 zoom in on cancer patients admitted to the ICU after 
elective and emergency surgery respectively. The objective of Chapter 3 was to determine the 
characteristics and outcomes of cancer patients with unplanned admissions to general ICUs, 
and to compare these with outcomes of unplanned critically ill patients without cancer. For this 
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we analyzed all unplanned ICU admissions in the Netherlands collected in the NICE registry be-
tween January 2007 and January 2011. Of the 140,154 patients with unforeseen ICU admission 
10.9% had a malignancy. There appeared to be a strong difference between cancer patients 
admitted to the ICU for medical or surgical reasons. Medical cancer patients were more severe-
ly ill on ICU admission in comparison with medical non-cancer patients, as reflected by higher 
needs for mechanical ventilation and vasopressors within 24 hours after admission, higher 
Acute Physiology and Chronic Health Evaluation (APACHE) IV scores and a longer ICU stay (5.1 
versus 4.6 days). In contrast, surgical cancer patients only displayed a modestly higher APACHE 
IV score on admission when compared with non-cancer surgical patients, whereas the oth-
er afore mentioned parameters were lower in the surgical cancer patients group. In-hospital 
mortality was almost twice as high in medical cancer patients  as in medical patients without 
cancer (40.6% versus 23.7%). In-hospital mortality of surgical cancer patients  was only slightly 
higher than in patients without cancer (17.4% versus 14.6%). Hence, the main conclusion of 
this chapter is that unplanned ICU admission is associated with a high mortality in patients with 
cancer when admitted for medical reasons, but much less so in cancer patients admitted for 
surgical reasons. In Chapter 4 we sought to analyze the characteristics and outcome of patients 
after ICU admission following elective surgery for different cancer diagnoses.  This survey com-
prised 28,973 elective surgical cancer patients admitted to 80 ICUs in the Netherlands during a 
five-year period (January 2007 through January 2012); these patients represented 9.0% of all 
ICU admissions. Of these admissions 77% were planned; in 23% of cases the decision for ICU 
admission was made during or directly after surgery. The most frequent malignancies were 
colorectal cancer (CRC, 25.6%), lung cancer (18.5%) and tumors of the central nervous system 
(14.3%).  Overall, ICU length of stay was short (median 0.9 days) with mechanical ventilation 
(one of four patients) and vasopressor use (one of five patients) as the most prevalent sup-
portive measures. Surgery for esophageal cancer was associated with the longest ICU length 
of stay (median 2.0 days). ICU and hospital mortality were 1.4% and 4.7% respectively. During 
the study period hospital mortality showed a significant decrease in time from 5.7% in 2007 
to 4.1% in 2011. This large analysis shows that elective cancer surgery represents a signifi-
cant part of all ICU admissions, with a short length of stay and low mortality.  In Chapter 5 
we focused our attention on emergency surgery, in particular on unplanned ICU admissions 
after acute surgery for CRC. The aims of this chapter were to compare short-term outcomes 
of unforeseen ICU admissions after emergency surgery for CRC with those of unplanned ICU 
admissions after emergency colorectal surgery for non-malignant disease. For this we analyzed 
all ICU admissions collected in the NICE registry from January 2007 through August 2012. This 
survey comprised 1,575 CRC patients who received postoperative care in one of 80 participat-
ing ICUs after unplanned surgery; these patients were compared with 9,920 patients who re-
ceived postoperative care after unplanned colorectal surgery for non-malignant disease during 
the same period in the same ICUs. On ICU admission, CRC patients had a lower prevalence of 
confirmed infection  than patients with non-malignant disease (22.3% versus 41.0%). Patients 
with CRC had a shorter ICU length of stay  than patients without CRC (median 2.3 versus 2.8 
days). In addition, CRC patients had a lower ICU mortality (10.3 versus 12.9%). Hospital length 
of stay and mortality did not differ between groups. In a multivariate analysis in-hospital mor-
tality was associated with high age, low body weight, high severity of illness at ICU admission, 
chronic comorbidities and metastasized carcinoma. CRC as reason for surgery and gender were 
not associated with mortality. 
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 The primary objective of Chapter 6 was to obtain insight into the distribution of 
pathogens causing blood stream infections (BSIs) in cancer patients (as compared with pa-
tient without malignancy) in the setting of a community teaching hospital. For this we ana-
lyzed all positive blood culture results obtained in the Reinier de Graaf Hospital in Delft, the 
Netherlands, from adult patients between January 2005 and January 2011. 4,918 episodes of 
BSI occurred in 2,891 patients, of whom 13.4% had a diagnosis of cancer. In both cancer and 
non-cancer patients Gram-positive isolates were more prevalent (58.7 and 61.4% respectively) 
than Gram-negative isolates (31.8 and 32.3% respectively). Amongst Gram-positive organisms, 
coagulase negative staphylococci, Staphylococcus (S.) aureus and enterococci were most fre-
quently isolated in both patient groups; in cancer patients twice as many BSIs were caused by 
Enterococcus (E.) faecalis and E. faecium. Amongst Gram-negative organisms, Escherichia (E.) 
coli was the most common isolate; in cancer patients twice as many BSIs were caused by Pseu-
domonas (P.) aeruginosa and Enterobacter cloacae. Yeasts were grown from 3.0% of blood cul-
tures from cancer patients versus 1.5% of cultures from non-cancer patients. Cancer patients 
had a 90-day mortality of 35.8% following BSI versus 23.5% in patients without cancer; the 
greatest difference in BSI associated mortality was caused by Gram-negative bacteria. Hence, 
these findings suggest specific pathogens are more present in cancer patients, in particular 
enterococci, P. aeruginosa, E. cloacae and yeasts, and that mortality rates after BSI are much 
higher in cancer patients than in patients without cancer. In patients with cancer and a central 
venous catheter, positive blood cultures more often yielded Gram-negative bacteria, in partic-
ular P. aeruginosa, while coagulase negative staphylococci were more common in non-cancer 
patients with a central venous catheter. There was no difference in antimicrobial resistance 
patterns between bacteria cultured in patients with cancer and non-cancer patients
  In Chapter 7 we sought to analyze the longevity and complications of Port-A-Caths 
(PACs) in cancer patients in the Reinier de Graaf Hospital. We report on the use of PACs in 
this 600-bed community hospital during a six-year period (January 2005 – December 2010), 
comparing indications, duration of use, complications and reasons for removal in consecutive 
patients with and without cancer. During the study period 152 cancer patients received a total 
of 170 PACs; in the same period, 21 patients received a total of 35 PACs for reasons unrelated 
to cancer. The total analysis encompassed 82,339 days of PAC use. Most cancer patients had 
a solid tumor (97%). Fewer PACs were removed because of a complication in cancer patients 
(14.7%) than in non-cancer patients (42.9%). In addition, the total number of PAC associated 
infections was lower in cancer patients  than in non-cancer patients (0.35 versus 1.43 infec-
tions per 1000 PAC days). PAC associated thrombosis did not occur. These results show that in 
clinical practice the use of PACs in cancer patients is safe with lower complication rates when 
compared with PAC use in patients without malignancy. 
General discussion
Intensive radiation and chemotherapy together with aggressive surgical techniques have re-
sulted in improved cancer cure rates [1, 2].  This success comes with a price: cancer treatment 
often is associated with drug- and radiation-related organ toxicities, surgical complications and 
increased susceptibility to infection [6]. While in the early 1980s the presence of a malignancy 
was considered a contraindication for admission to an ICU, the success of anti-cancer therapies 
has created a mind switch amongst clinicians with regard to the use of aggressive and invasive 
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supportive therapy in cancer patients with life threatening conditions due to their disease or 
treatment [6, 7].  Some investigators even defined ICU admission after 1996 as an independent 
predictor for a better outcome of cancer patients in the most recent decade [8, 9]. Factors 
that likely have contributed to improved outcomes include a better patient triage, enhanced 
management of oncologic emergencies and, in a more general way, advances in critical care 
management of common ICU conditions such as severe sepsis and acute respiratory distress 
syndrome. 
Indications for ICU admissions in cancer patients
Indications for ICU admission in patients with cancer include postoperative care, complications 
caused by the malignancy and/or its treatment and crises unrelated to the tumor or its thera-
py. The most commonly reported reasons for ICU admission of cancer patients are respiratory 
failure, postanesthetic recovery, infection and sepsis, bleeding and oncologic emergencies [10, 
11]. Decisions for ICU admissions of cancer patients with an acute crisis are notoriously diffi-
cult. Acute critical illness in patients with a malignancy can have many different clinical presen-
tations and can require a variety of interventions. Early recognition and timely ICU admission 
may limit or prevent life-threatening cancer-related complications. Current consensus is that 
the best candidates for use of ICU assets among patients with a malignancy are those with 
favorable therapeutic options for their cancer and critical illness, or when acute complications 
occur in patients in whom cancer is in complete remission [7, 12]. Thus, each patient in need 
for ICU care should be considered in the context of current malignant disease, the presence 
of comorbidity and capacity to survive the acute clinical event. In case there is not enough in-
formation to adequately predict the prognosis of an individual patient reliably, it is reasonable 
to provide ICU care with reassessment of the patient’s condition after several days [12, 13]. 
A decision not to escalate or stop care may follow if the patient’s condition has not improved 
during this “ICU trial”. This strategy is supported by recent data suggesting that duration of 
mechanical ventilation, use of vasopressors and dialysis are strong predictors of death. For 
example, patients who require mechanical ventilation for three days or more had a very low 
survival [14, 15].  Azoulay et l. summarized the ICU admission strategies for cancer patients in 
a five-step tranche varying from full code curative intent treatment and support to palliative 
care and support (Figure 1) [6].
 While the indications for ICU admission in cancer patients have been fairly well stud-
ied, specific knowledge of the percentage of cancer patients from a general population that is 
admitted to an ICU is highly limited. As such, the study reported in Chapter 2 is to the first to 
address this question. The finding that surgery was the most common treatment associated 
with ICU admission in cancer patients was not unexpected [7, 10, 11].  Notably, in Chapter 4 
we tried to estimate the proportion of cancer patients in the general population that needed 
ICU admission after elective surgery by comparing data from the Netherlands Cancer Registry, 
containing all patients with a cancer diagnosis [16], with the data from the NICE registry. The 
percentages of patients admitted to the ICU stratified according to cancer diagnosis presented 
in Chapters 2 and 4 show considerable differences, which at least in part can be explained by 
differences in the cancer populations studied (i.e. all ICU admissions in Chapter 2 versus elec-
tive surgical ICU admissions in Chapter 4) and the different methods to estimate these fractions 
(i.e. by linking DTC of cancer diagnoses in the general population with data in the NICE registry 
in Chapter 2 versus by approximation using data from the National Cancer Registry and NICE in 
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type of iCu admission Cinical situation
1. Full code ICU management Newly diagnosed malignancy.
Malignancy in complete remission.
2. ICU trial Clinical response to therapy not available or undetermined.
3. Exceptional ICU admission Available effective therapy should be tested in a patient who be-
comes critically ill.
4. Heroic ICU admission Oncologist/hematologist and intensivists agree that ICU admission is 
not appropiate, but patient or relatives disagree.
5. Other ICU admissions, not formally evaluated
- Prophylactic ICU admission Earliest phase of high risk malignancies, where admission to the ICU 
can avoid development of organ dysfunction (tumor-lysis, respiratory 
failure).
- Early ICU admission Admission to the ICU of patients with no organ dysfunction but 
physiological dysturbances, to prevent late ICU admission (associated 
with higher mortality).
- Palliative ICU admission Admission to the ICU for non-invasive ventilation only.
- In-ICU non-ICU care Short ICU admission for optimal and prompt management (catheter 
withdrawal, early antibiotica etc.).
- Terminal ICU admission ICU admission is required to best provide palliative care and symp-
tom control.
Terminal ICU admission?
Non-ICU Care in ICU?Palliative ICU Admission
Early ICU Admission?Prophylactic ICU Admission?
1. full Code iCu Management
2. iCu trial
3. Exceptional ICU Admission
4. heroic  
iCu admission
5.
Figure 1: Alternative in ICU refusal in cancer patients proposed for ICU admission
(reproduced with permission from ref. 6)
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Chapter 4). Nonetheless, both analyses revealed esophageal carcinoma, pancreatic-cholangio-
carcinoma and CRC as diagnoses that were associated with relatively high ICU admission rates. 
Characteristics and outcome of cancer patients in the ICU
Several studies have reported improved in-hospital survival rates of critically ill cancer patients 
during the past decade [8, 17-22].  The reasons for better survival rates are not totally clear, 
although several factors may contribute, including a better general ICU care due to improved 
diagnostic and therapeutic strategies and changes in triage patterns that result in ICU admis-
sion of cancer patients with the best chances for survival [6]. 
 Most previous data on the outcome of cancer patients on the ICU are derived from 
single-center studies conducted in specialized hemato-oncologic ICUs [6]. An important dis-
tinction between these earlier investigations and the studies reported in Chapters 2-5 of this 
thesis lies in the fact that we examined the impact of cancer on the outcome of patients admit-
ted to general ICUs. The analysis reported in Chapter 3 should be compared with two recent 
multicenter studies that also investigated the outcome of cancer patients in general ICUs [23, 
24].  Important differences between these studies and ours include the number of patients 
evaluated (> 34,000 versus 473 and 717 cancer patients respectively) and the period during 
which data were collected (four years versus two weeks and two months respectively) [23, 
24]. Chapter 3 and these two previous investigations [23, 24] are in agreement that a cancer 
diagnosis on admission to a general ICU is far from seldom, varying between 13.5% (Chapter 3), 
15.0% [23] and 21.5% [24]. Chapter 3 further shows that amongst unplanned ICU admissions 
the proportion of cancer patients is lower (9.5%), which possibly is a reflection of the reduced 
willingness of clinicians to admit cancer patients to the ICU in crisis situations. Moreover, Chap-
ter 3 clearly documents that the outcome of cancer patients in the ICU strongly depends on 
the admission type. The impact of cancer on mortality especially was large in medical patients, 
whereas in surgical patients the influence of a cancer diagnosis on mortality was modest at 
best.  In accordance, in a previous study medical cancer patients had a much higher ICU and 
hospital mortality (44 and 58% respectively) than cancer patients admitted for unplanned sur-
gery (23 and 37% respectively) [24]. Together these data demonstrate that only investigations 
containing information on the admission type (planned or unplanned, surgical or medical) pro-
vide insightful information on the involvement of cancer on ICU and hospital outcome. 
 The follow up of patients analyzed in Chapter 3 was limited to hospital discharge. This 
restriction is quite general in current literature and the knowledge of long-term outcome and/
or disease-free survival and quality of life after ICU admission of cancer patients is highly lim-
ited.  The investigations that did study of long-term survival of ICU patients have suggested 
an increase in mortality during several years after hospital discharge when compared with an 
age- and gender-matched population [25-27]. In accordance, a very recent study conducted 
in the Netherlands that analyzed post-ICU mortality up to three years after hospital discharge 
reported almost two-fold increased mortality rates of cancer patients relative to the total ICU 
population [28].  Chapter 2 extends these data, revealing a markedly increased long-term mor-
tality of cancer patients who had been admitted to the ICU relative to cancer patients who 
were never admitted to the ICU. 
Surgical cancer patients in the ICU
ICU physicians are faced with increasing numbers of surgical oncology patients. Surgical pro-
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cedures for different malignancies vary substantially, each carrying their own specific risks 
during acute postoperative care.  Many studies have reported on postoperative morbidity and 
mortality in unselected surgical patient populations [29-33] and many investigations studied 
postoperative mortality of elective cancer surgery [34-40].  However,  only one investigation 
specifically addressed cancer patients admitted to the ICU after elective surgery; this study, 
which did not specify the type of surgery, encompassed 381 patients who had a median length 
of stay on the ICU of two days and an ICU mortality of 6%  [24]. As such, the results presented 
in Chapter 4, providing information about the outcome of ICU admission after elective cancer 
surgery in almost 29,000 patients, are unique in its kind. Hospital mortality stratified according 
to different types of cancer surgeries was in the same range as reported previously for pa-
tients subjected to elective surgery for cancer of the lung [41], esophagus [42, 43], pancreas 
[44], female genital tract [45], bladder [46] and head and neck [47, 48]. Chapter 4 also shows 
that approximately one-quarter of elective surgical patients entered the ICU after surgery for 
CRC. Remarkably, in approximately one third of these patients ICU admission was not foreseen 
before surgery. In Chapter 5 we further focused on CRC patients, evaluating the outcome of 
emergency colorectal surgery in this group. We considered this of interest in light of previously 
published data showing that one in four cases of bowel cancer are diagnosed only after emer-
gency admission to the hospital [49] and that emergency surgery is as an important risk factor 
for mortality amongst CRC patients [50, 51].  The high ICU and hospital mortality after ICU ad-
mission for acute CRC surgery reported in Chapter 5 (10 and 22% respectively) is in accordance 
with these earlier studies [50, 51].  Notably, the risk of hospital mortality was not higher in 
patients with cancer as compared with patients with non-cancer reasons for colorectal surgery 
requiring ICU admission, and ICU mortality was even lower in patients with CRC. Importantly, 
our data involve a selected population and do not provide information on in-hospital outcomes 
of cancer patients who were not admitted to the ICU postoperatively. The decision to admit 
patients to the ICU is subjective and major differences in the indications for post-operative ICU 
care after cancer surgery may exist between different hospitals.  As such, our results should be 
interpreted in this context. 
Infections in patients with cancer
Infections are a major reason of lengthy hospitalization in patients with cancer [52].  Cancer is 
associated with a strongly increased risk to acquire BSIs [53-55] and BSIs are a major cause of 
mortality in patients with a malignancy [56-58]. Many different organisms have been isolated 
from cancer patients with documented infections, revealing that, besides common pathogens, 
microorganisms with low virulence can cause significant morbidity and mortality In patients 
with cancer [59, 60].  Several chapters in this thesis report on infections in cancer patients. 
Chapter 3 shows that approximately one third of all medical cancer patients with unplanned 
ICU admission have a documented infection, which is considerably more than medical patients 
without cancer. Chapter 5 documents that one out of ten patients admitted to the ICU after 
emergency CRC surgery have sepsis. The results presented in Chapter 6, showing a predom-
inance of Gram-positive organisms in BSIs in both patients with and without cancer, are in 
accordance with earlier studies [61-64]. We could not confirm previous investigations that ex-
posed cancer as a risk factor for BSIs by specific pathogens, including S. aureus [65], E. coli [66] 
and K. pneumoniae [67]. We did find an association between cancer and P. aeruginosa, howev-
er, which was reported in another study [68]. Clearly, causative pathogens can differ from cen-
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ter to center, depending on patient populations (e.g. general versus specialized cancer centers 
and solid versus hematological malignancy) and susceptibility to common antimicrobial agents 
in the community and hospital. 
 In Chapter 7 we addressed a specific risk factor for infections in cancer patients: the 
use of central vascular catheters, in particular PACs. PACs provide a simple way of accessing 
the venous system, especially for administration of chemotherapy. Remarkably, the risk for 
PAC removal for infectious reasons was lower in cancer patients than in non-cancer patients, 
which is unexpected considering the enhanced susceptibility of cancer patients to infection 
in general. Conceivably, the fact that oncology nurses likely have more experience than less 
specialized health care personnel in the management of PACs and/or differences in underlying 
diseases may contribute to this finding. The incidence of PAC associated infection amongst can-
cer patients (11.8%) was within the same range as that reported in previous studies [69-71]. 
In addition, causative pathogens (mainly coagulase negative staphylococci and S. aureus) were 
similar to those reported by others [71, 72]. 
Impact of gender
Gender may impact on the occurrence of complications and the type of therapeutic interven-
tions while on the ICU. Although overall ICU mortality does not seem to differ between sexes 
[73, 74], men are more likely to develop sepsis [74-76]. Additionally, men are more likely to 
receive invasive therapeutic procedures while on the ICU [73, 77].  In this thesis, we examined 
the influence of gender on several outcome parameters in cancer patients. Chapter 2 reports 
that more male than female cancer patients were admitted the ICU in spite of fact that in the 
general population of cancer patients women were more prevalent than men. While for the 
overall population this gender difference can be partly explained by the high prevalence of 
breast cancer (which very rarely results in ICU admission), men more often entered the ICU 
across all cancer diagnoses with the sole exception of esophageal cancer. This finding is not 
unprecedented: previous studies pointed out that in general men are more likely to receive 
ICU care than women [73, 77-79]. At present, it is unclear which factors are responsible for 
this discrepancy, and further studies are warranted to examine this issue.  In Chapter 5 we 
hypothesized, based on earlier studies  [80-83], that gender could have an important influence 
on outcome after emergency CRC surgery.  However, although in non-cancer emergency col-
orectal surgery patients admitted to the ICU mortality and in-hospital mortality were higher 
in female patients, this gender influence was not present in acute CRC surgery even not when 
adjusted for other covariates. 
Future Perspectives
Although knowledge of the characteristics and outcome of cancer patients in the ICU has in-
creased substantially over the past years, most studies on this topic are retrospective and many 
involve a very heterogeneous patient case mix with medical and surgical patients, solid and 
hematologic cancer patients, and allogeneic and autologous bone marrow transplant recipi-
ents. Results between studies are often difficult to compare because of variations in criteria 
for ICU admission and discharge, and for end-of-life decisions. As such, many questions remain 
with regard to care of critically ill cancer patients and future studies are warranted to answer 
these. Perhaps most importantly, there are very few studies that assessed long-term outcomes 
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of cancer patients who survive their ICU stay. It is crucial to establish whether ICU or hospital 
survival results in a real increase in survival with an acceptable quality of life. Hence, more in-
vestigations are needed that evaluate outcomes of cancer patients with regard to physical and 
mental health and quality of life one or several years after ICU admission. Along the same lines, 
it needs to be established whether cancer patients who survive the ICU are able to receive full 
chemotherapy regimens and/or other antineoplastic therapies. 
 In addition, further investigations are necessary to identify predictors of death in cancer 
patients admitted to the ICU. Factors historically considered to be of crucial importance for 
outcome of cancer patients on the ICU may no longer be valid. For example, whereas one study 
reported that the “classic” risk factor neutropenia indeed was associated with a higher mor-
tality in patients with a hematologic malignancy admitted to the ICU [84], a subsequent study 
from the same institution found no such association [85]. In accordance, a large multicenter 
study conducted in Brazil failed to find an association between neutropenia and mortality in pa-
tients with cancer [24]. Along the same lines, the prognostic importance of other presumptive 
mortality predictors, such as age or type of the malignancy, is not consistent among different 
studies and may at least in part depend on ICU admission criteria [6]. Moreover, ICU admission 
is strongly influenced by the development of less invasive treatment options, associated with 
less postoperative morbidity such as the implementation of endoscopic esophageal resection 
versus the traditional transthoracic esophageal resection [86].
 Likewise, there is an urgent need for adequate emergency ICU admission criteria for 
cancer patients. For optimal care of critically ill cancer patients, finding a balance between 
noninvasive treatments and avoiding delays in optimal therapies are crucial. Current triage cri-
teria for ICU admission are less trustworthy. Indeed, a prospective investigation that examined 
the outcomes of cancer patients suggested for ICU admission, revealed that 20% of patients 
who were not admitted because they were considered not sick enough died before hospital 
discharge (mostly following postponed ICU admission), while 25% of the patients not admitted 
because they were considered too ill survived [87]. Delayed ICU admission of cancer patients 
with multiple organ failure is associated with a grim prognosis, and the type and number of 
organ dysfunctions at ICU admission are good predictors of mortality [15, 21]. Although early 
ICU admission may improve survival [18], this issue needs proper evaluation, for example by 
randomizing patients with cancer for ICU admission (or not) in an early phase of their disease 
or treatment, with only one organ dysfunction. Important for triage, a high functional perfor-
mance before critical illness has been found to positively influence outcome [88]. Nonetheless, 
it remains to be established whether performance status scoring systems such as the Karnofsky 
Performance Scale Index, can assist in identifying patients who will either do well or poorly 
after ICU admission.  Categorizing patients with no improvement or with worsening condition 
after three days of ICU care, the afore mentioned “ICU trial”, may be effective to judge progno-
ses [12, 15]. However, further studies are warranted to establish the optimal time period for 
this “therapeutic trial” on the ICU. Once a decision for a “ICU trial” has been made, it is difficult 
to determine the adequate moment for end-of-life decisions [89]. The switch from curative to 
palliative care is demanding in cancer patients, not in the least in the setting of an ICU, and 
the quality of dying must be considered. In this context it should be clear that all patients 
with cancer admitted to a hospital need to be informed on the existence (or not) of treatment 
possibilities when acute worsening of their condition is in sight. Discussing the option of a 
do-not-resuscitate status, whether or not in the presence of relatives, is of great importance. 
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In case of clinical deterioration, the medical emergency team of that hospital should be aware 
of the vulnerable status of the patient with a malignant disease and not wait too long before 
transport to the ICU. A clear protocol on this will increase the efficiency for these patients and 
the different care-givers involved. When a patient with cancer is admitted to the ICU, daily 
follow-up (participating in the daily rounds) by the oncologist or hematologist is of great impor-
tance to inform the intensive care staff on specific issues regarding the underlying diseases and 
treatments in the past and future. In situations when a cancer patient can stay in the oncology 
unit, the medical and nursing staff should be aware of the critical condition of this patient. 
Meticulous evaluation in a two or three times daily schedule with appreciation of the different 
organ systems and vital signs should be included in such a routine. It is of great importance 
that the attending physicians fulfill these responsibilities themselves, teaching the house-staff/
fellows and accentuating that acute deterioration of the patient can result in admission to the 
ICU. 
 An aspect not discussed in this thesis are important dilemmas of whether ICU care can 
be provided simultaneously with cancer-specific treatments, including chemotherapy. Previ-
ous studies that addressed this issue have provided evidence that the administration of che-
motherapy in the ICU is feasible, with satisfactory short- and long-term results [90, 91]. More-
over, these studies demonstrated patients presenting with severe sepsis or septic shock after 
recent chemotherapy, may do better that patients who did not receive recent chemotherapy 
[90, 91]. Although NICE contains information about all patients admitted to the majority of 
Dutch ICUs, specific information on the complication rate and/or success of chemotherapy 
in the ICU is not available, and unfortunately very difficult to obtain due to the fact that the 
NICE database and information of the hospital pharmacist are not linked.  Since most cancer 
patients are treated with multi-modality approaches with curative intent, this information (and 
long-term follow-up) is of great interest to oncologists and hematologists. 
 To conclude, the survival rate of cancer patients who require ICU admission has im-
proved due to advances in hematology, oncology and ICU management. The management of 
critically ill cancer patients requires specialized skills by the intensivist and close collaboration 
between the intensivist and (hemato-)oncologist. Very likely, at least part of the improvement 
in the outcome of critically ill cancer patients is the result of tight interactions between in-
tensivists, cancer surgeons  and (hemato-)oncologists. Most importantly, (hemato-)oncologists 
should inform intensivists about curative possibilities for the underlying malignancy. ICU cli-
nicians are more experienced in setting aims of critical care based on the presence of (multi-
ple) organ failure and the potential of reversibility thereof. ICU admission decisions should be 
made by both specialties based on the acute condition, the prognosis of the malignancy and 
(obviously) the will of the patient. Decisions to withhold or withdraw life-sustaining therapies 
are best undertaken by both parties. Information given to patients’ relatives and shared deci-
sion-making should be presented by both parties together. As such, a close collaboration be-
tween intensivists and oncologists is needed to increase the expertise required for all aspects 
of the general management of cancer patients and to provide optimal care to this population. 
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Samenvatting
De overleving van patiënten met kanker neemt vooral in ontwikkelde landen sterk toe, waarbij 
geschat wordt dat ongeveer twee derde van deze patiënten zeer lang leeft met of na de diag-
nose kanker [1, 2]. Verbetering van de therapeutische opties en de ontwikkeling van een agres-
sievere en veelal multidisciplinaire aanpak van in opzet curatieve behandelingen liggen hieraan 
ten grondslag. De noodzaak van intensieve zorg voor deze populatie spreekt voor zich. Anti-
ciperen op en behandeling van acute complicaties van anti-kanker therapie zijn in de laatste 
decaden veranderd en vooral geïntensiveerd. Dit betreft niet alleen de direct postoperatieve 
zorg van de grote oncologische chirurgie, maar ook het gebruik van orgaan-ondersteunende en 
vervangende maatregelen noodzakelijk bij uitgebreide infiltratie van een maligniteit in longen, 
nier of lever. Ook de directe toxiciteit van de lokale en systemische therapie kan hieraan debet 
zijn. Dit proefschrift betreft meerdere studies en analyses van de epidemiologie en effecten 
van intensive care (IC) opnamen en behandelingen geassocieerd met een maligniteit en de 
therapie hiervoor. Hoofdstuk 2-5 beschrijven elk een specifieke groep kankerpatiënten opge-
nomen op de IC ten tijde van hun ziekte. In hoofdstuk 6 en 7 worden infectieuze complicaties 
van kanker en antikankerbehandelingen bestudeerd. 
 In hoofdstuk 2 bespreken we een kwantitatieve analyse van het opname patroon van 
kankerpatiënten op de IC, gestratificeerd naar type maligniteit. Het is een retrospectief on-
derzoek van volwassen kankerpatiënten over een periode van 5 jaar (januari 2006 tot januari 
2011). De database werd samengesteld vanuit een viertal grote ziekenhuizen in de Randstad. 
Inclusie van patiënten was gebaseerd op de primaire kankerdiagnose opgenomen in de zie-
kenhuisregistratie middels de Diagnose Behandel Combinatie (DBC). Sinds 2004 zijn in Neder-
land DBCs geïntroduceerd teneinde gelijkwaardige informatie te verkrijgen van alle patiënten 
behandeld in de ziekenhuizen met betrekking tot diagnose, type en aard van de behandeling, 
zoals gespecificeerd door de medische staf [3, 4]. Vervolgens werd dit cohort gekoppeld aan 
de database van de Nederlandse Intensive Care Evaluatie (NICE) zodat patiënten met kanker 
en opgenomen op de IC in deze periode, vergeleken konden worden met patiënten uit het-
zelfde cohort die niet opgenomen werden op de IC. NICE beschikt over een uitgebreide set 
gegevens van alle IC opnames van 84 ziekenhuizen in Nederland (ongeveer 90% van alle IC’s 
in Nederland) [5]. Uiteindelijk werden 36,860 patiënten met tenminste één kankerdiagnose in 
de data base opgenomen. Van hen werd 6.4% opgenomen op de IC gedurende de 5 jaar du-
rende evaluatie-periode. Chirurgie, al of niet gecombineerd met chemotherapie of bestraling, 
was de meest frequente behandelingsmodaliteit geassocieerd met IC opname (11.8% van alle 
patiënten die deze behandeling onderging). De fractie van patiënten die een curatieve behan-
deling onderging was hoger voor de groep die werd opgenomen op de IC dan voor de groep die 
niet opgenomen werd op de IC (42.2% versus 17.6%). De diagnose slokdarmkanker leidde het 
vaakst tot IC opname (27.3% van de totale groep met deze diagnose). Ook de andere gastro-in-
testinale maligniteiten zoals colorectaal carcinoom (CRC)(10.4%) en alvleesklier/galwegkanker 
(9.4%) waren frequent geassocieerd met IC opname.  Hoewel in het hele cohort was het aan-
tal vrouwen (54.0%) groter dan het aantal mannen, werden mannen meer dan twee maal zo 
frequent opgenomen op de IC (9.3% versus 4.0%). De overleving van kankerpatiënten opgeno-
men op de IC was significant lager (mediane overleving 771 dagen) dan die van de patiënten 
niet opgenomen op de IC (mediane overleving nog niet bereikt na 6 jaar) en uiteraard sterk 
afhankelijk van het type maligniteit. Desalniettemin was de lange termijn overleving van pati-
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enten met verschillend type kanker substantieel na IC opname.
 Ook voor hoofdstuk 3 tot 5 werd de NICE database gebruikt om de verschillende sub-
groepen van kankerpatiënten opgenomen op een Nederlandse IC verder te bestuderen: Hoofd-
stuk 3 betreft de analyse van kankerpatiënten die ongepland op de IC werden opgenomen. In 
hoofdstuk 4 en 5 beschrijven we de verschillende type chirurgische kankerpatiënten die of elec-
tief of na een spoed chirurgische ingreep op de IC werden opgenomen. Het doel van het onder-
zoek weergegeven in hoofdstuk 3 was een directe vergelijking van karakteristieken en mortali-
teit tussen kankerpatiënten en patiënten zonder kanker op een IC na een ongeplande opname. 
Hiervoor werden alle ongeplande IC opnames in Nederland uit de NICE-database geregistreerd 
in de periode van januari 2007 tot januari 2011 gebruikt. Van de 140,154 acuut opgenomen 
patiënten had 10.9% kanker. Er was een groot verschil tussen de ongeplande chirurgische kan-
kerpatiënten en de patiënten die om ongeplande medische reden werden opgenomen. Medi-
sche kankerpatiënten hadden bij opname een hogere morbiditeit; er was vaker een noodzaak 
tot mechanische beademing en gebruik van vasopressoren in de eerste 24 uur van de IC op-
name; deze groep had hogere Acute Physiology and Chronic Health Evaluation (APACHE) IV 
scores en verbleef  langer op de IC (5.1 versus 4.6 dagen) in vergelijking met de ongeplande 
niet oncologische populatie. De ongeplande chirurgische kankerpatiënten hadden een beperkt 
verhoogde APACHE IV score bij opname op de IC en minder noodzaak tot beademen en gebruik 
van vasopressoren. De ziekenhuissterfte van medische kankerpatiënten was bijna twee maal 
zo hoog dan die van medische niet-oncologische patiënten die ongepland op de IC werden 
opgenomen (40.6% versus 23.7%). Dit was in veel mindere mate het geval voor chirurgische 
kankerpatiënten versus niet kankerpatiënten (17.4% versus 14.6%). De uiteindelijke conclusie 
van het hoofdstuk is dat ongeplande IC opname van kankerpatiënten een hogere morbiditeit 
en mortaliteit hebben en dat dit vooral geldt voor de groep opgenomen om medische redenen. 
 hoofdstuk 4 betreft een studie naar karakteristieken, morbiditeit en mortaliteit van 
patiënten die opgenomen werden op de IC na het ondergaan van electieve oncologische chi-
rurgie voor verschillende typen van kanker. Dit onderzoek omvatte 28,973 electieve chirur-
gische kankerpatiënten opgenomen op één van de 80 IC’s aangesloten bij NICE gedurende 
een periode van vijf jaar (januari 2007 tot januari 2012). Deze groep vertegenwoordigde 9.0% 
van alle IC opnames in deze periode. Hiervan werd 77%  gepland opgenomen, terwijl bij 23% 
tot postoperatieve IC opname besloten werd tijdens of direct na de chirurgische procedure. 
De meest frequente diagnosen waren CRC (25.6%), long kanker (18.5%) en tumoren van het 
centrale zenuwstelsel (14.3%).  De mediane opnameduur voor alle patiënten tezamen was 
met 0.9 dagen, kort. Mechanische beademing (één op vier patiënten) en ondersteuning met 
vasopressoren (één op vijf patiënten) werden het meest frequent toegepast als ondersteunen-
de therapie. Chirurgie voor slokdarmkanker was geassocieerd met de langste IC opnameduur 
(mediaan 2.0 dagen). De mortaliteit was laag, namelijk 1.4% op de IC en 4.7% in het ziekenhuis. 
De ziekenhuissterfte nam geleidelijk af in de opeenvolgende jaren van de analyse: van 5.7% in 
2007 naar 4.1% in 2011. De uiteindelijke conclusie van te hoofdstuk is dat electieve oncolo-
gische chirurgie een significant deel van alle IC opnames betreft met een korte opnameduur 
en lage mortaliteit. In hoofdstuk 5 wordt vervolgens een andere oncologisch chirurgische po-
pulatie bestudeerd, namelijk patiënten met CRC die ongepland opgenomen werden op de IC 
na een spoedoperatie. Twee patiënt groepen werden vergeleken: de geselecteerde patiënten 
die acuut opgenomen werden op de IC na spoed chirurgie voor CRC en patiënten met een 
ongeplande IC opname na colorectale spoedchirurgie vanwege een niet oncologische reden. 
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Gegevens werden verkregen uit de NICE database in de periode januari 2007 tot augustus 
2012. Uiteindelijk voldeden 1,575 patiënten met CRC en 9,920 niet-oncologische patiënten 
aan deze criteria. Patiënten opgenomen op de IC na chirurgie voor CRC hadden minder infec-
tieuze complicaties (22.3% versus 41.0%) en een korter verblijf op de IC (mediaan 2.3 versus 
2.8 dagen). Tevens was de IC sterfte voor patiënten na spoedchirurgie voor CRC  lager (10.3% 
versus 12.9%). Ziekenhuis sterfte en verblijfsduur verschilden niet tussen beide groepen. In de 
multivariaat analyse bleek dat ziekenhuissterfte geassocieerd was met hoge leeftijd (>70 jaar), 
laag lichaamsgewicht, hoge APACHE IV score, chronische co-morbiditeit en gemetastaseerde 
maligniteit. Chirurgie voor CRC  en geslacht waren niet geassocieerd met sterfte. De uiteindelij-
ke conclusie van het onderzoek is dat spoedchirurgie voor CRC geen reden is om patiënten niet 
op de IC op te nemen.
 Het doel van het onderzoek beschreven in hoofdstuk 6 was het vergelijken van patho-
genen gevonden in bloedkweken bij kankerpatiënten en patiënten zonder een maligniteit, in 
een perifeer ziekenhuis in Nederland. Alle positieve bloedkweken van volwassen patiënten 
in de periode van januari 2005 tot januari 2011, verkregen in het Reinier de Graaf Gasthuis 
te Delft, werden hiervoor gebruikt. In totaal werden 4,918 positieve bloedkweken bij 2,891 
patiënten vastgesteld. Van hen had 13.4% een maligniteit. Zowel bij de kankerpatiënten als bij 
de niet kankerpatiënten kwamen Gram-positieve bacteriën frequenter voor (58.7 en 61.4%) 
dan Gram-negatieve micro-organismen (respectievelijk 31.8% en 32.3% ). Gram-positieve or-
ganismen betrof in beide groepen vooral coagulase negatieve stafylococcen, Staphylococcus 
(S.) aureus en enterococcen. Kanker patiënten hadden twee maal zo vaak een positieve bloed-
kweek met Enterococcus (E.) faecalis en E. faecium. Van de Gram-negatieve organisme was 
Escherichia (E.) coli de meest frequente verwekker in beide groepen. Pseudomonas (P.) aerugi-
nosa and Enterobacter cloacae werden twee keer zo vaak gekweekt in kankerpatiënten. Van de 
positieve bloedkweken van kankerpatiënten betrof 3.0% schimmels, tegen 1.5% van bloedkwe-
ken bij niet kanker patiënten. De 90 dagen mortaliteit na een positieve bloedkweek van kan-
kerpatiënten was hoger dan die van de niet oncologische populatie (respectievelijk 35.8% en 
23.5%); het grootste verschil in mortaliteit was aanwezig bij Gram-negatieve bacteriëmie. Deze 
data suggereren dat specifieke micro-organismen frequenter gevonden worden bij patiënten 
met kanker (zoals enterococci, P. aeruginosa, E. cloacae en schimmels) en dat de mortaliteit 
na een positieve bloedkweek veel hoger is voor patiënten met dan voor patiënten zonder een 
maligniteit. Kankerpatiënten met een centraal veneuze katheter hadden vaker Gram-negatieve 
bacteriën in de bloedkweek, en dit betrof vooral P. aeruginosa. Coagulase negatieve stafylococ-
cen werden frequenter gevonden in bloedkweken van niet kanker patiënten met een centraal 
veneuze lijn. Er is nagenoeg geen verschil in antimicrobiële resistentie tussen de bacteriën 
gekweekt bij kanker en niet kanker patiënten.
  In hoofdstuk 7 beschrijven we een studie naar de klinische meerwaarde en complica-
ties van geïnstalleerde  Port-A-Caths (PACs) bij kankerpatiënten in het Reinier de Graaf Gasthuis. 
We rapporteren data verzameld over een periode van 6 jaar (januari 2005 – december 2010) 
in dit ziekenhuis. We vergeleken indicaties, gebruiksduur en complicatie-aard en frequentie 
tussen patiënten met en zonder kanker bij wie een PAC geïnstalleerd werd. In de studieperiode 
werden bij 152 kankerpatiënten 170 PACs ingebracht, en bij 21 niet kankerpatiënten 35 PACs. 
Dit betekende in totaal 82,339 dagen PAC gebruik. De meerderheid van de kankerpatiënten 
had een solide tumor (97%). Verwijdering van de PAC om reden van complicaties geschiedde 
vaker in de groep van de niet oncologische patiënten (42.9% versus 14.7%), en ook het aantal 
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PAC geassocieerde infecties was lager in de patiënten met kanker dan in de groep zonder een 
maligniteit (0.35 versus 1.43 infecties per 1000 PAC dagen). In de bestudeerde groep werd 
geen PAC geassocieerde trombose aangetroffen. De uiteindelijke conclusie van het onderzoek 
luidt dan ook dat PAC gebruik in kankerpatiënten veilig is en gepaard gaat met weinig compli-
caties, wanneer vergeleken met PAC gebruik bij patiënten zonder kwaadaardige ziekte. 
discussie
Intensieve behandelingen voor maligne ziekten met bestraling, chemotherapie en agressie-
ve chirurgie hebben geleid tot een toename van de curatiekans [1, 2]. Dit succes heeft een 
prijs: intensieve anti-kanker therapieën zijn geassocieerd met kans op orgaanschade door de 
cytostatica, bestralingen, chirurgische complicaties en een verhoogde gevoeligheid voor infec-
ties [6]. Enkele decennia geleden werd de diagnose kanker nog als een contra-indicatie voor 
opname op een IC gezien. Maar als gevolg van de effectievere behandelingen voor vele malig-
niteiten is de houding van clinici, waaronder intensivisten betrokken bij de intensieve zorg en 
ondersteuning van deze populatie veranderd [6, 7]. Na 1996 wordt door enkele onderzoekers 
een IC-opname als onafhankelijke parameter voor betere uitkomst van kankerpatiënten beoor-
deeld [8, 9]. Factoren die bijdragen aan deze verandering op de IC zijn een betere en adequate 
triage voor overplaatsing, verbetering van herkenbaarheid en infrastructuur voor oncologische 
complicaties en uiteraard een verdere verbetering van de IC geneeskunde en management van 
bijvoorbeeld sepsis en acute longschade. 
Indicaties voor IC opname van kankerpatiënten
Redenen voor IC opname van kankerpatiënten betreffen complicaties veroorzaakt door de ma-
ligniteit zelf, postoperatieve zorg, andere complicaties als gevolg van de antikanker therapie en 
noodzaak van intensieve zorg niet gerelateerd aan de kanker (behandeling). De meest voorko-
mende redenen van opname zijn  postoperatieve zorg, respiratoire insufficiëntie, infectie en 
sepsis, bloedingen en direct oncologische spoedsituaties [10, 11]. Beslissingen betreffende IC 
opname van acuut zieke patiënten met een maligniteit blijken complex. Acute verslechtering 
van patiënten met kanker kan zich op verschillende wijzen manifesteren met als gevolg een 
veelheid aan mogelijke interventies. Vroege herkenning en overplaatsing naar de IC kan le-
vensbedreigende kanker gerelateerde complicaties minimaliseren. De huidige consensus is dat 
de beste kandidaten voor IC opname die kankerpatiënten zijn die goede therapeutische opties 
hebben voor de oncologische aandoening en het ontstane klinisch beeld, en uiteraard die pa-
tiënten bij  wie de maligniteit in een (langdurige) remissie is geraakt [7, 12]. Dat betekent dat 
voor elke kankerpatiënt bij wie een IC opname overwogen wordt de afweging gemaakt moeten 
worden tussen de prognose en behandelmogelijkheden van de onderliggende maligniteit, de 
mate van comorbiditeit en de therapeutische ruimte voor interventie in de acute klinische 
verslechtering. Wanneer er onvoldoende informatie is om de prognose van een patiënt voor 
IC opname te voorspellen is het redelijk een korte periode van intensieve zorg op de IC aan te 
bieden met afspraken voor een herbeoordeling na enkele dagen [12, 13]. Indien er gedurende 
deze “ICU-trial” geen verbetering is opgetreden kan dan in tweede instantie besloten worden 
de IC zorg te beëindigen. Deze strategie wordt ondersteund door recente publicaties waarin 
de duur van mechanische beademing (> 3 dagen), langdurige noodzaak van vasopressoren en 
dialyse een negatieve impact hebben op de overleving van patiënt [14, 15]. Figuur 1 beschrijft 
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in vijf stappen een strategie voor IC opname voor oncologische patiënten volgens Azoulay et al. 
De basis betreft de kankerpatiënt met een goede prognose en conditie die optimaal behandeld 
dient te worden op de IC.  Vervolgens zal elke andere klinische conditie van patiënten weer tot 
een volgend alternatief leiden, en dus tot nieuwe overwegingen tijdens de IC opname (Figuur 
1) [6].
 Terwijl de indicaties voor opname op een IC voor kankerpatiënten redelijk goed bestu-
deerd zijn, is de kennis over het relatieve aantal IC opnames van een algemene oncologische 
populatie beperkt. In Hoofdstuk 2 wordt deze vraag verder uitgewerkt en geanalyseerd. De 
eerste conclusie dat chirurgie het meest frequent leidt tot IC opname is op zich niet verrassend 
[7, 10, 11]. Ook in hoofdstuk 4 hebben we op basis van de data uit NICE en de gegevens van 
de Nederlandse Kankerregistratie een schatting gedaan naar de fractie van patiënten die na 
een oncologische operatie op de IC worden opgenomen in verhouding met de totale groep 
kankerpatiënten die een oncologische operatie ondergaan [16]. De gegevens uit hoofdstuk 2 
en 4 verschillen aanzienlijk, hetgeen zich laat verklaren doordat de bestudeerde populaties 
niet overlappen (bijvoorbeeld ‘alle type chirurgische opnamen’ in hoofdstuk 2 en alleen ‘elec-
tieve chirurgie’ in hoofdstuk 4). Tevens gebruikten we andere methoden om de verschillende 
groepen te definiëren (in hoofdstuk 2 met behulp van koppeling van de DBCs  aan NICE  en in 
hoofdstuk 4 een vergelijking van de gegevens van de NICE database met een ruwe schatting 
van de Nederlandse Kanker Registratie). Maar beide studies zijn consequent in de conclusies 
dat vooral slokdarmkanker, alvleesklier/ galwegkanker en CRC geassocieerd zijn met frequente 
IC opname. 
Klinische karakteristieken en mortaliteit van kankerpatiënten opgenomen op de IC
Meerdere publicaties rapporteren een verbetering van ziekenhuissterfte van kritisch zieke kan-
kerpatiënten in de laatste decennia [8, 17-22]. De oorzaak hiervan is niet helemaal duidelijk, 
maar een zekere rol is weggelegd voor verbeterde IC zorg als zodanig, verbeterde diagnostiek 
en behandelopties, alsmede een verandering in de triage voor opname op de IC van de oncolo-
gische populatie leidend tot selectie van hen met de beste kansen op overleving [6]. 
 De meest recente data aangaande mortaliteit en morbiditeit van kankerpatiënten op 
de IC zijn gegenereerd op basis van single-center analysen, en veelal in gespecialiseerde (he-
mato-)oncologische IC’s [6].  Een essentieel verschil met deze oudere data en de studies zoals 
beschreven in hoofdstuk 2-5 van dit proefschrift is dat dit onderzoek gericht is op de uitkomst 
van kankerpatiënten opgenomen op de algemene IC van de ziekenhuizen in Nederland. De stu-
die beschreven in hoofdstuk 3 kan vergeleken worden met twee recentere multicenter studies 
betreffende uitkomstanalyse van kankerpatiënten opgenomen op algemene IC’s [23, 24]. Deze 
studies verschillen echter kwantitatief met de data weergegeven in Hoofdstuk 3 (respectie-
velijk > 34,000 versus 473 en 717 kankerpatiënten) en ten aanzien van de periode waarin de 
data zijn verzameld (respectievelijk vier jaar versus twee weken en twee maanden) [23, 24]. 
De conclusies van de drie studies laten zich toch goed vergelijken en resumerend kan gesteld 
worden dat een diagnose van kanker bij opname op de IC niet zeldzaam is en varieert tussen 
13.5% (hoofdstuk 3), 15.0% [23] en 21.5% [24].  Uit hoofdstuk 3 blijkt verder dat ongeplande 
IC opname van kankerpatiënten minder frequent geschiedt (9.5%). Een mogelijke verklaring is 
dat men minder bereid is kankerpatiënten in acute nood over te plaatsen naar een IC gezien 
de onderliggende zorgelijke diagnose. Inderdaad blijkt uit de verkregen data in hoofdstuk 3 
dat de prognose van kankerpatiënten opgenomen op de IC sterk afhankelijk is van het opna-
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Figuur 1: Alternatieve overwegingen voor weigering van IC opname van kankerpati-
enten die behoefte hebben intensieve zorg en orgaanondersteunende therapie zoals 
verzorgd op de IC (gereproduceerd uit ref. 6, met toestemming)
type iC opname Klinische situatie
1. Volldige IC behandeling Nieuwe  kanker diagnose. 
Maligniteit in complete remissie.
2. IC - trial Verwachtingen van gestarte behandeling niet bekend of nog onzeker.
3. Uitzonderlijke IC opname Behandeling  nog niet getest in een kritisch zieke kankerpatient.
4. Heroïeke IC opname Behandelaars zoals (hemato-)oncoloog en intensivist adviseren tegen 
een IC opname, maar patient en naasten dringen aan.
5. Suggesties voor andere type IC opnamen
IC opname uit voorzorg IC opname kan, bij eerste presentatie van de maligniteit, kans op 
orgaan falen beperken/voorkomen. (bijv. tumor-lysis, respiratoire 
insufficientie).
Vroege IC opname Ter voorkoming van snelle verslechtering van orgaanfuncties die al 
gecompromiteerd zijn. Ter voorkoming van late IC opname (geasso-
cieerd met hogere mortaliteit).
IC opname ter palliatie IC opname voor maximaal niet- invasieve- beademing.
Non-IC zorg op de IC IC-opname voor korte interventie  (verwijdering lijnen, toedienen 
medicatie).
IC opname in terminale fase IC opname is noodzakelijk voor opstarten palliatieve maatregelen en 
symptoom behandeling.
IC opname in terminale fase?
Non-IC zorg op de IC?IC opname ter palliatie?
Vroege IC opname?IC opname uit voorzorg?
1. Volledige IC behandeling
2. iC trial
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me type. De mortaliteit van medische (niet-chirurgische) kankerpatiënten is veel hoger dan 
van medische patiënten zonder kanker. Dit geldt in mindere mate voor de vergelijking tussen 
chirurgische kankerpatiënten en chirurgische patiënten zonder kanker. Ook in de analyse van 
Soares is aangetoond dat medische kankerpatiënten een hogere IC- en ziekenhuissterfte ken-
nen (respectievelijk 44% en 58%) dan kankerpatiënten opgenomen op de IC na ongeplande 
chirurgie (respectievelijk 23% en 37%) ([24]. Hieruit blijkt dat data betreffende morbiditeit en 
mortaliteit van kankerpatiënten opgenomen op de IC alleen geïnterpreteerd kunnen worden 
indien informatie over opname type bekend is (gepland of ongepland en medisch versus chi-
rurgisch).
 De follow-up van de patiënten in hoofdstuk 3 is beperkt tot de duur van de ziekenhuis-
opname. Dit criterium wordt veelal gebruikt in de bestudering van deze populatie. Kennis over 
de impact op overleving, morbiditeit en kwaliteit van leven op langere termijn na IC opnames 
van oncologische patiënten is veel beperkter. Data zoals tot heden gepubliceerd suggereren 
een toename van mortaliteit van kankerpatiënten tot meerdere jaren na opname op de IC, in 
vergelijking met patiënten zonder kanker met dezelfde leeftijd, en geslacht [25-27]. Ook de re-
cent gepubliceerde data uit Nederland betreffende een 3-jaars follow-up na IC opname tonen 
aan dat de groep van kankerpatiënten een bijna twee maal zo hoge mortaliteit hebben dan 
andere IC populaties [28]. Uit hoofdstuk 2 blijkt tevens dat kankerpatiënten die opgenomen 
zijn op de IC een veel slechtere overleving hebben dan kankerpatiënten die niet op een IC op-
genomen zijn. 
Chirurgische kankerpatiënten op de IC
In de laatste jaren worden steeds meer kankerpatiënten opgenomen op de IC na grote oncolo-
gische operaties. Het type operatie voor de verschillende maligniteiten verschilt uiteraard met 
een eigen risico op postoperatieve complicaties en noodzaak van intensieve zorg. Vele studies 
hebben gerapporteerd over postoperatieve morbiditeit en mortaliteit in een ongeselecteerde 
chirurgische groep [29-33]. Minstens zoveel data zijn beschikbaar over postoperatieve mor-
taliteit na electieve oncologische chirurgie [34-40]. Echter, er is slechts beperkte informatie 
over het effect van IC opname na electieve kankerchirurgie. De enige studie tot heden, ge-
publiceerd in 2010, maakte geen onderscheid tussen het type kanker en operatie en betrof 
maar 381 patiënten. De mediane IC opnameduur was 2 dagen en de IC mortaliteit was 6% 
[24]. In hoofdstuk 4 worden unieke data van bijna 29,000 patiënten geanalyseerd met be-
trekking tot morbiditeit en mortaliteit na electieve oncologische chirurgie opgenomen op de 
IC. De ziekenhuismortaliteit voor de verschillende type oncologische chirurgie komt overeen 
met eerdere publicaties betreffende chirurgie voor longkanker [41], slokdarmkanker [42, 43], 
pancreas [44], gynaecologische tumoren [45], blaaskanker  [46] en KNO-tumoren [47, 48]. In 
hoofdstuk 4 wordt duidelijk dat ongeveer een kwart van de patiënten die een electief oncologi-
sche operatie ondergaan CRC hebben, maar dat bij een significant deel (één derde) de indicatie 
voor IC opname pas tijdens of na de operatie gesteld wordt. In hoofdstuk 5 ligt het accent op 
spoedoperaties van patiënten met CRC. Deze analyse is van actuele waarde daar recente data 
uit Groot-Brittannië aantonen dat een kwart van de patiënten met dikke darm kanker zich in 
een spoedsituatie presenteren en acuut geopereerd moeten worden [49], terwijl duidelijk is 
dat een spoedlaparotomie voor CRC een negatieve impact heeft op de overleving [50, 51]. We 
beschrijven in hoofdstuk 5 een hoge IC en ziekenhuis sterfte (respectievelijk 10% en 22%) na 
CRC spoedchirurgie. Dit is in overeenstemming met eerdere publicaties [50, 51]. Overigens 
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bleek er geen verschil in ziekenhuissterfte van patiënten die een spoedoperatie ondergaan 
voor CRC of om andere redenen; de IC sterfte was juist wat lager. De patiëntenpopulatie voor 
deze analyse kenmerkt zich door spoedchirurgie en spoed IC opname. Wij gebruikten geen 
gegevens van patiënten die niet postoperatief werden opgenomen op de IC en een vergelijking 
met deze groep is derhalve niet mogelijk. De beslissing om patiënten op te nemen op een IC is 
deels subjectief en kan verschillen per ziekenhuis of regio. De beschreven resultaten dienen in 
deze context geïnterpreteerd te worden. 
Infecties bij patienten met kanker
Infecties bij patiënten met een oncologische aandoening zijn vaak de oorzaak van een verleng-
de ziekenhuisopname [52]. Kanker is geassocieerd met een hogere kans op bacteriëmie en sep-
sis [53-55] en deze systemische infecties zijn een belangrijke doodsoorzaak bij kankerpatiënten 
[56-58]. Er is veel onderzoek gedaan naar de impact op morbiditeit en mortaliteit van infecties 
door de verschillende micro-organismen bij kanker patiënten. Daaruit komt naar voren dat niet 
alleen banale micro-organismen tot ernstige schade kunnen leiden, maar ook laag virulente 
verwekkers, zoals enterococcen, hebben een significante invloed op morbiditeit en mortaliteit 
in deze kwetsbare populatie [59, 60]. In verschillende hoofdstukken van dit proefschrift wordt 
aandacht besteed aan de rol van infecties bij kankerpatiënten. Uit hoofdstuk 3 blijkt dat onge-
veer een derde van de niet chirurgische kankerpatiënten die acuut op de IC opgenomen wordt 
een gedocumenteerde infectie heeft, wat veel meer is dan bij de niet oncologische patiënten. 
In hoofdstuk 5 blijkt dat bij één op de tien patiënten opgenomen op de IC na spoedchirur-
gie voor CRC een sepsis wordt gedocumenteerd. Uit de resultaten in hoofdstuk 6 blijkt dat 
Gram-positieve bacteriën het meest vertegenwoordigd zijn in bloedkweken van zowel kanker-
patiënten als patiënten zonder kanker, hetgeen overeenkomt met eerdere publicaties [61-64]. 
Wij vonden echter geen relatie met het risico op een bacteriëmie met een specifieke verwek-
ker, zoals eerder werd beschreven voor S. aureus [65], E. coli [66] en K. pneumoniae [67]. Alleen 
voor P. aeruginosa bleek een relatie met kanker, zoals eerder gerapporteerd [68]. Het lijdt 
geen twijfel dat veroorzakers van bacteriëmie en dientengevolge de morbiditeit kan verschillen 
tussen de ziekenhuizen, afhankelijk van patiëntenpopulatie, type ziekenhuis (oncologisch cen-
trum, transplantatie-unit of algemeen ziekenhuis) en het spectrum van antibiotica resistentie 
in het betreffende instituut.
 In hoofdstuk 7 bestuderen we het infectie- en complicatierisico van het gebruik van 
centraal veneuze lijnen, in het bijzonder PACs, in kankerpatiënten en niet-oncologische pa-
tiënten. PACs worden frequent gebruikt bij patiënten met noodzaak tot veneuze toegang 
voor intraveneuze medicatie, zoals chemotherapie en ondersteunende zorg. Een opvallende 
bevinding in deze studie is dat kankerpatiënten een minder grote kans hadden op verwijde-
ring van de PAC als gevolg van een infectie dan niet kankerpatiënten ondanks hun grotere 
kwetsbaarheid als gevolg van de verminderde weerstand voor infecties. De beste verklaring 
hiervoor lijkt het feit dat vooral verpleegkundigen op (hemato-)oncologie afdelingen veel 
ervaring hebben met PACs en kwetsbare patiënten, in tegenstelling tot verpleegkundigen op 
andere afdelingen in het ziekenhuis, waar patiënten met PACs veel minder frequent gezien 
en behandeld worden. De incidentie van PAC infecties in deze analyse (11.8%) is vergelijk-
baar met eerdere studies en publicaties [69-71]. Ook de veroorzakende micro-organismen 
(veelal coagulase negatieve stafylokokken en S.aureus)  komen overeen met eerdere data 
[71, 72]. 
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Invloed van geslacht 
Geslacht kan van invloed zijn  op de aard van de complicaties en therapeutische interventies op 
een IC. Hoewel de totale IC sterfte niet verschilt tussen mannen en vrouwen [73, 74], hebben 
mannen een grotere kans op sepsis [74-76]. Tevens vinden bij de mannen vaker therapeutische 
interventies plaats op de IC dan bij vrouwen [73, 77]. In dit proefschrift hebben we de impact 
van geslacht op de verschillende uitkomstparameters bij kankerpatiënten in kaart gebracht. 
Uit hoofdstuk 2 blijkt dat meer mannen dan vrouwen met kanker werden opgenomen op de 
IC terwijl de bestudeerde oncologische populatie uit meer vrouwen bestond. Dit kan deels 
verklaard worden door het feit dat de prevalentie van borstkanker bij vrouwen hoog is, deze 
patiënten lang leven en zij maar zelden op de IC worden opgenomen. Voor nagenoeg alle kan-
kerdiagnosen afzonderlijk vonden we een hoger percentage mannen opgenomen op de IC dan 
vrouwen met uitzondering van slokdarmkanker. Deze bevinding staat niet op zichzelf, ook uit 
andere studies blijkt een discrepante verhouding in IC zorg en opname tussen mannen en 
vrouwen [73, 77-79]. Tot heden is hiervoor geen goede verklaring gevonden, een goede reden 
voor verder onderzoek. In hoofdstuk 5 werd op basis van voorgaand onderzoek [80-83] ver-
wacht dat geslacht van invloed is op het ziektebeloop en mortaliteit van acute CRC chirurgie. 
Behoudens een klein geslachtsverschil in mortaliteit bij patiënten die een spoedlaparotomie 
ondergingen voor andere indicatie dan CRC, was de impact van het geslacht minimaal, ook na 
correctie voor andere co-variabelen. 
Suggesties voor de toekomst
De kennis over de karakteristieken van kankerpatiënten opgenomen op de IC is inmiddels uit-
gebreid. De meeste studies betreffen retrospectieve onderzoeken met een case mix van chi-
rurgische en niet-chirurgische kankerpatiënten en een diversiteit van oncologische diagnosen 
zoals solide tumoren, hematologische maligniteiten en patiënten die een beenmerg transplan-
tatie hebben ondergaan. De resultaten van deze studies zijn moeilijk te vergelijken als gevolg 
van variatie in criteria voor IC opname en ontslag, voor palliatieve maatregelen en voor besluit-
vorming ten aanzien van terminale zorg. Er zijn dus nog heel wat actuele onderzoeksvragen 
aangaande de impact van een IC opname op verschillende oncologische patiëntenpopulaties, 
vooral onderzoek bij patiënten die om andere reden opgenomen worden dan direct postope-
ratieve zorg. Een van de meest relevante vragen betreft de lange termijn effecten en overleving 
van kankerpatiënten na IC opname. Het is van grote waarde te kunnen onderbouwen of de IC 
opname uiteindelijk leidt tot een verbeterde overleving met acceptabele kwaliteit van leven. 
Verder onderzoek naar kwaliteit van leven en fysieke conditie in de jaren na de IC opname is 
hiervoor van belang. Kortom: wat is de patiënt (en de familie) er mee opgeschoten dat er een 
high-impact verblijf op de IC heeft plaatsgevonden? En belangrijk, kan deze patiënt uiteindelijk 
weer verder behandeld worden met bijvoorbeeld chemotherapie en bestraling ter verbetering 
van de oncologische conditie? 
 Dus verder onderzoek is noodzakelijk naar voorspellende factoren die de kans op sterfte 
op de IC van kankerpatiënten beter in kaart brengen. Factoren die een belangrijke rol speelden 
in het verleden, zoals neutropenie, hoeven niet meer actueel te zijn. Initieel werd neutropenie 
als een klassieke voorspeller van mortaliteit gezien [84], maar inmiddels bevestigen meerdere 
studies vanuit verschillende continenten (België en Brazilië) dat de IC sterfte niet meer gecorre-
leerd is aan neutropenie [85] [24]. Andere klassieke variabelen zoals leeftijd en type kanker zijn 
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ook niet meer consequent gerelateerd aan een hogere IC sterfte. Deze wordt namelijk vooral 
beïnvloed door de IC opname criteria [6], terwijl IC opname op haar beurt weer sterk beïnvloed 
wordt door de verdere ontwikkeling van minder invasieve procedures voor grote oncologische 
problemen, bijvoorbeeld laparoscopische ingrepen bij abdominale maligniteiten en de recent 
ontwikkelde endoscopische slokdarmresecties [86].
 Al met al is er een toenemende behoefte aan adequate opname criteria voor kankerpa-
tiënten op de IC. De balans tussen (niet-)invasieve behandelingen en voorkomen dat er onno-
dig uitstel optreedt van optimale therapie is kwetsbaar. Dit geldt vooral voor de oncologische 
populatie. De huidige triagecriteria voor IC opname kunnen hier ter discussie worden gesteld. 
In een recente publicatie is inderdaad aangetoond dat 20% van de kankerpatiënten die afgewe-
zen werden voor IC opname om reden van een te goede conditie, uiteindelijk toch overleed in 
het ziekenhuis (veelal nog na een uitgestelde IC opname), terwijl 25% van de kankerpatiënten 
die geweigerd werden om redenen van een te slechte conditie uiteindelijk overleefden [87]. 
Uitgestelde IC opname (of late IC opname) van kankerpatiënten met multipel orgaan falen 
heeft een slechte prognose, waarbij het type en aantal organen dat faalt een goede voorspel-
lende waarde hebben voor sterfte [15, 21]. Hoewel vroege IC opname de kans op sterfte ver-
mindert [18], zal voor de oncologische populatie de criteria nog verder uitgewerkt moeten 
worden door bijvoorbeeld in onderzoek verband te randomiseren tussen vroege IC opname 
(bij falen van één orgaansysteem) versus geen IC opname of verlate IC opname. Een goede 
klinische conditie van de patiënt voor start van de acute verslechtering leidende tot noodzaak 
van IC opname, geeft de beste kans op overleving op de IC [88]. Het is overigens niet duidelijk 
of de conventionele performance scores zoals gebruikt in de objectivering van de oncologische 
patiënt (bijvoorbeeld Karnofsky-status of WHO performance score) een meerwaarde hebben 
om het succes van een IC opname te bepalen. De eerder genoemde “ICU-trial”, waarbij na 
drie dagen van IC zorg opnieuw wordt beoordeeld of de conditie van patiënt ten goede ver-
andert (doorzetten intensieve zorg) of verslechtert (stop intensieve zorg), kan een geschikter 
instrument blijken om patiënten met kanker de maximale mogelijkheid tot herstel te bieden 
[12, 15]. De duur van een dergelijke “proefperiode op de IC” kan verder onderzocht worden, 
daar een verslechtering van de klinische toestand van patiënt uiteindelijk zal leiden tot een 
dialoog ter introductie van de terminale fase, met alle consequenties voor patiënt en familie 
[89]. Deze veranderde instelling van de zorggevers op de IC naar de patiënt en familie heeft 
veel implicaties. Gesprekken over beëindiging van orgaanfunctie vervangende therapieën en 
andere ondersteunende maatregelen, dienen helder en duidelijk te geschieden. Samenspraak 
tussen intensivisten en de oncologisch verantwoordelijken is onontbeerlijk. Protocollen, ge-
implementeerd om de kwetsbare dialoog aangaande reanimatie codes en consequenties van 
maximaal ondersteunende therapieën tussen patiënt, naasten en behandelaars, structuur te 
geven zijn onontbeerlijk. In geval van acute verslechtering van een dergelijke patiënt behoort 
het spoed-interventie team van het ziekenhuis hierover goed geïnformeerd te worden en dit 
team kan beslissen een patiënt vroeg in het beloop over te plaatsen naar de IC. Een goede, 
ziekenhuis brede, set van afspraken is hiervoor belangrijk. Indien een patiënt met kanker is 
opgenomen op de IC is dagelijks overleg tussen intensivist en oncologisch specialist vanzelf-
sprekend. De intensivisten behoren geïnformeerd te worden over het beloop van de kanker 
en het behandelperspectief van de patiënt wanneer hij of zij voldoende hersteld is. Indien een 
kankerpatiënt nog niet door de IC wordt overgenomen maar ernstig ziek is, zal de medische en 
verpleegkundige staf zich hiervan goed bewust moeten blijven. Klinische evaluatie door de ver-
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antwoordelijke specialist (al of niet begeleid door arts-assistenten) van de vitale parameters en 
verschillende orgaansystemen, is geïndiceerd. Zo kan een snelle verslechtering geconstateerd 
worden en leiden tot tijdige overplaatsing naar de IC. 
 In dit proefschrift is niet ingegaan op de mogelijkheid om intensieve kankertherapieën, 
zoals chemotherapie, te combineren met een verblijf op de IC. Uit de studies betreffende deze 
problematiek kan worden opgemaakt dat toedienen van chemotherapie op de IC mogelijk is 
en niet leidt tot hoge mortaliteit of onverwachte morbiditeit [90, 91]. Bovendien lijken kan-
kerpatiënten met een septische shock na chemotherapie een betere korte termijn prognose 
te hebben dan septische kankerpatiënten zonder chemotherapeutische behandeling [90, 91]. 
Hoewel NICE veel informatie bevat over de meerderheid van de Nederlandse IC patiënten, 
wordt specifieke oncologische informatie en dus verstrekking van chemotherapie op de IC, 
niet geregistreerd. Daar de NICE database op zichzelf staat en niet gelinkt is met bijvoorbeeld 
de ziekenhuisapotheek, is inzicht in cytostaticaverstrekkingen op de IC niet goed mogelijk. Te-
genwoordig worden veel kankerpatiënten intensief, multidisciplinair, behandeld ter vergroting 
van de kans op curatie. Inzicht in effecten van deze therapieën op uitkomst van de IC opname 
is van groot belang, niet alleen voor intensivisten, maar ook voor alle oncologisch specialisten 
zoals medisch oncologen, hematologen, radiotherapeuten en oncologisch chirurgen.
 Ter afsluiting kunnen we stellen dat de overleving van patiënten met kanker opgenomen 
op de IC allengs toeneemt als gevolg van verbeterde oncologische behandelingsstrategieën en 
ondersteuning op de IC. Het managen van kritisch zieke kankerpatiënten op de IC eist een spe-
ciale instelling van de intensivist en een nauwe samenwerking tussen hen en oncologisch spe-
cialisten. Goede afspraken onderling zullen een positieve impact hebben op de kansen van de 
patiënt met een maligniteit. De kankerspecialisten behoren de staf van de IC goed te informe-
ren over de curatieve behandelopties en prognose van de kwaadaardige ziekte. Op hun beurt, 
kunnen intensivisten, weer beter de prognose van een patiënt met acuut (multi-)orgaanfalen 
inschatten. Opname op de IC is een gezamenlijke beslissing van intensivist, oncologisch speci-
alist en uiteraard de wil van de patiënt en naasten. Beslissingen betreffende niet gebruiken of 
staken van orgaanfunctie vervangende therapieën moeten in gezamenlijkheid genomen wor-
den, en de informatie naar patiënt en naasten zal door beide medisch specialisten uitgedragen 
moeten worden. Een verdere uitbreiding van de samenwerking tussen beiden behandelaars is 
eminent, mede daar uitbreiding van expertise een verbetering en optimalisering van de zorg 
van deze bijzondere patiëntenpopulatie in onze ziekenhuizen garandeert.
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